<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005282.pub3" GROUP_ID="RENAL" ID="561704060114270001" MERGED_FROM="" MODIFIED="2016-08-15 01:33:10 +0100" MODIFIED_BY="Narelle Willis" REVIEW_NO="089" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2016-08-15 10:27:23 +1000" MODIFIED_BY="Narelle Willis">
<TITLE>Fish oil for kidney transplant recipients</TITLE>
<CONTACT>
<PERSON ID="8ED777D482E26AA200AC706A61242093" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Andy</FIRST_NAME>
<MIDDLE_INITIALS>KH</MIDDLE_INITIALS>
<LAST_NAME>Lim</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>Andy.lim@monash.edu</EMAIL_1>
<EMAIL_2>Andykhlim@hotmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Nephrology</DEPARTMENT>
<ORGANISATION>Monash Medical Centre</ORGANISATION>
<ADDRESS_1>246 Clayton Rd</ADDRESS_1>
<ADDRESS_2/>
<CITY>Clayton</CITY>
<ZIP>3168</ZIP>
<REGION>VIC</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 3 95943528</PHONE_1>
<PHONE_2/>
<FAX_1>+61 3 95946530</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2016-08-15 10:27:23 +1000" MODIFIED_BY="Narelle Willis">
<PERSON ID="8ED777D482E26AA200AC706A61242093" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Andy</FIRST_NAME>
<MIDDLE_INITIALS>KH</MIDDLE_INITIALS>
<LAST_NAME>Lim</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>Andy.lim@monash.edu</EMAIL_1>
<EMAIL_2>Andykhlim@hotmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Nephrology</DEPARTMENT>
<ORGANISATION>Monash Medical Centre</ORGANISATION>
<ADDRESS_1>246 Clayton Rd</ADDRESS_1>
<ADDRESS_2/>
<CITY>Clayton</CITY>
<ZIP>3168</ZIP>
<REGION>VIC</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 3 95943528</PHONE_1>
<PHONE_2/>
<FAX_1>+61 3 95946530</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="17946" ROLE="AUTHOR">
<PREFIX>Mrs</PREFIX>
<FIRST_NAME>Karen</FIRST_NAME>
<MIDDLE_INITIALS>J</MIDDLE_INITIALS>
<LAST_NAME>Manley</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>karen.manley@austin.org.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Nutrition and Dietetics</DEPARTMENT>
<ORGANISATION>Austin Health</ORGANISATION>
<ADDRESS_1>PO Box 5555</ADDRESS_1>
<ADDRESS_2/>
<CITY>Heidelberg</CITY>
<ZIP>3084</ZIP>
<REGION>VIC</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 3 94965646</PHONE_1>
<PHONE_2>+61 3 94965011</PHONE_2>
<FAX_1>+61 3 94963168</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="17140" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Matthew</FIRST_NAME>
<MIDDLE_INITIALS>A</MIDDLE_INITIALS>
<LAST_NAME>Roberts</LAST_NAME>
<SUFFIX/>
<POSITION>Nephrologist</POSITION>
<EMAIL_1>matthew.roberts@easternhealth.org.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Eastern Health Clinical School</DEPARTMENT>
<ORGANISATION>Monash University</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Box Hill</CITY>
<ZIP>3128</ZIP>
<REGION>VIC</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1>+61 3 90952410</PHONE_1>
<PHONE_2/>
<FAX_1>+61 3 98996810</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8EDA1B3F82E26AA200AC706AFFA654A8" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Margaret</FIRST_NAME>
<MIDDLE_INITIALS>B</MIDDLE_INITIALS>
<LAST_NAME>Fraenkel</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>Margaret.Fraenkel@easternhealth.org.au</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Eastern Health Clinical School</DEPARTMENT>
<ORGANISATION>Monash University</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Box Hill</CITY>
<ZIP>3128</ZIP>
<REGION>VIC</REGION>
<COUNTRY CODE="AU">Australia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<UP_TO_DATE>
<DATE DAY="17" MONTH="3" YEAR="2016"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="17" MONTH="3" YEAR="2016"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="17" MONTH="9" YEAR="2018"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="8" YEAR="2016"/>
</DATES>
<WHATS_NEW MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2016-04-04 11:26:03 +1000" MODIFIED_BY="Narelle Willis">
<DATE DAY="17" MONTH="3" YEAR="2016"/>
<DESCRIPTION>
<P>New search, 1 ongoing study identified</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2016-04-04 15:00:01 +1000" MODIFIED_BY="Narelle Willis">
<DATE DAY="17" MONTH="3" YEAR="2016"/>
<DESCRIPTION>
<P>New search; subheadings added; risk of bias assessment included</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2016-03-14 16:09:41 +1100" MODIFIED_BY="Narelle Willis">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2016-03-14 16:09:41 +1100" MODIFIED_BY="Narelle Willis">
<DATE DAY="12" MONTH="5" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2016-08-15 10:29:14 +1000" MODIFIED_BY="Narelle S Willis">
<SUMMARY MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<TITLE MODIFIED="2008-05-13 09:07:49 +1000" MODIFIED_BY="Narelle S Willis">Fish oil for kidney transplant recipients</TITLE>
<SUMMARY_BODY MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<P>This review set out to assess any benefit or harm in using fish oil to reduce the risk of kidney damage and heart disease in people who have had a kidney transplant and are receiving standard drugs to prevent rejection. Information from 15 studies was used and showed that fish oils provide a slight improvement in HDL cholesterol and diastolic blood pressure. These studies did not provide enough information on the differences in the risk of death, heart disease, kidney transplant rejection or kidney function between patients receiving fish oils and those receiving placebo. There appeared to be no harmful effects of taking fish oil. The benefits of taking fish oil after a kidney transplant are a mild improvement in some heart disease risk factors. There was not enough information to show any benefit in preventing heart disease or reduction in kidney function. Larger, better studies are needed before regular use of fish oil can be recommended.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<ABS_BACKGROUND>
<P>Calcineurin inhibitors used in kidney transplantation for immunosuppression have adverse effects that may contribute to nephrotoxicity and increased cardiovascular risk profile. Fish oils are rich in very long chain omega-3 fatty acids, which may reduce nephrotoxicity by improving endothelial function and reduce rejection rates through their immuno-modulatory effects. They may also modify the cardiovascular risk profile. Hence, fish oils may potentially prolong graft survival and reduce cardiovascular mortality.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2016-04-04 11:43:51 +1000" MODIFIED_BY="Narelle Willis">
<P>This review aimed to look at the benefits and harms of fish oil treatment in ameliorating the kidney and cardiovascular adverse effects of CNI-based immunosuppressive therapy in kidney transplant recipients.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<P>We searched the Cochrane Kidney and Transplant Specialised Register (up to 17 March 2016) through contact with the Information Specialist using search terms relevant to this review.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised controlled trials (RCTs) and quasi-RCTs of fish oils in kidney transplant recipients on a calcineurin inhibitor-based immunosuppressive regimen. RCTs of fish oil versus statins were included.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2016-03-21 14:31:33 +1100" MODIFIED_BY="Narelle Willis">
<P>Data was extracted and the quality of studies assessed by two authors, with differences resolved by discussion with a third independent author. Dichotomous outcomes were reported as risk ratio (RR) and continuous outcome measures were reported as the mean difference (MD) with 95% confidence intervals using the random effects model. Heterogeneity was assessed using a Chi<SUP>2</SUP> test on n-1 degrees of freedom and the I<SUP>2</SUP> statistic. Data not suitable for pooling were tabulated and described.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<P>Fifteen studies (733 patients) were suitable for analysis. All studies were small and had variable methodology. Fish oil did not significantly affect patient or graft survival, acute rejection rates, or calcineurin inhibitor toxicity when compared to placebo. Overall SCr was significantly lower in the fish oil group compared to placebo (5 studies, 237 participants: MD -30.63 µmol/L, 95% CI -59.74 to -1.53; I<SUP>2</SUP> = 88%). In the subgroup analysis, this was only significant in the long-course (six months or more) group (4 studies, 157 participants: MD -37.41 µmol/L, 95% CI -69.89 to -4.94; I<SUP>2</SUP> = 82%). Fish oil treatment was associated with a lower diastolic blood pressure (4 studies, 200 participants: MD -4.53 mm Hg, 95% CI -7.60 to -1.45) compared to placebo. Patients receiving fish oil for more than six months had a modest increase in HDL (5 studies, 178 participants: MD 0.12 mmol/L, 95% CI 0.03 to 0.21; I<SUP>2</SUP> = 47%) compared to placebo. Fish oil effects on lipids were not significantly different from low-dose statins. There was insufficient data to analyse cardiovascular outcomes. Fishy aftertaste and gastrointestinal upset were common but did not result in significant patient drop-out.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2016-03-14 16:10:59 +1100" MODIFIED_BY="Narelle Willis">
<P>There is insufficient evidence from currently available RCTs to recommend fish oil therapy to improve kidney function, rejection rates, patient survival or graft survival. The improvements in HDL cholesterol and diastolic blood pressure were too modest to recommend routine use. To determine a benefit in clinical outcomes, future RCTs will need to be adequately powered with these outcomes in mind.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<BACKGROUND MODIFIED="2016-04-04 11:42:34 +1000" MODIFIED_BY="Narelle Willis">
<INTERVENTION MODIFIED="2016-04-04 11:42:34 +1000" MODIFIED_BY="Narelle Willis">
<P>Fish oils contain high levels of polyunsaturated fatty acids (PUFAs) that may reduce cardiovascular risk and improve kidney transplant graft survival but they are not currently routinely used by kidney transplant recipients. There are two types of PUFAs, namely omega-6 (n-6 PUFA) and omega-3 (n-3 PUFA). n-6 PUFA (linoleic acid) is mainly derived from vegetable oils such as corn oil and sunflower oil. The n-3 PUFAs (linolenic acid) include &#945;-linolenic acid (ALA, C18:3 n-3), eicosapentaenoic acid (EPA, C20:5 n-3) and docosahexaenoic acid (DHA, C22:6 n-3). While ALA is available from certain plants such as linseed, soy, flaxseed and walnut, EPA and DHA are derived from fish and fish oils. The typical Western diet is abundant in plant n-6 PUFA relative to n-3 PUFA, with a ratio of approximately 10:1 (<LINK REF="REF-Kris_x002d_Etherton-2000" TYPE="REFERENCE">Kris-Etherton 2000</LINK>). However, humans lack the enzymes to convert n-6 to n-3 PUFA, and convert only about 5% of ALA to EPA or DHA (<LINK REF="REF-Brenna-2002" TYPE="REFERENCE">Brenna 2002</LINK>).</P>
<P>Evidence is accumulating in the general population that the very long chain n-3 PUFAs (EPA/DHA) found in fatty fish or fish oil supplements are beneficial in the prevention of cardiovascular disease (<LINK REF="REF-Psota-2006" TYPE="REFERENCE">Psota 2006</LINK>). This is probably the most common indication for fish oil supplementation. Potential benefits include antiarrhythmic, antithrombotic (decreased platelet aggregation), antiatherosclerotic and anti-inflammatory actions, lowering of blood pressure, and improvements in endothelial function and lipid profile (<LINK REF="REF-Din-2004" TYPE="REFERENCE">Din 2004</LINK>). The common side effects of fish oil include gastrointestinal upset and fishy aftertaste. The inhibition of platelet aggregation theoretically increases the risk of bleeding but its clinical significance is debatable.</P>
<P>There are special circumstances in the kidney transplant population that increase the risk of graft dysfunction and cardiovascular disease that may be reduced by fish oil. The majority of kidney transplant immunosuppressive regimens include corticosteroids and a calcineurin-inhibitor (CNI), such as cyclosporin A (CSA) and tacrolimus. CNIs can cause endothelial dysfunction by reducing production of vasodilators (nitric oxide and prostaglandins, particularly prostacyclin) and increased release of vasoconstrictors (endothelin and thromboxane A<SUB>2</SUB>). In the kidney, this imbalance in the arachidonic acid-derived eicosanoid system results in a concentration-dependent vasoconstriction of the glomerular arterioles, decreasing renal plasma flow and glomerular filtration rate (GFR). CNI vasoconstriction causes dose-dependent azotaemia, increasing the risk of acute tubular necrosis and poor graft function. Chronically, CNIs can cause progressive kidney disease with tubular atrophy, striped tubulointerstitial fibrosis and an arteriolopathy characterised by hyalinosis of the afferent arteriole (<LINK REF="REF-Ader-1998" TYPE="REFERENCE">Ader 1998</LINK>; <LINK REF="REF-Andoh-1997" TYPE="REFERENCE">Andoh 1997</LINK>; <LINK REF="REF-Andoh-1998" TYPE="REFERENCE">Andoh 1998</LINK>; <LINK REF="REF-de-Mattos-2000" TYPE="REFERENCE">de Mattos 2000</LINK>). This increased risk of kidney failure due to CNI nephrotoxicity is apparent in non-kidney organ recipients (<LINK REF="REF-Ojo-2003" TYPE="REFERENCE">Ojo 2003</LINK>).</P>
<P>Corticosteroid and CNI use is associated with a higher prevalence of hypertension (<LINK REF="REF-Braun-2003" TYPE="REFERENCE">Braun 2003</LINK>), where CSA has been shown to stimulate the renin-angiotensin system and enhance sympathetic nervous system activity (<LINK REF="REF-Ader-1998" TYPE="REFERENCE">Ader 1998</LINK>). Furthermore, an abnormal lipid profile occurs in 50% to 80% of kidney transplant recipients treated with prednisolone and CSA, characterised by an increase in total cholesterol, low-density lipoprotein (LDL), very low-density lipoprotein, and apolipoprotein B levels (<LINK REF="REF-Braun-2003" TYPE="REFERENCE">Braun 2003</LINK>). Hypertension is an independent risk factor for graft failure (<LINK REF="REF-Opelz-1998" TYPE="REFERENCE">Opelz 1998</LINK>) and cardiovascular disease is an important contributor to mortality in kidney transplant recipients. For example, 38% of deaths in kidney transplant recipients in Australia and New Zealand are due to cardiovascular causes, where the risk of death is 5 to 10 times that of the age-matched population under 60 (<LINK REF="REF-McDonald-2003" TYPE="REFERENCE">McDonald 2003</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2016-03-24 18:03:29 +1100" MODIFIED_BY="Narelle S Willis">
<P>The potential specific benefits of fish oil for the kidney transplant population include:</P>
<OL>
<LI>Reversing the endothelial dysfunction caused by CNI-induced disturbance in the eicosanoid pathway: Fish oil treatment is associated with a decreased synthesis of thromboxane and increased synthesis of prostacyclin, and reduced CSA-induced kidney dysfunction in rats (<LINK REF="REF-Norris-1990" TYPE="REFERENCE">Norris 1990</LINK>).</LI>
<LI>Immunomodulatory effects: Fish oil has been shown to reduce the pro-inflammatory cytokines involved in acute transplant rejection such as TNF-&#945;, IL-1 and IL-2 (<LINK REF="REF-Endres-1989" TYPE="REFERENCE">Endres 1989</LINK>; <LINK REF="REF-Ford-1991" TYPE="REFERENCE">Ford 1991</LINK>; <LINK REF="REF-Endres-1993" TYPE="REFERENCE">Endres 1993</LINK>; <LINK REF="REF-Noronha-1992" TYPE="REFERENCE">Noronha 1992</LINK>; <LINK REF="REF-Noronha-1993" TYPE="REFERENCE">Noronha 1993</LINK>; <LINK REF="REF-Vandenbroecke-1991" TYPE="REFERENCE">Vandenbroecke 1991</LINK>; <LINK REF="REF-Yard-1994" TYPE="REFERENCE">Yard 1994</LINK>), enhance the immunosuppressive effects of cyclosporine (<LINK REF="REF-Kelley-1989" TYPE="REFERENCE">Kelley 1989</LINK>), inhibit delayed type hypersensitivity in rat models of cardiac transplant (<LINK REF="REF-Otto-1990" TYPE="REFERENCE">Otto 1990</LINK>), and slow the deterioration of graft function in chronic vascular rejection (<LINK REF="REF-Sweny-1989" TYPE="REFERENCE">Sweny 1989</LINK>).</LI>
</OL>
</THEORY>
<IMPORTANCE MODIFIED="2016-03-14 16:12:38 +1100" MODIFIED_BY="Narelle Willis">
<P>A recent large observational study looking at plasma n-3 PUFA levels in kidney transplant recipients in a Norwegian population noted reduced cardiovascular mortality with higher n-3 PUFA levels (<LINK REF="REF-Eide-2015" TYPE="REFERENCE">Eide 2015</LINK>). Furthermore, high levels of n-PUFA were also associated with better kidney allograft survival (<LINK REF="REF-Eide-2016" TYPE="REFERENCE">Eide 2016</LINK>). These observations were based on a population with a generally high dietary intake of marine n-3 PUFA.</P>
<P>Hence, fish oil may potentially prolong graft survival in addition to lowering cardiovascular risk. The addition of fish oil to kidney transplant protocols may therefore improve both short- and long-term outcomes for kidney transplant recipients.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>This review aimed to look at the benefits and harms of fish oil treatment in ameliorating the kidney and cardiovascular adverse effects of CNI-based immunosuppressive therapy in kidney transplant recipients.</P>
</OBJECTIVES>
<METHODS MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<SELECTION_CRITERIA MODIFIED="2016-03-21 14:27:38 +1100" MODIFIED_BY="Narelle Willis">
<CRIT_STUDIES>
<P>All randomised controlled trials (RCTs) and quasi-RCTs (RCTs in which allocation to treatment was obtained by alternation, use of alternate medical records, date of birth or other predictable methods) examining fish oils in kidney transplant recipients. The first period of randomised cross-over studies were included.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-05-13 09:19:56 +1000" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="4">Inclusion criteria</HEADING>
<P>All recipients of cadaveric or living kidney transplants on a CNI-based immunosuppressive protocol.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Exclusion criteria</HEADING>
<UL>
<LI>CNI-free transplant immunosuppression protocol</LI>
<LI>Multi-organ combined transplants, e.g. liver-kidney, pancreas-kidney</LI>
</UL>
</SUBSECTION>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-05-13 09:20:10 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Fish oil versus control oil</LI>
<LI>Fish oil versus statin</LI>
<LI>Early versus late introduction (&gt; three months)</LI>
<LI>Short-course versus long-course (&gt; three months)</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2016-03-21 14:27:38 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Patient survival/death: yes/no</LI>
<LI>Graft failure, defined as creatinine clearance (CrCl)/GFR &lt; 15 mL/min OR dialysis: yes/no</LI>
<LI>Acute rejection (biopsy proven) present: yes/no</LI>
<LI>CNI toxicity (biopsy proven) present: yes/no</LI>
<LI>Cardiovascular events (stroke, myocardial infarction and cardiovascular death): yes/no</LI>
<LI>Adverse effects (gastrointestinal upset, taste, breath): yes/no</LI>
<LI>Compliance (percentage drop-out rate during study period) and satisfaction (quality of life assessment by standard validated method e.g. the SF-36)</LI>
<LI>Kidney function (GFR, CrCl, serum creatinine (SCr))</LI>
<LI>Blood pressure (systolic, diastolic, mean arterial pressure (MAP))</LI>
<LI>Serum lipid levels (total cholesterol, LDL, HDL, triglycerides)</LI>
</UL>
<P>For dichotomous outcomes, the events were combined to 12 months (or earlier for shorter studies). For continuous outcomes, the data was assessed at the 12-month time point (or earlier time point for shorter studies).</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<ELECTRONIC_SEARCHES MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<P>We searched the <A HREF="http://kidneyandtransplant.cochrane.org/cochrane-kidney-and-transplant-specialised-register">Cochrane Kidney and Transplant Specialised Register</A> (up to 17 March 2016) through contact with the Information Specialist using search terms relevant to this review. The Cochrane Kidney and Transplant Specialised Register contains studies identified from several sources.</P>
<OL>
<LI>Monthly searches of the Cochrane Central Register of Controlled Trials (CENTRAL)</LI>
<LI>Weekly searches of MEDLINE OVID SP</LI>
<LI>Handsearching of kidney-related journals and the proceedings of major kidney conferences</LI>
<LI>Searching of the current year of EMBASE OVID SP</LI>
<LI>Weekly current awareness alerts for selected kidney journals</LI>
<LI>Searches of the International Clinical Trials Register (ICTRP) Search Portal and ClinicalTrials.gov.</LI>
</OL>
<P>Studies contained in the Specialised Register are identified through search strategies for CENTRAL, MEDLINE, and EMBASE based on the scope of Cochrane Kidney and Transplant. Details of these strategies, as well as a list of handsearched journals, conference proceedings and current awareness alerts, are available in the Specialised Register section of information about the <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/RENAL/frame.html">Cochrane Kidney and Transplant</A>.</P>
<P>See <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> for search terms used in strategies for this review.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2016-03-16 08:38:21 +1100" MODIFIED_BY="Gail Y Higgins">
<OL>
<LI>Reference lists of review articles, relevant studies and clinical practice guidelines.</LI>
<LI>Letters seeking information about unpublished or incomplete trials to investigators known to be involved in previous studies.</LI>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2016-04-04 14:52:02 +1000" MODIFIED_BY="Narelle Willis">
<STUDY_SELECTION MODIFIED="2016-03-21 14:29:56 +1100" MODIFIED_BY="Narelle Willis">
<P>The review was undertaken by four authors. The search strategy described was used to obtain titles and abstracts of studies that were potentially relevant to the review. The titles and abstracts were screened independently by two authors, who discarded studies that were not applicable. However, studies and reviews that included relevant data or information on studies were retained initially. Two authors independently assessed the retrieved abstracts and, if necessary, the full text of these studies to determine which studies satisfied the inclusion criteria.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2016-03-21 14:30:19 +1100" MODIFIED_BY="Narelle Willis">
<P>Data extraction was carried out by the same authors independently using standard data extraction forms. Studies reported in non-English language journals were translated before assessment. Where more than one publication of the same study existed, reports were grouped together and the publication with the most complete data was used. Disagreements were resolved in consultation with a third author.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2016-04-04 14:10:41 +1000" MODIFIED_BY="Narelle Willis">
<P>For this update the following items were used to assess the risk of bias (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) (see <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>).</P>
<UL>
<LI>Was there adequate sequence generation (selection bias)?</LI>
<LI>Was allocation adequately concealed (selection bias)?</LI>
<LI>Was knowledge of the allocated interventions adequately prevented during the study?</LI>
<UL>
<LI>Participants and personnel (performance bias)</LI>
<LI>Outcome assessors (detection bias)</LI>
</UL>
<LI>Were incomplete outcome data adequately addressed (attrition bias)?</LI>
<LI>Are reports of the study free of suggestion of selective outcome reporting (reporting bias)?</LI>
<LI>Was the study apparently free of other problems that could put it at a risk of bias?</LI>
</UL>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2016-03-14 15:40:50 +1100" MODIFIED_BY="Narelle Willis">
<P>Results for dichotomous outcomes (death, graft failure, acute rejection, CNI toxicity, cardiovascular events, non-compliance with patient drop-out) were expressed as risk ratio (RR) with 95% confidence intervals (CI). Where continuous scales of measurement were used to assess the effects of treatment (kidney function, blood pressure, lipid levels), the mean difference (MD) was used, or the standardised mean difference (SMD) if different scales had been used. Adverse effects were tabulated and assessed descriptively, as there was insufficient data to calculate a RR or MD.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2016-03-14 15:42:55 +1100" MODIFIED_BY="Narelle Willis">
<P>Further information required from the original authors were requested by written correspondence and information obtained in this manner was included in the review.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2016-03-21 14:31:18 +1100" MODIFIED_BY="Narelle Willis">
<P>Heterogeneity was analysed using a Chi<SUP>2</SUP> test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance, and also using the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2016-04-04 11:11:34 +1000" MODIFIED_BY="Narelle Willis">
<P>Funnel plots were to be used to assess for the potential existence of small study bias (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) however there were insufficient studies to do this.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2016-03-14 15:40:54 +1100" MODIFIED_BY="Narelle Willis">
<P>Data was pooled using the random effects model but the fixed effects model was also analysed to ensure robustness of the model chosen and susceptibility to outliers.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2016-04-04 14:52:02 +1000" MODIFIED_BY="Narelle Willis">
<P>Subgroup analyses were planned to assess possible sources of heterogeneity. This was only possible for duration of treatment, dividing treatment courses into short (three months or less) and long (more than three months). The other subgroups which were considered but not analysed due to lack of data include:</P>
<OL>
<LI>Heterogeneity among participants related to patient age, underlying risk of graft failure (high if panel reactive antibodies &gt; 50%, previous transplant, cold ischaemia &gt; 24 hours) or diabetes.</LI>
<LI>Heterogeneity in treatments related to the dose of fish oil (g/d) or CNI (as assessed by serum CSA or tacrolimus level), duration and timing of treatment initiation.</LI>
<LI>Blood pressure control and specifically the use of calcium channel antagonists, renin-angiotensin antagonists or both.</LI>
<LI>Different immunosuppressive combinations.</LI>
</OL>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<STUDY_DESCRIPTION MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<SEARCH_RESULTS MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="4">2007 review</HEADING>
<P>A total of 65 reports were identified after searching the Specialised Register, CENTRAL, MEDLINE and EMBASE. Of these, 45 reports (44 studies) were excluded and 20 reports (15 studies) were included.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2016 review update</HEADING>
<P>A search of the Specialised Register identified 16 new reports: seven new reports of five existing included studies (<LINK REF="STD-Busnach-1998" TYPE="STUDY">Busnach 1998</LINK>; <LINK REF="STD-Homan-van-der-Heide-1990a" TYPE="STUDY">Homan van der Heide 1990a</LINK>; <LINK REF="STD-Homan-van-der-Heide-1990b" TYPE="STUDY">Homan van der Heide 1990b</LINK>; <LINK REF="STD-Homan-van-der-Heide-1992" TYPE="STUDY">Homan van der Heide 1992</LINK>; <LINK REF="STD-Kooijmans_x002d_Coutinho-1996" TYPE="STUDY">Kooijmans-Coutinho 1996</LINK>); four new reports of two existing excluded studies (<LINK REF="STD-Alexander-2005" TYPE="STUDY">Alexander 2005</LINK>; <LINK REF="STD-Levi-1992" TYPE="STUDY">Levi 1992</LINK>); four reports of four new excluded studies (<LINK REF="STD-Alexander-2006" TYPE="STUDY">Alexander 2006</LINK>; <LINK REF="STD-Alexander-2008" TYPE="STUDY">Alexander 2008</LINK>; <LINK REF="STD-Ramezani--2011" TYPE="STUDY">Ramezani 2011</LINK>; <LINK REF="STD-Romo-2012" TYPE="STUDY">Romo 2012</LINK>); and one recently completed study which is yet to publish any results (<LINK REF="STD-NCT01744067" TYPE="STUDY">NCT01744067</LINK>).</P>
<P>See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
</SUBSECTION>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<P>Of the 15 included studies (733 patients), 13 compared fish oil to control/placebo (658 patients) (<LINK REF="STD-Bennett-_x0028_high_x0029_-1995" TYPE="STUDY">Bennett (high) 1995</LINK>; <LINK REF="STD-Bennett-_x0028_low_x0029_-1995" TYPE="STUDY">Bennett (low) 1995</LINK>; <LINK REF="STD-Berthoux-1992" TYPE="STUDY">Berthoux 1992</LINK>; <LINK REF="STD-Busnach-1998" TYPE="STUDY">Busnach 1998</LINK>; <LINK REF="STD-Hernandez-2002" TYPE="STUDY">Hernandez 2002</LINK>; <LINK REF="STD-Homan-van-der-Heide-1990a" TYPE="STUDY">Homan van der Heide 1990a</LINK>; <LINK REF="STD-Homan-van-der-Heide-1990b" TYPE="STUDY">Homan van der Heide 1990b</LINK>; <LINK REF="STD-Homan-van-der-Heide-1992" TYPE="STUDY">Homan van der Heide 1992</LINK>; <LINK REF="STD-Homan-van-der-Heide-1993" TYPE="STUDY">Homan van der Heide 1993</LINK>; <LINK REF="STD-Kooijmans_x002d_Coutinho-1996" TYPE="STUDY">Kooijmans-Coutinho 1996</LINK>; <LINK REF="STD-Maachi-1995" TYPE="STUDY">Maachi 1995</LINK>; <LINK REF="STD-Santos-2000" TYPE="STUDY">Santos 2000</LINK>; <LINK REF="STD-Schut-1992a" TYPE="STUDY">Schut 1992a</LINK>; <LINK REF="STD-Schut-1992b" TYPE="STUDY">Schut 1992b</LINK>; <LINK REF="STD-Yoa-1994" TYPE="STUDY">Yoa 1994</LINK>), and two compared fish oil to statin treatment (75 patients) (<LINK REF="STD-Castro-1997" TYPE="STUDY">Castro 1997</LINK>; <LINK REF="STD-Rodriguez-1997" TYPE="STUDY">Rodriguez 1997</LINK>).</P>
<P>
<LINK REF="STD-Bennett-_x0028_high_x0029_-1995" TYPE="STUDY">Bennett (high) 1995</LINK> is the same study as <LINK REF="STD-Bennett-_x0028_low_x0029_-1995" TYPE="STUDY">Bennett (low) 1995</LINK>. The high dose arm is analysed compared to half of the control group for continuous outcomes. Dichotomous outcomes analysed together. Results for low and high dose corn oil were combined (n = 50) in the published report.</P>
<P>
<LINK REF="STD-Schut-1992a" TYPE="STUDY">Schut 1992a</LINK> is the same study as <LINK REF="STD-Schut-1992b" TYPE="STUDY">Schut 1992b</LINK>. <LINK REF="STD-Schut-1992a" TYPE="STUDY">Schut 1992a</LINK> presents the data for patients receiving cyclosporin A and <LINK REF="STD-Schut-1992b" TYPE="STUDY">Schut 1992b</LINK> presents the data for patients receiving cyclosporin A plus prednisone.</P>
<P>Four studies (<LINK REF="STD-Homan-van-der-Heide-1990a" TYPE="STUDY">Homan van der Heide 1990a</LINK>; <LINK REF="STD-Homan-van-der-Heide-1990b" TYPE="STUDY">Homan van der Heide 1990b</LINK>; <LINK REF="STD-Homan-van-der-Heide-1992" TYPE="STUDY">Homan van der Heide 1992</LINK>; <LINK REF="STD-Homan-van-der-Heide-1993" TYPE="STUDY">Homan van der Heide 1993</LINK>) reported median rather than mean values for several continuous data variables and were not suitable for meta-analysis. Their continuous outcomes were assessed in a separate table but their dichotomous data was included in the analysis. All available studies contained small patient numbers and reporting on outcome measures was highly variable. The duration of treatment and follow-up was also variable, ranging from one to 12 months. No study exceeded 12 months in duration. The dose of fish oil ranged from 2 g/d to 18 g/d, comprising 0.6 g/d to 5.4 g/d of EPA and DHA. Three studies examined delayed introduction of fish oil (<LINK REF="STD-Bennett-_x0028_high_x0029_-1995" TYPE="STUDY">Bennett (high) 1995</LINK>; <LINK REF="STD-Homan-van-der-Heide-1990b" TYPE="STUDY">Homan van der Heide 1990b</LINK>; <LINK REF="STD-Schut-1992a" TYPE="STUDY">Schut 1992a</LINK>). One study (<LINK REF="STD-Hernandez-2002" TYPE="STUDY">Hernandez 2002</LINK>) used soy oil as the control, which is potentially a weak source ALA. However, we considered ALA to be sufficiently different from EPA/DHA to include this study. Two studies were identified which compared fish oil with statins. Both were small, single centre studies with late introduction of fish oil. <LINK REF="STD-Castro-1997" TYPE="STUDY">Castro 1997</LINK> compared low-dose simvastatin 10 mg/d to fish oil (duration three months), while <LINK REF="STD-Rodriguez-1997" TYPE="STUDY">Rodriguez 1997</LINK> compared lovastatin 20 mg/d with fish oil (six months).</P>
<P>The reporting of outcome measures was variable (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> - <I>Summary of reported outcome measures</I>). The primary outcomes of interest for most of these studies were kidney function and graft survival (except for the statin studies). The definition of the end points were also variable. Graft failure/loss was generally not defined. Reporting on acute rejection was either in terms of rejection episodes or number of patients with rejection. Some studies did not specify biopsy-proven rejection to define acute rejection episodes. Only <LINK REF="STD-Hernandez-2002" TYPE="STUDY">Hernandez 2002</LINK> provided unpublished data on biopsy-proven CNI toxicity, whereas in <LINK REF="STD-Bennett-_x0028_low_x0029_-1995" TYPE="STUDY">Bennett (low) 1995</LINK> it was physician-diagnosed. Cardiovascular events were not a primary outcome measure for any of the included studies but data on cardiovascular death could be obtained from the reported cause of death. Adverse effects were not quantified but merely stated if present. Some studies reported drop-out rates from non-compliance but no standard quality of life assessment was used. The method of reporting kidney function was inconsistent, with some reports using SCr and CrCl, while others used nuclear GFR (methodology also varied e.g. EDTA, iothalamate, DTPA, inulin). Where data for different time points were available, only data at the latest follow-up was analysed.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<P>A total of 48 studies did not meet our inclusion criteria and were excluded (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). The main reasons for exclusion were:</P>
<UL>
<LI>Not randomised: 40 studies</LI>
<LI>Wrong population: 1 study</LI>
<LI>Wrong intervention: 5 studies</LI>
<LI>Other: 2 studies (full-text publication not available; crossover study with no outcomes of interest reported or available)</LI>
</UL>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<P>All studies were small and had variable methodology (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). </P>
<ALLOCATION MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<P>Random sequence generation was judged to be at low risk of bias in one study (<LINK REF="STD-Busnach-1998" TYPE="STUDY">Busnach 1998</LINK>) and unclear in the remaining 14 studies.</P>
<P>Allocation concealment was judged to be at ow risk of bias in two studies (<LINK REF="STD-Busnach-1998" TYPE="STUDY">Busnach 1998</LINK>; <LINK REF="STD-Kooijmans_x002d_Coutinho-1996" TYPE="STUDY">Kooijmans-Coutinho 1996</LINK>) and unclear in the remaining 13 studies.</P>
<P>Intention-to-treat analysis was not always explicitly stated but was apparent in 10 studies (<LINK REF="STD-Busnach-1998" TYPE="STUDY">Busnach 1998</LINK>; <LINK REF="STD-Castro-1997" TYPE="STUDY">Castro 1997</LINK>; <LINK REF="STD-Homan-van-der-Heide-1990a" TYPE="STUDY">Homan van der Heide 1990a</LINK>; <LINK REF="STD-Homan-van-der-Heide-1992" TYPE="STUDY">Homan van der Heide 1992</LINK>; <LINK REF="STD-Homan-van-der-Heide-1993" TYPE="STUDY">Homan van der Heide 1993</LINK>; <LINK REF="STD-Kooijmans_x002d_Coutinho-1996" TYPE="STUDY">Kooijmans-Coutinho 1996</LINK>; <LINK REF="STD-Rodriguez-1997" TYPE="STUDY">Rodriguez 1997</LINK>; <LINK REF="STD-Santos-2000" TYPE="STUDY">Santos 2000</LINK>; <LINK REF="STD-Schut-1992a" TYPE="STUDY">Schut 1992a</LINK>; <LINK REF="STD-Schut-1992b" TYPE="STUDY">Schut 1992b</LINK>; <LINK REF="STD-Yoa-1994" TYPE="STUDY">Yoa 1994</LINK>).</P>
</ALLOCATION>
<BLINDING MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<P>Eight studies were judged to be at low risk of performance bias (<LINK REF="STD-Bennett-_x0028_high_x0029_-1995" TYPE="STUDY">Bennett (high) 1995</LINK>; <LINK REF="STD-Bennett-_x0028_low_x0029_-1995" TYPE="STUDY">Bennett (low) 1995</LINK>; <LINK REF="STD-Busnach-1998" TYPE="STUDY">Busnach 1998</LINK>; <LINK REF="STD-Hernandez-2002" TYPE="STUDY">Hernandez 2002</LINK>; <LINK REF="STD-Homan-van-der-Heide-1990a" TYPE="STUDY">Homan van der Heide 1990a</LINK>; <LINK REF="STD-Homan-van-der-Heide-1990b" TYPE="STUDY">Homan van der Heide 1990b</LINK>; <LINK REF="STD-Homan-van-der-Heide-1992" TYPE="STUDY">Homan van der Heide 1992</LINK>; <LINK REF="STD-Homan-van-der-Heide-1993" TYPE="STUDY">Homan van der Heide 1993</LINK>; <LINK REF="STD-Kooijmans_x002d_Coutinho-1996" TYPE="STUDY">Kooijmans-Coutinho 1996</LINK>) (using fish flavour or similar capsules). Three studies were judge to be at high risk of bias (<LINK REF="STD-Berthoux-1992" TYPE="STUDY">Berthoux 1992</LINK>; <LINK REF="STD-Castro-1997" TYPE="STUDY">Castro 1997</LINK>; <LINK REF="STD-Maachi-1995" TYPE="STUDY">Maachi 1995</LINK>), and four studies were judged to be unclear (<LINK REF="STD-Rodriguez-1997" TYPE="STUDY">Rodriguez 1997</LINK>; <LINK REF="STD-Santos-2000" TYPE="STUDY">Santos 2000</LINK>; <LINK REF="STD-Schut-1992a" TYPE="STUDY">Schut 1992a</LINK>; <LINK REF="STD-Schut-1992b" TYPE="STUDY">Schut 1992b</LINK>; <LINK REF="STD-Yoa-1994" TYPE="STUDY">Yoa 1994</LINK>)</P>
<P>Three studies were judged to be at low risk of detection bias (<LINK REF="STD-Busnach-1998" TYPE="STUDY">Busnach 1998</LINK>; <LINK REF="STD-Hernandez-2002" TYPE="STUDY">Hernandez 2002</LINK>; <LINK REF="STD-Kooijmans_x002d_Coutinho-1996" TYPE="STUDY">Kooijmans-Coutinho 1996</LINK>); two were judged to be at high risk of bias (<LINK REF="STD-Berthoux-1992" TYPE="STUDY">Berthoux 1992</LINK>; <LINK REF="STD-Castro-1997" TYPE="STUDY">Castro 1997</LINK>), and the remaining 10 studies were judged to be unclear (<LINK REF="STD-Bennett-_x0028_high_x0029_-1995" TYPE="STUDY">Bennett (high) 1995</LINK>; <LINK REF="STD-Bennett-_x0028_low_x0029_-1995" TYPE="STUDY">Bennett (low) 1995</LINK>; <LINK REF="STD-Homan-van-der-Heide-1990a" TYPE="STUDY">Homan van der Heide 1990a</LINK>; <LINK REF="STD-Homan-van-der-Heide-1990b" TYPE="STUDY">Homan van der Heide 1990b</LINK>; <LINK REF="STD-Homan-van-der-Heide-1992" TYPE="STUDY">Homan van der Heide 1992</LINK>; <LINK REF="STD-Homan-van-der-Heide-1993" TYPE="STUDY">Homan van der Heide 1993</LINK>; <LINK REF="STD-Maachi-1995" TYPE="STUDY">Maachi 1995</LINK>; <LINK REF="STD-Rodriguez-1997" TYPE="STUDY">Rodriguez 1997</LINK>; <LINK REF="STD-Santos-2000" TYPE="STUDY">Santos 2000</LINK>; <LINK REF="STD-Schut-1992a" TYPE="STUDY">Schut 1992a</LINK>; <LINK REF="STD-Schut-1992b" TYPE="STUDY">Schut 1992b</LINK>; <LINK REF="STD-Yoa-1994" TYPE="STUDY">Yoa 1994</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<P>Studies of three months or less showed complete follow-up of patients, with the exception of <LINK REF="STD-Homan-van-der-Heide-1990b" TYPE="STUDY">Homan van der Heide 1990b</LINK> (14% lost to follow-up). In studies lasting longer than six months, patients lost to follow-up ranged from 0% to 32%. Eight studies were judged to be at low risk of attrition bias (<LINK REF="STD-Busnach-1998" TYPE="STUDY">Busnach 1998</LINK>; <LINK REF="STD-Castro-1997" TYPE="STUDY">Castro 1997</LINK>; <LINK REF="STD-Homan-van-der-Heide-1990a" TYPE="STUDY">Homan van der Heide 1990a</LINK>; <LINK REF="STD-Homan-van-der-Heide-1992" TYPE="STUDY">Homan van der Heide 1992</LINK>; <LINK REF="STD-Kooijmans_x002d_Coutinho-1996" TYPE="STUDY">Kooijmans-Coutinho 1996</LINK>; <LINK REF="STD-Santos-2000" TYPE="STUDY">Santos 2000</LINK>; <LINK REF="STD-Schut-1992a" TYPE="STUDY">Schut 1992a</LINK>; <LINK REF="STD-Schut-1992b" TYPE="STUDY">Schut 1992b</LINK>; <LINK REF="STD-Yoa-1994" TYPE="STUDY">Yoa 1994</LINK>); one study was judge to be at high risk of bias (<LINK REF="STD-Bennett-_x0028_high_x0029_-1995" TYPE="STUDY">Bennett (high) 1995</LINK>; <LINK REF="STD-Bennett-_x0028_low_x0029_-1995" TYPE="STUDY">Bennett (low) 1995</LINK>); and the remaining six studies were judged to be at unclear risk (<LINK REF="STD-Berthoux-1992" TYPE="STUDY">Berthoux 1992</LINK>; <LINK REF="STD-Hernandez-2002" TYPE="STUDY">Hernandez 2002</LINK>; <LINK REF="STD-Homan-van-der-Heide-1990b" TYPE="STUDY">Homan van der Heide 1990b</LINK>; <LINK REF="STD-Homan-van-der-Heide-1993" TYPE="STUDY">Homan van der Heide 1993</LINK>; <LINK REF="STD-Maachi-1995" TYPE="STUDY">Maachi 1995</LINK>; <LINK REF="STD-Rodriguez-1997" TYPE="STUDY">Rodriguez 1997</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<P>Five studies were judged to be at low risk of reporting bias (<LINK REF="STD-Bennett-_x0028_high_x0029_-1995" TYPE="STUDY">Bennett (high) 1995</LINK>; <LINK REF="STD-Bennett-_x0028_low_x0029_-1995" TYPE="STUDY">Bennett (low) 1995</LINK>; <LINK REF="STD-Busnach-1998" TYPE="STUDY">Busnach 1998</LINK>; <LINK REF="STD-Hernandez-2002" TYPE="STUDY">Hernandez 2002</LINK>; <LINK REF="STD-Kooijmans_x002d_Coutinho-1996" TYPE="STUDY">Kooijmans-Coutinho 1996</LINK>; <LINK REF="STD-Santos-2000" TYPE="STUDY">Santos 2000</LINK>), nine studies were judged to be at high risk of bias (<LINK REF="STD-Berthoux-1992" TYPE="STUDY">Berthoux 1992</LINK>; <LINK REF="STD-Castro-1997" TYPE="STUDY">Castro 1997</LINK>; <LINK REF="STD-Homan-van-der-Heide-1990a" TYPE="STUDY">Homan van der Heide 1990a</LINK>; <LINK REF="STD-Homan-van-der-Heide-1990b" TYPE="STUDY">Homan van der Heide 1990b</LINK>; <LINK REF="STD-Homan-van-der-Heide-1992" TYPE="STUDY">Homan van der Heide 1992</LINK>; <LINK REF="STD-Homan-van-der-Heide-1993" TYPE="STUDY">Homan van der Heide 1993</LINK>; <LINK REF="STD-Rodriguez-1997" TYPE="STUDY">Rodriguez 1997</LINK>; <LINK REF="STD-Schut-1992a" TYPE="STUDY">Schut 1992a</LINK>; <LINK REF="STD-Schut-1992b" TYPE="STUDY">Schut 1992b</LINK>; <LINK REF="STD-Yoa-1994" TYPE="STUDY">Yoa 1994</LINK>), and one study was unclear (<LINK REF="STD-Maachi-1995" TYPE="STUDY">Maachi 1995</LINK>).</P>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<SUBSECTION>
<HEADING LEVEL="3">Fish oil versus control</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">All-cause mortality</HEADING>
<P>There were six deaths in 12 studies where survival information was available (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> (12 studies, 645 participants): RR 1.65, 95% CI 0.34 to 8.10; I<SUP>2</SUP> = 0%). Deaths were limited to three studies (<LINK REF="STD-Busnach-1998" TYPE="STUDY">Busnach 1998</LINK>; <LINK REF="STD-Homan-van-der-Heide-1993" TYPE="STUDY">Homan van der Heide 1993</LINK>; <LINK REF="STD-Kooijmans_x002d_Coutinho-1996" TYPE="STUDY">Kooijmans-Coutinho 1996</LINK>). Of the six deaths, there were three deaths in each of the fish oil and control groups. All patients died with a functioning graft. The cause of deaths were:</P>
<UL>
<LI>Fish oil group - intestinal infarction (1), haemorrhagic shock post-removal of polycystic native kidney (1), not specified (1)</LI>
<LI>Control group - myocardial infarction (1), not specified (2).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Graft loss</HEADING>
<P>Twelve studies reported data on graft survival. Two studies in the short-course and five studies in the long-course reported one or more graft loss events. Graft survival was not affected by fish oil (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK> (12 studies, 640 participants): RR 0.91, 95% CI 0.51 to 1.63; participants = 640; studies = 12; I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Acute rejection</HEADING>
<P>Nine studies contained data on acute rejection but data was only pooled from the eight studies reporting the proportion of patients with rejection as a dichotomous outcome within the study period. Pooled data from three short-course and five long-course studies showed no significant difference in acute rejection (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> (8 studies, 482 participants): RR 1.00, 95% CI 0.80 to 1.25; I<SUP>2</SUP> = 0%). There was also no significant difference between short-course (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>.1(3 studies, 197 participants): RR 1.21, 95% CI 0.82 to 1.79; I<SUP>2</SUP> = 1%) and long-course (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>.2 (5 studies, 285 participants): RR 0.92, 95% CI 0.70 to 1.20; I<SUP>2</SUP> = 0%) subgroups. However <LINK REF="STD-Homan-van-der-Heide-1993" TYPE="STUDY">Homan van der Heide 1993</LINK> found less rejection episodes in the fish oil group at 12 months (8 versus 20, P = 0.029). The largest difference occurred in the second and third months after transplantation (1 versus 9, P = 0.016).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Calcineurin inhibitor toxicity</HEADING>
<P>
<LINK REF="STD-Hernandez-2002" TYPE="STUDY">Hernandez 2002</LINK> reported biopsy-proven CNI toxicity. In this three-month study, there was no significant difference between fish oil and control (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK> (1 study, 90 participants): RR 1.19, 95% CI 0.56 to 2.51).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Calcineurin inhibitor levels</HEADING>
<P>A <I>post-hoc </I>analysis of CNI levels was performed to look for any potential differences in CNI levels between the fish oil and control groups. No significant difference was detected in the six studies reporting trough CSA (C<SUB>o</SUB>) levels at the end of the studies (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK> (6 studies, 275 participants): MD 4.25 ng/mL, 95% CI -11.57 to 20.07; I<SUP>2</SUP> = 17%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cardiovascular events</HEADING>
<P>None of the studies specifically reported myocardial infarction, stroke or cardiovascular death. Three studies had data on myocardial infarction (<LINK REF="STD-Bennett-_x0028_low_x0029_-1995" TYPE="STUDY">Bennett (low) 1995</LINK>; <LINK REF="STD-Homan-van-der-Heide-1993" TYPE="STUDY">Homan van der Heide 1993</LINK>; <LINK REF="STD-Kooijmans_x002d_Coutinho-1996" TYPE="STUDY">Kooijmans-Coutinho 1996</LINK>), with only one event in the fish oil and control groups each. Myocardial infarction was not a pre-specified end-point in these studies but was reported as a reason why patients were not evaluated at the end of the study. One study noted no stroke events (<LINK REF="STD-Bennett-_x0028_low_x0029_-1995" TYPE="STUDY">Bennett (low) 1995</LINK>). Cardiovascular causes of death could be gleaned from the description of the causes of death in some studies. However, events were too infrequent for a reliable estimate to be made.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects</HEADING>
<P>None of the included studies quantitatively reported rates of adverse effects. Reported adverse effects are presented in <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>: <I>Fish oil versus control: adverse effects</I>. Two studies reported no adverse effects (<LINK REF="STD-Bennett-_x0028_low_x0029_-1995" TYPE="STUDY">Bennett (low) 1995</LINK>; <LINK REF="STD-Santos-2000" TYPE="STUDY">Santos 2000</LINK>). Seven studies reported a fishy aftertaste as the most common problem, with one (<LINK REF="STD-Hernandez-2002" TYPE="STUDY">Hernandez 2002</LINK>) reporting a fishy aftertaste in 70% of patients. Gastrointestinal upset such as bloating, nausea, vomiting and diarrhoea was reported in four studies (<LINK REF="STD-Berthoux-1992" TYPE="STUDY">Berthoux 1992</LINK>; <LINK REF="STD-Homan-van-der-Heide-1993" TYPE="STUDY">Homan van der Heide 1993</LINK>; <LINK REF="STD-Kooijmans_x002d_Coutinho-1996" TYPE="STUDY">Kooijmans-Coutinho 1996</LINK>; <LINK REF="STD-Rodriguez-1997" TYPE="STUDY">Rodriguez 1997</LINK>). Significant bleeding problems were not encountered.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Compliance and satisfaction</HEADING>
<P>Reporting of patient compliance was variable, with attempts at monitoring non-compliance having included pill counting, self-monitoring and biochemical measurements. The biochemical assays have included measuring plasma EPA as a percentage of total fatty acids (<LINK REF="STD-Bennett-_x0028_low_x0029_-1995" TYPE="STUDY">Bennett (low) 1995</LINK>) and analyses of plasma cholesterol esters (<LINK REF="STD-Homan-van-der-Heide-1993" TYPE="STUDY">Homan van der Heide 1993</LINK>). However, these data could not be pooled due to the lack of a uniform and consistent measure of compliance among the studies. Hence, only data regarding significant non-compliance resulting in patient drop-out was sufficient for analysis. Information on such non-compliant patients was available in eight RCTs (two short-course and six long-course) (<LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK> (8 studies, 412 participants): RR 1.88, 95% CI 0.56 to 6.26; I<SUP>2</SUP> = 0%). Patient satisfaction was not assessed quantitatively or qualitatively in any of the included studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Kidney function</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Serum creatinine</HEADING>
<P>Overall SCr was significantly lower in the fish oil group compared to control (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK> (5 studies, 237 participants): MD -30.63 µmol/L, 95% CI -59.74 to -1.53; I<SUP>2</SUP> = 88%). In the subgroup analysis, this was only significant in the long-course group (<LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>.2 (4 studies, 157 participants): MD -37.41 µmol/L, 95% CI -69.89 to -4.94; I<SUP>2</SUP> = 82%). There was also significant heterogeneity among the studies.</P>
<P>Three other studies used median values, which were not pooled (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Two (<LINK REF="STD-Homan-van-der-Heide-1990a" TYPE="STUDY">Homan van der Heide 1990a</LINK>; <LINK REF="STD-Homan-van-der-Heide-1992" TYPE="STUDY">Homan van der Heide 1992</LINK>) showed no significant difference between fish oil and control, while another (<LINK REF="STD-Homan-van-der-Heide-1990b" TYPE="STUDY">Homan van der Heide 1990b</LINK>) found a small difference favouring fish oil (120 &#956;mol/L versus 147 &#956;mol/L; P &lt; 0.05).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Creatinine clearance</HEADING>
<P>Overall there was no significant difference in CrCl between fish oil and control (<LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK> (8 studies, 353 participants): MD -0.61 mL/min, 95% CI -5.67 to 4.45; I<SUP>2</SUP> = 0%). There was also no difference in subgroup analyses.</P>
<P>Of the three studies reporting median values, two (<LINK REF="STD-Homan-van-der-Heide-1990a" TYPE="STUDY">Homan van der Heide 1990a</LINK>; <LINK REF="STD-Homan-van-der-Heide-1992" TYPE="STUDY">Homan van der Heide 1992</LINK>) found no significant difference however (<LINK REF="STD-Homan-van-der-Heide-1990b" TYPE="STUDY">Homan van der Heide 1990b</LINK>) found a better CrCl in the fish oil group (88.4 mL/min versus 79.5 mL/min; P &lt; 0.05).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Glomerular filtration rate</HEADING>
<P>Overall there was no significant difference in GFR between fish oil and control (<LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK> (9 studies, 343 participants): MD 2.18 mL/min, 95% CI -2.90 to 7.26; I<SUP>2</SUP> = 25%).</P>
<P>Of the three studies reporting median GFR, <LINK REF="STD-Homan-van-der-Heide-1990a" TYPE="STUDY">Homan van der Heide 1990a</LINK> and <LINK REF="STD-Homan-van-der-Heide-1990b" TYPE="STUDY">Homan van der Heide 1990b</LINK> found no difference between the two groups while <LINK REF="STD-Homan-van-der-Heide-1993" TYPE="STUDY">Homan van der Heide 1993</LINK> reported an improved GFR with fish oil (53 mL/min versus 40 mL/min; P = 0.038).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blood pressure</HEADING>
<P>Systolic pressure, diastolic pressure and MAP were reported variably among the included studies. Generally, MAP was defined as systolic + (2 x diastolic)/3.</P>
<P>Concomitant antihypertensive medication use was poorly reported. Therefore, data on antihypertensive medication use could not be analysed.</P>
<SUBSECTION>
<HEADING LEVEL="5">Systolic/diastolic blood pressure</HEADING>
<P>There was no significant difference in systolic blood pressure between fish oil and control (<LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK> (4 studies, 200 participants): MD 2.45 mm Hg, 95% CI -5.93 to 10.83; I<SUP>2</SUP> = 66%); significant heterogeneity was evident. There was a modest but significant reduction in diastolic blood pressure in the fish oil group (<LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK> (4 studies, 200 participants): MD -4.53 mm Hg, 95% CI -7.60 to -1.45; I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Mean arterial blood pressure</HEADING>
<P>There was a non-significant reduction in MAP in fish oil-treated patients (<LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK> (4 studies, 138 participant): MD -3.45 mm Hg, 95% CI -7.43 to 0.53; I<SUP>2</SUP> = 0%).</P>
<P>Of the four studies reporting median values (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>), three (<LINK REF="STD-Homan-van-der-Heide-1990a" TYPE="STUDY">Homan van der Heide 1990a</LINK>; <LINK REF="STD-Homan-van-der-Heide-1990b" TYPE="STUDY">Homan van der Heide 1990b</LINK>; <LINK REF="STD-Homan-van-der-Heide-1992" TYPE="STUDY">Homan van der Heide 1992</LINK>) found no difference in MAP between fish oil and control groups, while one (<LINK REF="STD-Homan-van-der-Heide-1993" TYPE="STUDY">Homan van der Heide 1993</LINK>) found a lower MAP with fish oil (103 mm Hg versus 118 mm Hg; P = 0.0011).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Serum lipids</HEADING>
<P>The full lipid profile was not reported in all the included studies, hence variable patient numbers were available for each parameter for analysis.</P>
<SUBSECTION>
<HEADING LEVEL="5">Total cholesterol</HEADING>
<P>There was no significant difference in TC between fish oil and control (<LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK> (6 studies, 260 participants): MD -0.11 mmol/L, 95% CI -0.36 to 0.14; I<SUP>2</SUP> = 26%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">LDL cholesterol</HEADING>
<P>There was no significant difference in LDL cholesterol between the two groups (<LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>.2 (3 studies, 120 participants): MD 0.30 mmol/L, 95% CI -0.62 to 1.22; I<SUP>2</SUP> = 93%). The high heterogeneity was attributed to <LINK REF="STD-Bennett-_x0028_low_x0029_-1995" TYPE="STUDY">Bennett (low) 1995</LINK>, however removal of this study from the analysis did not change the significance (MD -0.10 mmol/L, 95% CI -0.40 to 0.20; I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">HDL cholesterol</HEADING>
<P>Overall there was no significant difference in HDL cholesterol between fish oil and control (<LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK> (6 studies, 258 participants): MD 0.09 mmol/L, 95% CI -0.01 to 0.19; I<SUP>2</SUP> = 59%). Subgroup analysis showed long-course fish oil had a small but significant increase in HDL compared to control (<LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>.2 (5 studies, 178 participants): MD 0.12 mmol/L, 95% CI 0.03 to 0.21; I<SUP>2</SUP> = 47%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Triglycerides</HEADING>
<P>Overall there was no significant difference in triglycerides between fish oil and control (<LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK> (MD -0.26 mmol/L, 95% CI -0.58 to 0.05; participants = 260; studies = 6; I<SUP>2</SUP> = 73%). There was substantial heterogeneity which could not be attributed to any one study.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Fish oil versus statins</HEADING>
<P>Two studies compared fish oil with statins. <LINK REF="STD-Castro-1997" TYPE="STUDY">Castro 1997</LINK> compared the effects of simvastatin (10 mg/d) with fish oil (6 g/d) (50% EPA/DHA) in 43 patients over three months. <LINK REF="STD-Rodriguez-1997" TYPE="STUDY">Rodriguez 1997</LINK> compared fish oil (2 g/d) (30% EPA/DHA) with lovastatin (20 mg/d) in 34 patients over three months.</P>
<P>Total cholesterol was higher in the fish oil group but this was not significant (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> (2 studies, 75 participants): MD 0.36 mmol/L, 95% CI -0.10 to 0.82; I<SUP>2</SUP> = 0%).</P>
<P>LDL cholesterol was higher in the fish oil group but this was not significant (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK> (2 studies, 75 participants): MD 0.41 mmol/L, 95% CI -0.06 to 0.88; I<SUP>2</SUP> = 0%).</P>
<P>HDL cholesterol was lower in the fish oil group but this was not significant (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK> (2 studies, 75 participants): MD -0.18 mmol/L, 95% CI -0.39 to 0.02; I<SUP>2</SUP> = 44%).</P>
<P>Triglycerides were higher in the fish oil group but this was not significant (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK> (2 studies, 75 participants): MD 0.18 mmol/L, 95% CI -0.18 to 0.55; I<SUP>2</SUP> = 0%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Patient subgroups</HEADING>
<P>Subgroup analysis could only be performed dividing studies into short (three months or less) and long (greater than three months) courses of treatment. The only difference found was the better HDL result in the long-course as described. When we re-analysed the data using the different patient numbers for the continuous variables reported in <LINK REF="STD-Hernandez-2002" TYPE="STUDY">Hernandez 2002</LINK> (see <I>Table of included studies</I>), i.e. 45/40 versus 42/38, no significant change in the any of the results were found.</P>
<P>The results for those studies that only provided median and range for short- and long-course treatment are presented in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>: <I>Short course fish oil versus control/miscellaneous</I> and <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>: <I>Long course fish oil versus control/miscellaneous.</I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Fixed effects model</HEADING>
<P>This model gave different results for the following outcomes.</P>
<SUBSECTION>
<HEADING LEVEL="4">Fish oil versus controls</HEADING>
<UL>
<LI>LDL cholesterol was higher with fish oil treatment (MD 0.49 mmol/L, 95% CI 0.27 to 0.70; I<SUP>2</SUP> = 93%).</LI>
<LI>HDL cholesterol was higher with fish oil treatment (MD 0.14 mmol/L, 95% CI 0.10 to 0.19; I<SUP>2</SUP> = 59%).</LI>
<LI>Triglyceride was lower with fish oil treatment (MD -0.43 mmol/L, 95% CI -0.54 to -0.32; I<SUP>2</SUP> = 73%).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Fish oil versus statins</HEADING>
<UL>
<LI>HDL cholesterol was higher with statin treatment (MD -0.18 mmol/L, 95% CI -0.34 to -0.03; P = 0.02).</LI>
</UL>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2016-04-04 14:55:13 +1000" MODIFIED_BY="Narelle Willis">
<SUMMARY_OF_RESULTS MODIFIED="2016-04-04 11:38:59 +1000" MODIFIED_BY="Narelle Willis">
<P>In kidney transplant recipients on CSA-based immunosuppression, fish oil treatment has no effect on patient survival, graft survival, acute rejection and CNI toxicity. There was a modest lowering of diastolic blood pressure, and increased HDL in patients treated for six months or more. Clinical events were small and whilst an effect was not seen, a benefit cannot be ruled out by this analysis. The data on cardiovascular events was particularly limited as these were often not pre-specified end points. Where event data is reported, it has been used, but should be interpreted with caution because it is unclear whether cardiovascular event data was carefully collected for all patients.</P>
<P>The lowering of diastolic blood pressure was a consistent finding, with no heterogeneity. No data on antihypertensive medication use was available to allow stratification by antihypertensives in this analysis to explore the specific influences of calcium-channel or renin-angiotensin antagonists. Calcium channel blockers are known to reduce CSA mediated vasoconstriction, while renin-angiotensin inhibitors are capable of affecting GFR. There was evidence for heterogeneity in the finding of a higher HDL in the long course group (I<SUP>2</SUP> = 47%). The discrepancy between the I<SUP>2</SUP> and the Chi<SUP>2</SUP> test for heterogeneity (Chi<SUP>2</SUP> = 7.53, P = 0.11) reflects the lower power of the latter test to detect true heterogeneity when the number of studies is low (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). Such heterogeneity may arise from the use of different fish oil doses and duration, and different methods in measuring serum lipids.</P>
<P>There was no effect on kidney function and a discrepancy existed between serum creatinine and the other measures of kidney function. While SCr appeared lower with fish oil, there was substantial heterogeneity (I<SUP>2</SUP> = 88%; Chi<SUP>2</SUP> = 33.96, P &lt; 0.00001). In addition to some of the potential sources listed above, heterogeneity between studies may have been impacted by the differing methods of measuring serum creatinine. Given that nuclear GFR is a better measure of kidney function in the transplant population, this is the more important measure on which to base conclusions. A fishy aftertaste was the most common adverse effect followed by gastrointestinal upset. Bleeding did not seem to be a problem despite the potential antithrombotic effect of fish oil. There was a suggestion of poorer compliance with fish oil compared to control but it was not statistically significant and did not significantly effect drop-out rates. The overall deficiencies in patient blinding made the comparisons of adverse effects and compliance difficult to assess. Patient satisfaction or quality of life assessments were not performed by any of the studies. With the exception of HDL cholesterol, there was no difference in short versus longer course treatment. There was also no difference in early versus late introduction of fish oils.</P>
<P>The fixed effects model showed different results for the lipid outcomes of LDL, HDL and triglycerides. This model is based on the assumption that the true effect of treatment (in both magnitude and direction) is the same value in every study, that there is no statistical heterogeneity, and that the observed differences are due to chance. However, there was significant heterogeneity among the studies included for these variables, with an I<SUP>2</SUP> ranging from 44% to 94%. As the cause of heterogeneity is not readily apparent and the typical treatment effect is not known, the random effects model appears more applicable. However, it does introduce uncertainty as to whether a true effect may be missed.</P>
</SUMMARY_OF_RESULTS>
<QUALITY_OF_EVIDENCE MODIFIED="2016-04-04 10:41:41 +1000" MODIFIED_BY="Narelle Willis">
<P>There are several limitations of this review. Many of the studies were of poor or average quality due to small patient numbers, inadequate randomisation or allocation concealment, and lack of blinding (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). Some data from one group publishing several studies were expressed in a way that could not be incorporated in our analysis (<LINK REF="STD-Homan-van-der-Heide-1990a" TYPE="STUDY">Homan van der Heide 1990a</LINK>; <LINK REF="STD-Homan-van-der-Heide-1990b" TYPE="STUDY">Homan van der Heide 1990b</LINK>; <LINK REF="STD-Homan-van-der-Heide-1992" TYPE="STUDY">Homan van der Heide 1992</LINK>; <LINK REF="STD-Homan-van-der-Heide-1993" TYPE="STUDY">Homan van der Heide 1993</LINK>). There were several potential sources of heterogeneity, including differing doses of fish oils, duration of treatment, and timing of initiation of treatment. The studies were too small for these issues to be adequately explored through subgroup analyses. The majority of studies were conducted in the early to mid-1990s, prior to the common use of tacrolimus. Therefore, differences between CSA and tacrolimus could not be examined.</P>
</QUALITY_OF_EVIDENCE>
<AGREEMENT MODIFIED="2016-04-04 14:55:13 +1000" MODIFIED_BY="Narelle Willis">
<P>A recent study in rats has demonstrated that DHA can increase the bioavailability of CSA possibly through inhibition of intestinal CYP 3A enzyme responsible for the first pass metabolism (<LINK REF="REF-Hirunpanich-2006" TYPE="REFERENCE">Hirunpanich 2006</LINK>). In our post-hoc analysis, we found that fish oil did not effect CSA levels. However, there are limitations to this finding. Firstly, the doses of CSA were not kept constant, as it is usual practice to adjust doses according to levels. Secondly, the studies included in the analysis where a benefit was significant were different to those which reported CSA levels. Thirdly, the use of a single trough level to indicate CNI exposure has limitations. The question whether fish oil influences CSA levels is difficult to answer as all but one of the included studies were not set up to assess CSA pharmacokinetics. In the only study to do so, fish oil treated patients had a higher maximum serum concentration (C<SUB>max</SUB>) than control patients but the area under curve (AUC) was not significantly higher despite similar trough levels (<LINK REF="STD-Busnach-1998" TYPE="STUDY">Busnach 1998</LINK>). As AUC is probably a better indicator of overall drug exposure, the higher C<SUB>max</SUB> may not necessarily translate to increased CNI toxicity in the long term. However, effects on other outcomes such as blood pressure are theoretically possible but the lower diastolic blood pressure found in our analysis suggests that this positive effect of fish oil may have outweighed any possible adverse pharmacokinetic interactions, or that CNI dose adjustments have compensated for this possible effect.</P>
<P>Overall, this analysis agrees with a published meta-analysis of fish oil supplementation in kidney transplantation (<LINK REF="REF-Tatsioni-2005" TYPE="REFERENCE">Tatsioni 2005</LINK>), which demonstrated no difference in clinical outcomes except a modest reduction in triglycerides. The same studies were included in that analysis, however we have included CrCl data from the study by <LINK REF="STD-Yoa-1994" TYPE="STUDY">Yoa 1994</LINK> which was only reported in an earlier abstract. They included one study that we excluded (<LINK REF="STD-Urakaze-1989" TYPE="STUDY">Urakaze 1989</LINK>) that reported rejection episodes, GFR, lipid and blood pressure data. We excluded the latter study as it was unclear which patients received CSA and which did not. This study was included in their analysis of triglycerides, which found a significant lowering by fish oils whereas we did not. These authors also used different statistical methodology for continuous variables. Rather than calculating MD, these authors calculated the net change in triglyceride for each study (<LINK REF="REF-Bonis-2005" TYPE="REFERENCE">Bonis 2005</LINK>; <LINK REF="REF-Tatsioni-2005" TYPE="REFERENCE">Tatsioni 2005</LINK>) and evaluated the aggregate. Although they appear to include the two studies comparing fish oil to statins in their publication (<LINK REF="REF-Tatsioni-2005" TYPE="REFERENCE">Tatsioni 2005</LINK>), they do separate these from the placebo comparison in a separate publication (<LINK REF="REF-Bonis-2005" TYPE="REFERENCE">Bonis 2005</LINK>).</P>
<P>Systematic reviews of n-3 PUFAs in the general population have demonstrated conflicting results. A reduction in triglycerides, increased HDL and increased LDL has been found with n-3 PUFA supplementation (<LINK REF="REF-Balk-2006" TYPE="REFERENCE">Balk 2006</LINK>) but a systematic review by <LINK REF="REF-Hooper-2006" TYPE="REFERENCE">Hooper 2006</LINK> showed no reduction in mortality or cardiovascular events. In this review, studies of ALA, EPA and DHA were pooled together, and composite end-points were analysed. In the review by <LINK REF="REF-Wang-2006" TYPE="REFERENCE">Wang 2006</LINK> fish oil reduced rates of all-cause mortality, cardiac and sudden death, and possibly stroke. These authors analysed ALA separately from fish-derived n-3 PUFAs (EPA/DHA) and found that ALA was not associated with these positive findings, suggesting that ALA is sufficiently different from EPA/DHA to be analysed separately. We did not include studies using ALA in our analysis.</P>
<P>An important issue in these studies is the dose of fish oil used, which varied from 0.6 to 5.4 g/d (EPA + DHA). Active n-3 PUFAs (EPA, DHA) constitute only about 30% to 50% of common fish oil supplements, although higher doses may be available. This, and the duration and timing of treatment, may have contributed to the heterogeneity seen in a number of comparisons. There is some suggestion of a dose-dependent effect of fish oil. In the review by <LINK REF="REF-Balk-2006" TYPE="REFERENCE">Balk 2006</LINK> there was an association between the dose of fish oil and reduction in TG. In our analysis, only one study directly compared two different doses (2.7 g/d and 5.4 g/d of EPA/DHA) and found no difference with the higher dose (<LINK REF="STD-Bennett-_x0028_high_x0029_-1995" TYPE="STUDY">Bennett (high) 1995</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2016-03-24 18:03:02 +1100" MODIFIED_BY="Narelle S Willis">
<IMPLICATIONS_PRACTICE MODIFIED="2016-03-24 10:46:25 +1100" MODIFIED_BY="Narelle S Willis">
<P>There is insufficient evidence from currently available RCTs to recommend fish oil supplementation to improve kidney function, rejection rates, graft survival or patient survival in kidney transplantation. A dose of at least 6 g/d for longer than three months may be useful for improving HDL and lowering diastolic blood pressure. However, the safety and availability of conventional lipid modifying and antihypertensive agents makes fish oil an unlikely first-line choice. Fish oils were well tolerated with only minor adverse effects.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2016-03-24 18:03:02 +1100" MODIFIED_BY="Narelle S Willis">
<P>Clearly, the studies included in this meta-analysis were too small, and the number of events too few to draw conclusions regarding benefit. These questions can only be answered by larger RCTs powered for specific clinical outcomes and of adequate duration. The introduction of non-CNI immunosuppressive protocols (such as those based on sirolimus) means that further studies with these medications are needed to assess the effects of fish oils in this subset of kidney transplant recipients. It is recommended that future RCTs use a higher dose of fish oil to compare to controls, ideally 6 g/d or more. No studies have assessed the benefits fish oil as "add-on" therapy to statins and a subgroup of kidney transplant recipients with recurrent IgA nephropathy may also derive benefit from fish oil treatment and could be evaluated. Further studies on the effect of fish oil on CSA pharmacokinetics may be useful and future studies should report CNI levels (including C<SUB>max</SUB>) and doses, and AUC where possible.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2016-04-04 11:55:32 +1000" MODIFIED_BY="Narelle Willis">
<P>We thank the library staff at Austin Health for their assistance.<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2016-08-15 10:29:14 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Andy KH Lim: none known</LI>
<LI>Karen J Manley: none known</LI>
<LI>Matthew A Roberts: none known</LI>
<LI>Margaret B Fraenkel: none known</LI>
</UL>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2016-04-04 14:52:46 +1000" MODIFIED_BY="Narelle Willis">
<P>AL: researched background, established protocol, performed search and reviewed identified studies, co-author of review<BR/>KM: researched background, established protocol, performed search and reviewed identified studies, co-author of review<BR/>MR: conflict arbitration as independent third author, co-author of review<BR/>MF: project supervisor, proof-reading, editorial comments</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2016-04-04 11:17:18 +1000" MODIFIED_BY="Narelle Willis">
<P>Risk of bias assessment tool has replaced the Quality checklist.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2016-08-15 01:33:10 +0100" MODIFIED_BY="Narelle Willis">
<STUDIES MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<INCLUDED_STUDIES MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<STUDY DATA_SOURCE="MIX" ID="STD-Bennett-_x0028_high_x0029_-1995" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Bennett (high) 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bennett WM, Carpenter CB, Shapiro ME, Strom TB, Hefty D, Tillman M, et al</AU>
<TI>Delayed omega-3 fatty acid supplements in renal transplantation. A double-blind, placebo-controlled study</TI>
<SO>Transplantation</SO>
<YR>1995</YR>
<VL>59</VL>
<NO>3</NO>
<PG>352-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915961"/><IDENTIFIER TYPE="MEDLINE" VALUE="7871564"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2915960"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Bennett-_x0028_low_x0029_-1995" MODIFIED="2014-03-04 10:57:53 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Bennett (low) 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-03-04 10:57:53 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bennett WM, Carpenter CB, Shapiro ME, Strom TB, Hefty D, Tillman M, et al</AU>
<TI>Delayed omega-3 fatty acid supplements in renal transplantation. A double-blind, placebo-controlled study</TI>
<SO>Transplantation</SO>
<YR>1995</YR>
<VL>59</VL>
<NO>3</NO>
<PG>352-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915963"/><IDENTIFIER TYPE="MEDLINE" VALUE="7871564"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2915962"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berthoux-1992" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Berthoux 1992" YEAR="1992">
<REFERENCE MODIFIED="2008-05-13 09:47:12 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berthoux F, Guerrin C, Bertoux P, Alamarine E</AU>
<TI>A randomised trial with omega-3 fatty acid-fish oil (FO) in renal transplants [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1990</YR>
<VL>5</VL>
<NO>8</NO>
<PG>745</PG>
<IDENTIFIERS MODIFIED="2008-05-13 09:47:12 +1000" MODIFIED_BY="Narelle S Willis"><IDENTIFIER MODIFIED="2008-05-13 09:47:12 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00260575"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915965"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Berthoux FC, Guerin C, Burgard G, Berthoux P, Alamartine E</AU>
<TI>One-year randomized controlled trial with omega-3 fatty acid-fish oil in clinical renal transplantation</TI>
<SO>Transplantation Proceedings</SO>
<YR>1992</YR>
<VL>24</VL>
<NO>6</NO>
<PG>2578-82</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915966"/><IDENTIFIER TYPE="MEDLINE" VALUE="1465872"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2915964"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Busnach-1998" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Busnach 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Busnach G, Stragliotto E, Minetti E, Perego A, Brando B, Broggi ML, et al</AU>
<TI>Effect of n-3 polyunsaturated fatty acids on cyclosporine pharmacokinetics in kidney graft recipients: a randomised placebo-controlled study</TI>
<SO>Journal of Nephrology</SO>
<YR>1998</YR>
<VL>11</VL>
<NO>2</NO>
<PG>87-93</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915968"/><IDENTIFIER TYPE="MEDLINE" VALUE="9589380"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-04 14:22:38 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Busnach G, Stragliotto E, Perego A, Brando B, Civati G</AU>
<TI>Cyclosporine pharmacokinetics modifications with n-3 PUFA treatment: a randomized placebo-controlled study in kidney graft recipients [abstract]</TI>
<SO>Nephrology</SO>
<YR>1997</YR>
<VL>3</VL>
<NO>Suppl 1</NO>
<PG>S443</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915969"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2915967"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Castro-1997" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Castro 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Castro R, Queiros J, Fonseca I, Pimentel JP, Henriques AC, Sarmento AM, et al</AU>
<TI>Therapy of post-renal transplantation hyperlipidaemia: comparative study with simvastatin and fish oil</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>10</NO>
<PG>2140-3</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915971"/><IDENTIFIER TYPE="MEDLINE" VALUE="9351079"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2915970"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Hernandez-2002" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Hernandez 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hernandez D, Guerra R, Milena A, Garcia S, Garcia C, Abreu P, et al</AU>
<TI>Dietary fish oil does not influence acute rejection rate and graft survival after renal transplantation a randomized placebo-controlled study</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2002</YR>
<VL>17</VL>
<NO>5</NO>
<PG>897-904</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915973"/><IDENTIFIER TYPE="MEDLINE" VALUE="11981081"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2915972"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Homan-van-der-Heide-1990a" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Homan van der Heide 1990a" YEAR="1990">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Homan van der Heide JJ, Bilo HJ, Donker AJ, Wilmink JM, Sluiter WJ, Tegzess AM</AU>
<TI>Dietary supplementation with fish oil modifies renal reserve filtration capacity in postoperative, cyclosporin A-treated renal transplant recipients</TI>
<SO>Transplant International</SO>
<YR>1990</YR>
<VL>3</VL>
<NO>3</NO>
<PG>171-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915975"/><IDENTIFIER TYPE="MEDLINE" VALUE="2271089"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-16 08:32:27 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Homan van der Heide JJ, Bilo HJG, Tegzess AM, Donker AJM</AU>
<TI>Omega-3 polynsaturated fatty acids improve renal function in renal transplant recipients treated with cyclosporin-A [abstract]</TI>
<SO>Kidney International</SO>
<YR>1989</YR>
<VL>35</VL>
<NO>1</NO>
<PG>516</PG>
<IDENTIFIERS MODIFIED="2016-03-16 08:32:27 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-03-16 08:32:27 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00626077"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915976"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2915974"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Homan-van-der-Heide-1990b" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Homan van der Heide 1990b" YEAR="1990">
<REFERENCE MODIFIED="2014-03-04 10:39:25 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Homan van der Heide JJ, Bilo HJ, Sluiter WJ, Donker AJ, Tegzess AM</AU>
<TI>Dietary fish-oil Improves renal reserve capacity after amino-acid infusion in acute postoperative cyclosporin-treated renal transplant recipients [abstract]</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1990</YR>
<VL>5</VL>
<NO>4</NO>
<PG>308</PG>
<IDENTIFIERS MODIFIED="2014-03-04 10:39:25 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2014-03-04 10:39:25 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00260597"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915978"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Homan van der Heide JJ, Bilo HJ, Tegzess AM, Donker AJ</AU>
<TI>The effects of dietary supplementation with fish oil on renal function in cyclosporine-treated renal transplant recipients</TI>
<SO>Transplantation</SO>
<YR>1990</YR>
<VL>49</VL>
<NO>3</NO>
<PG>523-7</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915979"/><IDENTIFIER TYPE="MEDLINE" VALUE="2316014"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-16 08:33:30 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Homan van der Heide JJ, Bilo HJG, Sluiter WJ, Donker AJM, Tegzess AM</AU>
<TI>Dietary fish oil improves renal reserve filtration capacity (RRFC) after amino acid infusion in ciclosporin-treated renal transplant patients. [abstract]</TI>
<SO>Kidney International</SO>
<YR>1990</YR>
<VL>37</VL>
<NO>1</NO>
<PG>614</PG>
<IDENTIFIERS MODIFIED="2016-03-16 08:33:30 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-03-16 08:33:30 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00615877"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915980"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-03-16 08:34:29 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Homan van der Heide JJ, Bilo HJG, Tegzess AM, Donker AJM</AU>
<TI>Omega-3 polyunsaturated fatty acids improve renal function in renal transplant recipients treated with cyclosporin A [abstract]</TI>
<SO>Kidney International</SO>
<YR>1989</YR>
<VL>35</VL>
<NO>6</NO>
<PG>1432</PG>
<IDENTIFIERS MODIFIED="2016-03-16 08:34:29 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2016-03-16 08:34:29 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00775629"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915981"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2915977"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Homan-van-der-Heide-1992" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Homan van der Heide 1992" YEAR="1992">
<REFERENCE MODIFIED="2016-02-17 13:46:33 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Homan van der Heide J, Bilo HJG, Donker AJM, Wilmink JM, Tegzess AM</AU>
<TI>Better renal function, lower mean arterial pressure (MAP) and less rejection episodes in cyslosporin A (CsA)-treated renal transplant recipients fed dietary fish oil (FO) [abstract]</TI>
<SO>Kidney International</SO>
<YR>1991</YR>
<VL>40</VL>
<NO>5</NO>
<PG>979</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915983"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Homan van der Heide JJ, Bilo HJ, Donker AJ, Wilmink JM, Sluiter WJ, Tegzess AM</AU>
<TI>The effects of dietary supplementation with fish oil on renal function and the course of early postoperative rejection episodes in cyclosporine-treated renal transplant recipients</TI>
<SO>Transplantation</SO>
<YR>1992</YR>
<VL>54</VL>
<NO>2</NO>
<PG>257-63</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915984"/><IDENTIFIER TYPE="MEDLINE" VALUE="1496538"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-02-17 13:47:41 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Homan van der Heide JJ, Bilo HJG, Donker AJM, Wilmink JM, Sluiter WJ, Tegzess AM</AU>
<TI>Dietary fish oil modifies renal function during early postoperative rejection episodes in cyclosporin (CsA) treated renal allograft recipients [abstract]</TI>
<SO>Kidney International</SO>
<YR>1990</YR>
<VL>38</VL>
<NO>6</NO>
<PG>1233</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915985"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2915982"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Homan-van-der-Heide-1993" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Homan van der Heide 1993" YEAR="1993">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Homan van der Heide JJ, Bilo HJ, Donker JM, Wilmink JM, Tegzess AM</AU>
<TI>Effect of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants</TI>
<SO>New England Journal of Medicine</SO>
<YR>1993</YR>
<VL>329</VL>
<NO>11</NO>
<PG>769-73</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915987"/><IDENTIFIER TYPE="MEDLINE" VALUE="8350886"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2915986"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kooijmans_x002d_Coutinho-1996" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Kooijmans-Coutinho 1996" YEAR="1996">
<REFERENCE MODIFIED="2011-03-16 09:47:14 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kooijmans-Coutinho MF, Homan van der Heide JJ, Rischen-Vos J, Hermans J, van Es LA, van der Woude FJ</AU>
<TI>The effects of dietary fish oil in cyclosporine-A treated renal transplant recipients [abstract]</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1994</YR>
<VL>5</VL>
<NO>3</NO>
<PG>1018</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915989"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kooijmans-Coutinho MF, Rischen-Vos J, Hermans J, Arndt JW, van der Woude FJ</AU>
<TI>Dietary fish oil in renal transplant recipients treated with cyclosporin-A: no beneficial effects shown</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>3</NO>
<PG>513-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915990"/><IDENTIFIER TYPE="MEDLINE" VALUE="8704119"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2915988"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maachi-1995" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Maachi 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maachi K, Berthoux P, Burgard G, Alamartine E, Berthoux F</AU>
<TI>Results of a 1-year randomized controlled trial with omega-3 fatty acid fish oil in renal transplantation under triple immunosuppressive therapy</TI>
<SO>Transplantation Proceedings</SO>
<YR>1995</YR>
<VL>27</VL>
<NO>1</NO>
<PG>846-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915992"/><IDENTIFIER TYPE="MEDLINE" VALUE="7879202"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2915991"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodriguez-1997" MODIFIED="2014-03-04 10:58:45 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Rodriguez 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-03-04 10:58:45 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez AP, De Bonis E, Gonzalez-Posada JM, Torres A, Perez L, Dominguez ML, et al</AU>
<TI>Treatment of hyperlipidemia after renal transplantation: Comparative effect of lovastatin and omega-3 fatty acids</TI>
<TO>Tratamiento de la dislipemia postrasplante renal: efecto comparativo de la lovastatina y acidos grasos pliinsaturados omega-3</TO>
<SO>Nefrologia</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>1</NO>
<PG>49-54</PG>
<IDENTIFIERS MODIFIED="2008-05-13 09:49:23 +1000" MODIFIED_BY="Narelle S Willis"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915994"/><IDENTIFIER MODIFIED="2008-05-13 09:49:23 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1997130521"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2915993"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santos-2000" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Santos 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santos J, Queiros J, Silva F, Cabrita A, Rodrigues A, Henriques AC, et al</AU>
<TI>Effects of fish oil in cyclosporine-treated renal transplant recipients</TI>
<SO>Transplantation Proceedings</SO>
<YR>2000</YR>
<VL>32</VL>
<NO>8</NO>
<PG>2605-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915996"/><IDENTIFIER TYPE="MEDLINE" VALUE="11134724"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2915995"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schut-1992a" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Schut 1992a" YEAR="1992">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schut NH, Bilo HJ, Popp-Snijders C, Goedhart PT, Wilmink JM</AU>
<TI>Erythrocyte deformability, endothelin levels, and renal function in cyclosporin-treated renal transplant recipients: effects of intervention with fish oil and corn oil</TI>
<SO>Scandinavian Journal of Clinical &amp; Laboratory Investigation</SO>
<YR>1993</YR>
<VL>53</VL>
<NO>5</NO>
<PG>499-506</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915998"/><IDENTIFIER TYPE="MEDLINE" VALUE="8210973"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schut NH, Hardeman MR, Goedhart PT, Bilo HJ, Wilmink JM</AU>
<TI>Blood viscosity measurements are not sensitive enough to detect changes in erythrocyte deformability in cyclosporin-treated patients and its subsequent reversal with fish and corn oil</TI>
<SO>Clinical Hemorheology</SO>
<YR>1993</YR>
<VL>13</VL>
<NO>4</NO>
<PG>465-72</PG>
<IDENTIFIERS MODIFIED="2008-05-13 09:49:37 +1000" MODIFIED_BY="Narelle S Willis"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2915999"/><IDENTIFIER MODIFIED="2008-05-13 09:49:37 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1993223288"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schut NH, Hardeman MR, Wilmink JM</AU>
<TI>Decrease of erythrocyte deformability in cyclosporine-treated renal transplant patients: correction with fish oil as well as corn oil</TI>
<SO>Transplant International</SO>
<YR>1992</YR>
<VL>5 Suppl 1</VL>
<PG>S536-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916000"/><IDENTIFIER TYPE="MEDLINE" VALUE="14621869"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2915997"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schut-1992b" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Schut 1992b" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schut NH, Bilo HJ, Popp-Snijders C, Goedhart PT, Wilmink JM</AU>
<TI>Erythrocyte deformability, endothelin levels, and renal function in cyclosporin-treated renal transplant recipients: effects of intervention with fish oil and corn oil</TI>
<SO>Scandinavian Journal of Clinical &amp; Laboratory Investigation</SO>
<YR>1993</YR>
<VL>53</VL>
<NO>5</NO>
<PG>499-506</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916002"/><IDENTIFIER TYPE="MEDLINE" VALUE="8210973"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schut NH, Hardeman MR, Goedhart PT, Bilo HJ, Wilmink JM</AU>
<TI>Blood viscosity measurements are not sensitive enough to detect changes in erythrocyte deformability in cyclosporin-treated patients and its subsequent reversal with fish and corn oil</TI>
<SO>Clinical Hemorheology</SO>
<YR>1993</YR>
<VL>13</VL>
<NO>4</NO>
<PG>465-72</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916003"/><IDENTIFIER TYPE="EMBASE" VALUE="1993223288"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Schut NH, Hardeman MR, Wilmink JM</AU>
<TI>Decrease of erythrocyte deformability in cyclosporine-treated renal transplant patients: correction with fish oil as well as corn oil</TI>
<SO>Transplant International</SO>
<YR>1992</YR>
<VL>5 Suppl 1</VL>
<PG>S536-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916004"/><IDENTIFIER TYPE="MEDLINE" VALUE="14621869"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916001"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yoa-1994" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Yoa 1994" YEAR="1994">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corda C, Mounie J, Mousson C, Charfeddine K, Chulopin JM, Escousse A</AU>
<TI>Randomised double blind study of the possible protective effects by fish oil polyunsaturated omega 3 fatty acids, against cyclosporine A (CyA) induced renal damage in kidney transplants [abstract]</TI>
<SO>Fundamental &amp; Clinical Pharmacology</SO>
<YR>1992</YR>
<VL>6</VL>
<NO>4-5</NO>
<PG>223</PG>
<IDENTIFIERS MODIFIED="2008-05-13 09:49:47 +1000" MODIFIED_BY="Narelle S Willis"><IDENTIFIER MODIFIED="2008-05-13 09:49:47 +1000" MODIFIED_BY="Narelle S Willis" TYPE="CENTRAL" VALUE="CN-00305208"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916006"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yoa RG, Corda C, Rapin JR, Santona L, Goudonnet H, Rifle G, et al</AU>
<TI>Hemorheological benefits of omega-3 polyunsatured fatty acids on erythrocyte deformability in renal transplanted patients</TI>
<SO>Clinical Hemorheology</SO>
<YR>1994</YR>
<VL>14</VL>
<NO>5</NO>
<PG>663-75</PG>
<IDENTIFIERS MODIFIED="2008-05-13 09:49:58 +1000" MODIFIED_BY="Narelle S Willis"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916007"/><IDENTIFIER MODIFIED="2008-05-13 09:49:58 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1994288697"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916005"/></IDENTIFIERS>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-A_x002d_Echevarria-2004" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="A-Echevarria 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aldamiz-Echevarria L, Vallo A, Sanjurjo P, Elorz J, Prieto JA, Ruiz JI, et al</AU>
<TI>Influence of diet on atherogenic risk in children with renal transplants</TI>
<SO>Pediatric Nephrology</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>9</NO>
<PG>1039-45</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916009"/><IDENTIFIER TYPE="MEDLINE" VALUE="15258843"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916008"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alexander-2005" MODIFIED="2016-04-04 14:30:13 +1000" MODIFIED_BY="Narelle Willis" NAME="Alexander 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-04-04 14:29:05 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Alexander JW, Metze TJ, Goodman HR, Greenberg NA, First MR, McIntosh MJ, et al</AU>
<TI>Transplant success and immunomodulating diets [abstract]</TI>
<SO>XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami, FL</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2016-04-04 14:29:05 +1000" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-04-04 14:29:05 +1000" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00415168"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916011"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-04 14:29:30 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alexander JW, Metze TJ, Goodman HR, McIntosh MJ, Zeng L, Cardi MA, et al</AU>
<TI>Transplant success and immunomodulating diets [abstract]</TI>
<SO>American Journal of Transplantation</SO>
<YR>2003</YR>
<VL>3</VL>
<NO>Suppl 5</NO>
<PG>562</PG>
<IDENTIFIERS MODIFIED="2016-04-04 14:29:30 +1000" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-04-04 14:29:30 +1000" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00444140"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916012"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2014-03-04 10:57:23 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alexander JW, Metze TJ, McIntosh MJ, Goodman HR, First MR, Munda R, et al</AU>
<TI>The influence of immunomodulatory diets on transplant success and complications</TI>
<SO>Transplantation</SO>
<YR>2005</YR>
<VL>79</VL>
<NO>4</NO>
<PG>460-5</PG>
<IDENTIFIERS MODIFIED="2014-03-04 10:57:20 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916013"/><IDENTIFIER TYPE="MEDLINE" VALUE="15729173"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-04-04 14:30:13 +1000" MODIFIED_BY="Narelle Willis" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Alexander JW, Ofstedal T, Stanley L, Erickson A, Greenberg N, First MR, et al</AU>
<TI>L-arginine and canola oil improve outcome after renal transplantation [abstract]</TI>
<SO>XVIII International Congress of the Transplantation Society; 2000 Aug 27-Sep 1; Rome, Italy</SO>
<YR>2000</YR>
<IDENTIFIERS MODIFIED="2016-04-04 14:30:13 +1000" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-04-04 14:30:13 +1000" MODIFIED_BY="Narelle Willis" TYPE="CENTRAL" VALUE="CN-00444141"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916014"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2016-03-02 12:53:02 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916010"/><IDENTIFIER MODIFIED="2016-03-02 12:53:02 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="CTG" VALUE="NCT00047983"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alexander-2006" MODIFIED="2016-02-17 12:11:12 +1100" MODIFIED_BY="[Empty name]" NAME="Alexander 2006" YEAR="2006">
<REFERENCE MODIFIED="2015-06-03 23:41:39 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alexander JW, Goodman HR, Cardi M, Austin J, Goel S, Safdar S, et al</AU>
<TI>Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation</TI>
<SO>Transplant International</SO>
<YR>2006</YR>
<VL>19</VL>
<NO>4</NO>
<PG>295-302</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916016"/><IDENTIFIER TYPE="MEDLINE" VALUE="16573545"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916015"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alexander-2008" MODIFIED="2016-02-17 12:11:20 +1100" MODIFIED_BY="[Empty name]" NAME="Alexander 2008" YEAR="2008">
<REFERENCE MODIFIED="2016-02-17 12:09:46 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alexander JW, Goodman HR, Succop P, Light JA, Kuo PC, Moser AB, et al</AU>
<TI>Influence of long chain polyunsaturated fatty acids and ornithine concentrations on complications after renal transplant</TI>
<SO>Experimental &amp; Clinical Transplantation</SO>
<YR>2008</YR>
<VL>6</VL>
<NO>2</NO>
<PG>118-26</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916018"/><IDENTIFIER TYPE="MEDLINE" VALUE="18816238"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916017"/><IDENTIFIER TYPE="CTG" VALUE="NCT00560014"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arnadottir-1997" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Arnadottir 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Arnadottir M, Berg AL</AU>
<TI>Treatment of hyperlipidemia in renal transplant recipients</TI>
<SO>Transplantation</SO>
<YR>1997</YR>
<VL>63</VL>
<NO>3</NO>
<PG>339-45</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916020"/><IDENTIFIER TYPE="MEDLINE" VALUE="9039920"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916019"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Balasubramaniam-1998" MODIFIED="2014-03-04 10:50:32 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Balasubramaniam 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-03-04 10:50:32 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Balasubramaniam J, Balasubramaniam S, Palaniappan N</AU>
<TI>Effect of eicosapentanoic acid (EPA) therapy to donors in prevention of ischemic renal injury in live donor renal transplantation - a study [abstract]</TI>
<SO>35th Congress. European Renal Association. European Dialysis and Transplantation Association; 1998 Jun 6-9; Rimini, Italy</SO>
<YR>1998</YR>
<PG>371</PG>
<IDENTIFIERS MODIFIED="2014-03-04 10:50:32 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER MODIFIED="2014-03-04 10:50:32 +1100" MODIFIED_BY="Gail Y Higgins" TYPE="CENTRAL" VALUE="CN-00483112"/><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916022"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916021"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bellomo-2002" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Bellomo 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bellomo R</AU>
<TI>How to feed patients with renal dysfunction</TI>
<SO>Blood Purification</SO>
<YR>2002</YR>
<VL>20</VL>
<NO>3</NO>
<PG>296-303</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916024"/><IDENTIFIER TYPE="MEDLINE" VALUE="11867879"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916023"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bennett-1992" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Bennett 1992" YEAR="1992">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bennett WM</AU>
<TI>Therapeutic implications of arachidonic acid metabolism in transplant-associated acute renal failure</TI>
<SO>Renal Failure</SO>
<YR>1992</YR>
<VL>14</VL>
<NO>3</NO>
<PG>261-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916026"/><IDENTIFIER TYPE="MEDLINE" VALUE="1509159"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916025"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bloomgarden-2004" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Bloomgarden 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bloomgarden ZT</AU>
<TI>Aspects of blood pressure, lipid, and glycemic treatment</TI>
<SO>Diabetes Care</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>1</NO>
<PG>264-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916028"/><IDENTIFIER TYPE="MEDLINE" VALUE="14693999"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916027"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Butani-2000" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Butani 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Butani L, Palmer J</AU>
<TI>Effect of fish oil in a patient with post-transplantation IgA nephropathy</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2000</YR>
<VL>15</VL>
<NO>8</NO>
<PG>1264-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916030"/><IDENTIFIER TYPE="MEDLINE" VALUE="10910466"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916029"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clark-1994" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Clark 1994" YEAR="1994">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clark WF</AU>
<TI>Treatment of lupus nephritis: immunosuppression, general therapy, dialysis and transplantation</TI>
<SO>Clinical &amp; Investigative Medicine - Medecine Clinique et Experimentale</SO>
<YR>1994</YR>
<VL>17</VL>
<NO>6</NO>
<PG>588-601</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916032"/><IDENTIFIER TYPE="MEDLINE" VALUE="7895423"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916031"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davis-2002" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Davis 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davis CL, Gonwa TA, Wilkinson AH</AU>
<TI>Pathophysiology of renal disease associated with liver disorders: implications for liver transplantation. Part 1</TI>
<SO>Liver Transplantation</SO>
<YR>2002</YR>
<VL>8</VL>
<NO>2</NO>
<PG>91-109</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916034"/><IDENTIFIER TYPE="MEDLINE" VALUE="11862584"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916033"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Mattos-1996" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="de Mattos 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Mattos AM, Olyaei AJ, Bennett WM</AU>
<TI>Pharmacology of immunosuppressive medications used in renal diseases and transplantation</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>1996</YR>
<VL>28</VL>
<NO>5</NO>
<PG>631-67</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916036"/><IDENTIFIER TYPE="MEDLINE" VALUE="9158202"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916035"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donadio-1997" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Donadio 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donadio JV Jr, Grande JP</AU>
<TI>Immunoglobulin A nephropathy: a clinical perspective</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1997</YR>
<VL>8</VL>
<NO>8</NO>
<PG>1324-32</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916038"/><IDENTIFIER TYPE="MEDLINE" VALUE="9259362"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916037"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Donadio-2002" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Donadio 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Donadio JV, Grande JP</AU>
<TI>IgA nephropathy</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>347</VL>
<NO>10</NO>
<PG>738-48</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916040"/><IDENTIFIER TYPE="MEDLINE" VALUE="12213946"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916039"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Endres-1995" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Endres 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Endres S, De Caterina R, Schmidt EB, Kristensen SD</AU>
<TI>n-3 polyunsaturated fatty acids: update 1995</TI>
<SO>European Journal of Clinical Investigation</SO>
<YR>1995</YR>
<VL>25</VL>
<NO>9</NO>
<PG>629-38</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916042"/><IDENTIFIER TYPE="MEDLINE" VALUE="7498235"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916041"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Endres-1996" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Endres 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Endres S, von Schacky C</AU>
<TI>n-3 polyunsaturated fatty acids and human cytokine synthesis</TI>
<SO>Current Opinion in Lipidology</SO>
<YR>1996</YR>
<VL>7</VL>
<NO>1</NO>
<PG>48-52</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916044"/><IDENTIFIER TYPE="MEDLINE" VALUE="8925190"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916043"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farbakhsh-2005" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Farbakhsh 2005" YEAR="2005">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farbakhsh K, Kasiske BL</AU>
<TI>Dyslipidemias in patients who have chronic kidney disease</TI>
<SO>Medical Clinics of North America</SO>
<YR>2005</YR>
<VL>89</VL>
<NO>3</NO>
<PG>689-99</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916046"/><IDENTIFIER TYPE="MEDLINE" VALUE="15755473"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916045"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerster-1995" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Gerster 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerster H</AU>
<TI>The use of n-3 PUFAs (fish oil) in enteral nutrition</TI>
<SO>International Journal for Vitamin &amp; Nutrition Research</SO>
<YR>1995</YR>
<VL>65</VL>
<NO>1</NO>
<PG>3-20</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916048"/><IDENTIFIER TYPE="MEDLINE" VALUE="7657477"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916047"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grekas-2001" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Grekas 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grekas D, Kassimatis E, Makedou A, Bacharaki D, Bamichas G, Tourkantonis A</AU>
<TI>Combined treatment with low-dose pravastatin and fish oil in post-renal transplantation dislipidemia</TI>
<SO>Nephron</SO>
<YR>2000</YR>
<VL>88</VL>
<NO>4</NO>
<PG>329-33</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916050"/><IDENTIFIER TYPE="MEDLINE" VALUE="11474227"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916049"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Grimble-2001" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Grimble 2001" YEAR="2001">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Grimble RF</AU>
<TI>Stress proteins in disease: metabolism on a knife edge</TI>
<SO>Clinical Nutrition</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>6</NO>
<PG>469-76</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916052"/><IDENTIFIER TYPE="MEDLINE" VALUE="11883994"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916051"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hansen-1995a" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Hansen 1995a" YEAR="1995">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hansen JM, Hoy CE, Strandgaard S</AU>
<TI>Fish oil and cyclosporin A-induced renal hypoperfusion in kidney-transplanted patients</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>9</NO>
<PG>1745-50</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916054"/><IDENTIFIER TYPE="MEDLINE" VALUE="8559499"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916053"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hansen-1995b" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Hansen 1995b" YEAR="1995">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hansen JM, Lokkegaard H, Hoy CE, Fogh-Andersen N, Olsen NV, Strandgaard S</AU>
<TI>No effect of dietary fish oil on renal hemodynamics, tubular function, and renal functional reserve in long-term renal transplant recipients</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>1995</YR>
<VL>5</VL>
<NO>7</NO>
<PG>1434-40</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916056"/><IDENTIFIER TYPE="MEDLINE" VALUE="7703381"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916055"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hejaili-2003" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Hejaili 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hejaili FF, Moist LM, Clark WF</AU>
<TI>Treatment of lupus nephritis</TI>
<SO>Drugs</SO>
<YR>2003</YR>
<VL>63</VL>
<NO>3</NO>
<PG>257-74</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916058"/><IDENTIFIER TYPE="MEDLINE" VALUE="12534331"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916057"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Homan-van-der-Heide-1994" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Homan van der Heide 1994" YEAR="1994">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Homan van der Heide JJ, Lynch CT</AU>
<TI>Dietary fish oil after renal transplantation</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1994</YR>
<VL>120</VL>
<NO>6 Suppl 2</NO>
<PG>41</PG>
<IDENTIFIERS MODIFIED="2008-05-13 09:50:47 +1000" MODIFIED_BY="Narelle S Willis"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916060"/><IDENTIFIER MODIFIED="2008-05-13 09:50:47 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1994084101"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916059"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Julian-1997" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Julian 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Julian BA, Bake AW</AU>
<TI>Treatment options in IgA nephropathy</TI>
<SO>Nephrology</SO>
<YR>1997</YR>
<VL>3</VL>
<NO>1</NO>
<PG>103-8</PG>
<IDENTIFIERS MODIFIED="2008-05-13 09:51:12 +1000" MODIFIED_BY="Narelle S Willis"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916062"/><IDENTIFIER MODIFIED="2008-05-13 09:51:12 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="1997113212"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916061"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kasiske-2003" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Kasiske 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kasiske B, Cosio FG, Beto J, Chavers B, Grimm Jr R, Levin A et al</AU>
<TI>K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2003</YR>
<VL>41</VL>
<NO>4 Suppl 3</NO>
<PG>i-s91</PG>
<IDENTIFIERS MODIFIED="2008-05-13 09:51:24 +1000" MODIFIED_BY="Narelle S Willis"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916064"/><IDENTIFIER MODIFIED="2008-05-13 09:51:24 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="2003140838"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916063"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kasiske-2004" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Kasiske 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kasiske B, Cosio FG, Beto J, Bolton K, Chavers BM, Grimm Jr R, et al</AU>
<TI>Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: A report from the Managing Dyslipidemias in Chronic Kidney Disease Work gGroup of the National Kidney Foundation Disease Outcomes Quality Initiative</TI>
<SO>American Journal of Transplantation</SO>
<YR>2004</YR>
<VL>4 Suppl 7</VL>
<PG>13-53</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916066"/><IDENTIFIER TYPE="MEDLINE" VALUE="15027968"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916065"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kho-1989" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Kho 1989" YEAR="1989">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kho TL, Leunissen KM, Wirtz JJ, van den Dries PJ, Noordzij TZ, Rijnders A, et al</AU>
<TI>Cyclosporine and urinary prostaglandins</TI>
<SO>Transplantation Proceedings</SO>
<YR>1989</YR>
<VL>21</VL>
<NO>1 Pt 2</NO>
<PG>1504-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916068"/><IDENTIFIER TYPE="MEDLINE" VALUE="2652485"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916067"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kobashigawa-1997" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Kobashigawa 1997" YEAR="1997">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kobashigawa JA, Kasiske BL</AU>
<TI>Hyperlipidemia in solid organ transplantation</TI>
<SO>Transplantation</SO>
<YR>1997</YR>
<VL>63</VL>
<NO>3</NO>
<PG>331-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916070"/><IDENTIFIER TYPE="MEDLINE" VALUE="9039919"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916069"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levi-1992" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Levi 1992" YEAR="1992">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levi M, Wilmink J, Buller HR, Surachno J, ten Cate JW</AU>
<TI>Impaired fibrinolysis in cyclosporine-treated renal transplant patients. Analysis of the defect and beneficial effect of fish-oil</TI>
<SO>Transplantation</SO>
<YR>1992</YR>
<VL>54</VL>
<NO>6</NO>
<PG>978-83</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916072"/><IDENTIFIER TYPE="MEDLINE" VALUE="1465791"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2015-05-25 14:31:12 +1000" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levi M, Wilmink JM, ten Cate JW</AU>
<TI>Defective fibrinolysis in patients using cyclosporine after renal transplantation; Beneficial effects of fish oil [abstract]</TI>
<SO>Kidney International</SO>
<YR>1991</YR>
<VL>40</VL>
<NO>5</NO>
<PG>974</PG>
<IDENTIFIERS MODIFIED="2015-05-25 14:31:12 +1000" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916073"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916071"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maes-2000" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Maes 2000" YEAR="2000">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maes B</AU>
<TI>IgA nephropathy</TI>
<SO>Tijdschrift voor Geneeskunde</SO>
<YR>2000</YR>
<VL>56</VL>
<NO>20</NO>
<PG>1496-508</PG>
<IDENTIFIERS MODIFIED="2008-05-13 09:51:42 +1000" MODIFIED_BY="Narelle S Willis"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916075"/><IDENTIFIER MODIFIED="2008-05-13 09:51:42 +1000" MODIFIED_BY="Narelle S Willis" TYPE="EMBASE" VALUE="2000383155"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916074"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mathis-2004" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Mathis 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mathis AS, Dave N, Knipp GT, Friedman GS</AU>
<TI>Drug-related dyslipidemia after renal transplantation</TI>
<SO>American Journal of Health-System Pharmacy</SO>
<YR>2004</YR>
<VL>61</VL>
<NO>6</NO>
<PG>565-87</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916077"/><IDENTIFIER TYPE="MEDLINE" VALUE="15061429"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916076"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naber-2003" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Naber 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naber AH</AU>
<TI>Sense and nonsense of lipids in artificial nutrition</TI>
<SO>Scandinavian Journal of Gastroenterology - Supplement</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>239</NO>
<PG>11-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916079"/><IDENTIFIER TYPE="MEDLINE" VALUE="14743877"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916078"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nakamura-1998" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Nakamura 1998" YEAR="1998">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nakamura H, Asano T, Suzuki S, Tokonabe S, Hayakawa M</AU>
<TI>Evaluation of ethyl icosapentate in the treatment of hypercholesterolemia in kidney transplant recipients</TI>
<SO>Transplantation Proceedings</SO>
<YR>1998</YR>
<VL>30</VL>
<NO>7</NO>
<PG>3047-8</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916081"/><IDENTIFIER TYPE="MEDLINE" VALUE="9838343"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916080"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ramezani--2011" MODIFIED="2016-02-17 12:25:36 +1100" MODIFIED_BY="[Empty name]" NAME="Ramezani  2011" YEAR="2011 Mar">
<REFERENCE MODIFIED="2016-02-17 12:24:41 +1100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ramezani M, Nazemian F, Shamsara J, Koohrokhi R, Mohammadpour AH</AU>
<TI>Effect of omega-3 fatty acids on plasma level of 8-isoprostane in kidney transplant patients</TI>
<SO>Journal of Renal Nutrition</SO>
<YR>2011</YR>
<VL>21</VL>
<NO>2</NO>
<PG>196-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916083"/><IDENTIFIER TYPE="MEDLINE" VALUE="21093286"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916082"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rodicio-1993" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Rodicio 1993" YEAR="1993">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rodicio JL, Morales JM, Ruilope LM</AU>
<TI>Lipophilic dihydropyridines provide renal protection from cyclosporin toxicity</TI>
<SO>Journal of Hypertension - Supplement</SO>
<YR>1993</YR>
<VL>11</VL>
<NO>6</NO>
<PG>S21-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916085"/><IDENTIFIER TYPE="MEDLINE" VALUE="8169378"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916084"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Romo-2012" MODIFIED="2016-03-31 08:47:09 +1100" MODIFIED_BY="Gail Y Higgins" NAME="Romo 2012" YEAR="2012">
<REFERENCE MODIFIED="2016-03-31 08:47:09 +1100" MODIFIED_BY="Gail Y Higgins" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Romo JC, Hernandez AM, Toussaint G, Lopez S, Navarro B, Velasquez L, et al</AU>
<TI>Treatment of dyslipidemia in renal transplant children, a comparative, prospective, randomized study [abstract]</TI>
<SO>Blood Purification</SO>
<YR>2012</YR>
<VL>33</VL>
<NO>1-3</NO>
<PG>215</PG>
<IDENTIFIERS MODIFIED="2016-03-31 08:47:09 +1100" MODIFIED_BY="Gail Y Higgins"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916087"/><IDENTIFIER TYPE="EMBASE" VALUE="70723740"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916086"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schiele-1999" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Schiele 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schiele J, Nowack R, Julian BA, van der Woude FJ</AU>
<TI>Treatment of immunoglobulin A nephropathy</TI>
<SO>Annales de Medicine Interne</SO>
<YR>1999</YR>
<VL>150</VL>
<NO>2</NO>
<PG>127-36</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916089"/><IDENTIFIER TYPE="MEDLINE" VALUE="10392261"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916088"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shah-1994" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Shah 1994" YEAR="1994">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shah B, Nair S, Sirsat RA, Ashavaid TF, Nair KG</AU>
<TI>Dyslipidemia in patients with chronic renal failure and in renal transplant patients</TI>
<SO>Journal of Postgraduate Medicine</SO>
<YR>1994</YR>
<VL>40</VL>
<NO>2</NO>
<PG>57-60</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916091"/><IDENTIFIER TYPE="MEDLINE" VALUE="8737552"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916090"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shihab-1996" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Shihab 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shihab FS</AU>
<TI>Cyclosporine nephropathy: pathophysiology and clinical impact</TI>
<SO>Seminars in Nephrology</SO>
<YR>1996</YR>
<VL>16</VL>
<NO>6</NO>
<PG>536-47</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916093"/><IDENTIFIER TYPE="MEDLINE" VALUE="9125798"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916092"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singer-2004" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Singer 2004" YEAR="2004">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Singer P, Zolotarski V, Yussim A, Lustig S, Attal-Singer J, Cohen J</AU>
<TI>Renal effects of parenteral fish oil administered to heart-beating organ donors and renal-transplant recipients: a tolerance study</TI>
<SO>Clinical Nutrition</SO>
<YR>2004</YR>
<VL>23</VL>
<NO>4</NO>
<PG>597-603</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916095"/><IDENTIFIER TYPE="MEDLINE" VALUE="15297096"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916094"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Soylu-2002" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Soylu 2002" YEAR="2002">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Soylu A, Kavucku S, Turkmen M, Bora S, Gulay H</AU>
<TI>Eight-year experience in pediatric renal transplantation</TI>
<SO>Transplantation Proceedings</SO>
<YR>2002</YR>
<VL>34</VL>
<NO>6</NO>
<PG>2062-5</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916097"/><IDENTIFIER TYPE="MEDLINE" VALUE="12270314"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916096"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Urakaze-1989" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Urakaze 1989" YEAR="1989">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Urakaze M, Hamazaki T, Kashiwabara H, Omori K, Fischer S, Yano S</AU>
<TI>Favorable effects of fish oil concentrate on risk factors for thrombosis in renal allograft recipients</TI>
<SO>Nephron</SO>
<YR>1989</YR>
<VL>53</VL>
<NO>2</NO>
<PG>102-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916099"/><IDENTIFIER TYPE="MEDLINE" VALUE="2812166"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Urakaze M, Hamazaki T, Yano S, Kashiwabara H, Oomori K, Yokoyama T</AU>
<TI>Effect of fish oil concentrate on risk factors of cardiovascular complications in renal transplantation</TI>
<SO>Transplantation Proceedings</SO>
<YR>1989</YR>
<VL>21</VL>
<NO>1 Pt 2</NO>
<PG>2134-6</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916100"/><IDENTIFIER TYPE="MEDLINE" VALUE="2652688"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916098"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wierzbicki-1999" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Wierzbicki 1999" YEAR="1999">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wierzbicki AS</AU>
<TI>The role of lipid lowering in transplantation</TI>
<SO>International Journal of Clinical Practice</SO>
<YR>1999</YR>
<VL>53</VL>
<NO>1</NO>
<PG>54-9</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916102"/><IDENTIFIER TYPE="MEDLINE" VALUE="10344068"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916101"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Young-1995" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Young 1995" YEAR="1995">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Young JB</AU>
<TI>Fish oil and antioxidants after heart transplantation: future strategies or eye of newt and wing of bat revisited?</TI>
<SO>Journal of Heart &amp; Lung Transplantation</SO>
<YR>1995</YR>
<VL>14</VL>
<NO>6 Pt 2</NO>
<PG>S250-4</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916104"/><IDENTIFIER TYPE="MEDLINE" VALUE="8719496"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916103"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zak-1996" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Zak 1996" YEAR="1996">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zak A, Zeman M, Tvrzicka E, Stolba P</AU>
<TI>Effects of fish oils in patients with type 2 diabetes with associated dyslipidaemia</TI>
<TO>Ucinky rybich oleju na nektere metabolicke parametry nemocnych s diabetes mellitus 2. typu a pruvodnou dyslipidemii</TO>
<SO>Casopis Lekaru Ceskych</SO>
<YR>1996</YR>
<VL>135</VL>
<NO>11</NO>
<PG>354-9</PG>
<IDENTIFIERS MODIFIED="2016-04-04 14:36:33 +1000" MODIFIED_BY="Narelle Willis"><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916106"/><IDENTIFIER MODIFIED="2016-04-04 14:36:33 +1000" MODIFIED_BY="Narelle Willis" TYPE="EMBASE" VALUE="1996174498"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916105"/></IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zolotarski-2003" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="Zolotarski 2003" YEAR="2003">
<REFERENCE MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zolotarski V, Cohen J, Sharabani E, Bar Nathan N, Yussim A, Lustig S, et al</AU>
<TI>Parenteral fish oil administered to heart-beating organ donors and to renal transplant recipients: effects on renal function</TI>
<SO>Transplantation Proceedings</SO>
<YR>2003</YR>
<VL>35</VL>
<NO>2</NO>
<PG>624</PG>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916108"/><IDENTIFIER TYPE="MEDLINE" VALUE="12644071"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916107"/></IDENTIFIERS>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01744067" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NAME="NCT01744067" YEAR="2014">
<REFERENCE MODIFIED="2016-03-24 18:04:05 +1100" MODIFIED_BY="Narelle S Willis" PRIMARY="NO" TYPE="OTHER">
<AU>Eide IA</AU>
<TI>The effects of n-3 polyunsaturated fatty acids on renal and cardiovascular risk markers in renal transplant recipients: a randomized double blinded placebo controlled intervention study</TI>
<SO>www.clinicaltrials.gov/ct2/show/NCT01744067</SO>
<YR>(accessed 1 March 2016)</YR>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSREF" TYPE="OTHER" VALUE="2916110"/></IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS><IDENTIFIER OTHERTYPE="CRSSTD" TYPE="OTHER" VALUE="2916109"/><IDENTIFIER TYPE="CTG" VALUE="NCT01744067"/></IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2016-03-01 14:55:43 +1100" MODIFIED_BY="Gail Y Higgins"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2016-04-04 14:48:04 +1000" MODIFIED_BY="Narelle Willis">
<ADDITIONAL_REFERENCES MODIFIED="2016-04-04 14:48:04 +1000" MODIFIED_BY="Narelle Willis">
<REFERENCE ID="REF-Ader-1998" NAME="Ader 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ader JL, Rostaing L</AU>
<TI>Cyclosporin nephrotoxicity: pathophysiology and comparison with FK-506</TI>
<SO>Current Opinion in Nephrology &amp; Hypertension</SO>
<YR>1998</YR>
<VL>7</VL>
<NO>5</NO>
<PG>539-45</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="9818201"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Andoh-1997" NAME="Andoh 1997" TYPE="JOURNAL_ARTICLE">
<AU>Andoh TF, Burdmann EA, Bennett WM</AU>
<TI>Nephrotoxicity of immunosuppressive drugs: experimental and clinical observations</TI>
<SO>Seminars in Nephrology</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>1</NO>
<PG>34-45</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="9000548"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Andoh-1998" NAME="Andoh 1998" TYPE="JOURNAL_ARTICLE">
<AU>Andoh TF, Bennett WM</AU>
<TI>Chronic cyclosporine nephrotoxicity</TI>
<SO>Current Opinion in Nephrology &amp; Hypertension</SO>
<YR>1998</YR>
<VL>7</VL>
<NO>3</NO>
<PG>265-70</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="9617556"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Balk-2006" MODIFIED="2016-04-04 14:38:19 +1000" MODIFIED_BY="Narelle Willis" NAME="Balk 2006" TYPE="JOURNAL_ARTICLE">
<AU>Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J</AU>
<TI>Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review</TI>
<SO>Atherosclerosis</SO>
<YR>2006</YR>
<VL>189</VL>
<NO>1</NO>
<PG>19-30</PG>
<IDENTIFIERS MODIFIED="2016-04-04 14:38:19 +1000" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-04-04 14:38:19 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="16530201"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bonis-2005" MODIFIED="2016-04-04 14:39:35 +1000" MODIFIED_BY="Narelle Willis" NAME="Bonis 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bonis PA, Chung M, Tatsioni A, Sun Y, Kupelnick B, Lichtenstein A, et al</AU>
<TI>Effects of omega-3 fatty acids on organ transplantation</TI>
<SO>Evidence Report: Technology Assessment (Summary)</SO>
<YR>2005</YR>
<NO>115</NO>
<PG>1-11</PG>
<IDENTIFIERS MODIFIED="2016-04-04 14:39:35 +1000" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-04-04 14:39:35 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="15810864"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Braun-2003" MODIFIED="2016-04-04 14:42:51 +1000" MODIFIED_BY="Narelle Willis" NAME="Braun 2003" TYPE="BOOK_SECTION">
<AU>Braun WE</AU>
<TI>The medical management of renal transplant recipients</TI>
<SO>Comprehensive Clinical Nephrology</SO>
<YR>2003</YR>
<PG>1105-10</PG>
<EN>2nd</EN>
<ED>Johnson RJ, Feehally J</ED>
<PB>Mosby</PB>
<CY>London</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brenna-2002" NAME="Brenna 2002" TYPE="JOURNAL_ARTICLE">
<AU>Brenna JT</AU>
<TI>Efficiency of conversion of alpha-linolenic acid to long chain n-3 fatty acids in man</TI>
<SO>Current Opinion in Clinical Nutrition &amp; Metabolic Care</SO>
<YR>2002</YR>
<VL>5</VL>
<NO>2</NO>
<PG>127-32</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="11844977"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-de-Mattos-2000" NAME="de Mattos 2000" TYPE="JOURNAL_ARTICLE">
<AU>de Mattos AM, Olyaei AJ, Bennett WM</AU>
<TI>Nephrotoxicity of immunosuppressive drugs: Long-term consequences and challenges for the future</TI>
<SO>American Journal of Kidney Diseases</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>2</NO>
<PG>333-46</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="10676738"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Din-2004" NAME="Din 2004" TYPE="JOURNAL_ARTICLE">
<AU>Din JN, Newby DE, Flapan AD</AU>
<TI>Omega 3 fatty acids and cardiovascular disease-fishing for a natural treatment</TI>
<SO>BMJ</SO>
<YR>2004</YR>
<VL>328</VL>
<NO>7430</NO>
<PG>30-5</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="14703544"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Eide-2015" MODIFIED="2016-04-04 14:45:26 +1000" MODIFIED_BY="Narelle Willis" NAME="Eide 2015" TYPE="JOURNAL_ARTICLE">
<AU>Eide IA, Jenssen T, Hartmann A, Diep LM, Dahle DO, Reisaeter AV, et al</AU>
<TI>The association between marine n-3 polyunsaturated fatty acid levels and survival after renal transplantation</TI>
<SO>Clinical Journal of The American Society of Nephrology: CJASN</SO>
<YR>2015</YR>
<VL>10</VL>
<NO>7</NO>
<PG>1246-56</PG>
<IDENTIFIERS MODIFIED="2016-04-04 14:44:08 +1000" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-04-04 14:44:08 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="26063768"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Eide-2016" MODIFIED="2016-04-04 14:45:18 +1000" MODIFIED_BY="Narelle Willis" NAME="Eide 2016" TYPE="JOURNAL_ARTICLE">
<AU>Eide IA, Jenssen T, Hartmann A, Diep LM, Dahle DO, Reisaeter AV, et al</AU>
<TI>Plasma levels of marine n-3 polyunsaturated fatty acids and renal allograft survival</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>2016</YR>
<VL>31</VL>
<NO>1</NO>
<PG>160-7</PG>
<IDENTIFIERS MODIFIED="2016-04-04 14:45:05 +1000" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-04-04 14:45:05 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="26410884"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Endres-1989" NAME="Endres 1989" TYPE="JOURNAL_ARTICLE">
<AU>Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, Van der Meer JW et al</AU>
<TI>The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells</TI>
<SO>New England Journal of Medicine</SO>
<YR>1989</YR>
<VL>320</VL>
<NO>5</NO>
<PG>265-71</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="2783477"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Endres-1993" NAME="Endres 1993" TYPE="JOURNAL_ARTICLE">
<AU>Endres S, Meydani SN, Ghorbani R, Schindler R, Dinarello CA</AU>
<TI>Dietary supplementation with n-3 fatty acids suppresses interleukin-2 production and mononuclear cell proliferation</TI>
<SO>Journal of Leukocyte Biology</SO>
<YR>1993</YR>
<VL>54</VL>
<NO>6</NO>
<PG>599-603</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="8245713"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ford-1991" NAME="Ford 1991" TYPE="JOURNAL_ARTICLE">
<AU>Ford HR, Hoffman RA, Tweardy DJ, Kispert P, Wang S, Simmons RL</AU>
<TI>Evidence that production of interleukin 6 within the rejecting allograft coincides with cytotoxic T lymphocyte development</TI>
<SO>Transplantation</SO>
<YR>1991</YR>
<VL>51</VL>
<NO>3</NO>
<PG>656-61</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="2006523"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7417</NO>
<PG>557-60</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="12958120"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2016-03-31 15:03:41 +1100" MODIFIED_BY="Narelle S Willis" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JP, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hirunpanich-2006" NAME="Hirunpanich 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hirunpanich V, Katagi J, Sethabouppha B, Sato H</AU>
<TI>Demonstration of docosahexaenoic acid as a bioavailability enhancer for CYP3A substrates: in vitro and in vivo evidence using cyclosporin in rats</TI>
<SO>Drug Metabolism &amp; Disposition</SO>
<YR>2006</YR>
<VL>34</VL>
<NO>2</NO>
<PG>305-10</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="16299163"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hooper-2006" MODIFIED="2016-04-04 14:45:56 +1000" MODIFIED_BY="Narelle Willis" NAME="Hooper 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hooper L, Thompson RL, Harrison RA, Summerbell CD, Ness AR, Moore HJ, et al</AU>
<TI>Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review</TI>
<SO>BMJ</SO>
<YR>2006</YR>
<VL>332</VL>
<NO>7544</NO>
<PG>752-60</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="16565093"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kelley-1989" NAME="Kelley 1989" TYPE="JOURNAL_ARTICLE">
<AU>Kelley VE, Kirkman RL, Bastos M, Barrett LV, Strom TB</AU>
<TI>Enhancement of immunosuppression by substitution of fish oil for olive oil as a vehicle for cyclosporine</TI>
<SO>Transplantation</SO>
<YR>1989</YR>
<VL>48</VL>
<NO>1</NO>
<PG>98-102</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="2665242"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kris_x002d_Etherton-2000" MODIFIED="2016-04-04 14:46:08 +1000" MODIFIED_BY="Narelle Willis" NAME="Kris-Etherton 2000" TYPE="JOURNAL_ARTICLE">
<AU>Kris-Etherton PM, Taylor DS, Yu-Poth S, Huth P, Moriarty K, Fishell V, et al</AU>
<TI>Polyunsaturated fatty acids in the food chain in the United States</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2000</YR>
<VL>71</VL>
<NO>1 Suppl</NO>
<PG>179S-88S</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="10617969"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McDonald-2003" NAME="McDonald 2003" TYPE="BOOK_SECTION">
<AU>McDonald S, Russ G</AU>
<TI>Deaths</TI>
<SO>26th Report of the ANZDATA Registry</SO>
<YR>2003</YR>
<PG>15-23</PG>
<PB>Australia and New Zealand Dialysis and Transplant Registry</PB>
<CY>Adelaide</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Noronha-1992" NAME="Noronha 1992" TYPE="JOURNAL_ARTICLE">
<AU>Noronha IL, Eberlein-Gonska M, Hartley B, Stephens S, Cameron JS, Waldherr R</AU>
<TI>In situ expression of tumor necrosis factor-alpha, interferon-gamma, and interleukin-2 receptors in renal allograft biopsies</TI>
<SO>Transplantation</SO>
<YR>1992</YR>
<VL>54</VL>
<NO>6</NO>
<PG>1017-24</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="1281560"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Noronha-1993" NAME="Noronha 1993" TYPE="JOURNAL_ARTICLE">
<AU>Noronha IL, Hartley B, Cameron JS, Waldherr R</AU>
<TI>Detection of IL-1 beta and TNF-alpha message and protein in renal allograft biopsies</TI>
<SO>Transplantation</SO>
<YR>1993</YR>
<VL>56</VL>
<NO>4</NO>
<PG>1026-9</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="8212184"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Norris-1990" NAME="Norris 1990" TYPE="JOURNAL_ARTICLE">
<AU>Norris SH</AU>
<TI>Renal eicosanoids</TI>
<SO>Seminars in Nephrology</SO>
<YR>1990</YR>
<VL>10</VL>
<NO>1</NO>
<PG>64-88</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="2104991"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ojo-2003" MODIFIED="2016-04-04 14:47:09 +1000" MODIFIED_BY="Narelle Willis" NAME="Ojo 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ojo AO, Held PJ, Port FK, Wolfe RA, Leichtman AB, Young EW, et al</AU>
<TI>Chronic renal failure after transplantation of a nonrenal organ</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>349</VL>
<NO>10</NO>
<PG>931-40</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="12954741"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Opelz-1998" NAME="Opelz 1998" TYPE="JOURNAL_ARTICLE">
<AU>Opelz G, Wujciak T, Ritz E</AU>
<TI>Association of chronic kidney graft failure with recipient blood pressure (Collaborative Transplant Study)</TI>
<SO>Kidney International</SO>
<YR>1998</YR>
<VL>53</VL>
<NO>1</NO>
<PG>217-22</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="9453022"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Otto-1990" NAME="Otto 1990" TYPE="JOURNAL_ARTICLE">
<AU>Otto DA, Kahn DR, Hamm MW, Forrest DE, Wooten JT</AU>
<TI>Improved survival of heterotopic cardiac allografts in rats with dietary n-3 polyunsaturated fatty acids</TI>
<SO>Transplantation</SO>
<YR>1990</YR>
<VL>50</VL>
<NO>2</NO>
<PG>193-8</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="2382285"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Psota-2006" NAME="Psota 2006" TYPE="JOURNAL_ARTICLE">
<AU>Psota TL, Gebauer SK, Kris-Etherton P</AU>
<TI>Dietary omega-3 fatty acid intake and cardiovascular risk</TI>
<SO>American Journal of Cardiology</SO>
<YR>2006</YR>
<VL>98</VL>
<NO>4A</NO>
<PG>3i-18i</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="16919512"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sweny-1989" MODIFIED="2016-04-04 14:47:32 +1000" MODIFIED_BY="Narelle Willis" NAME="Sweny 1989" TYPE="JOURNAL_ARTICLE">
<AU>Sweny P, Wheeler DC, Lui SF, Amin NS, Barradas MA, Jeremy JY, et al</AU>
<TI>Dietary fish oil supplements preserve renal function in renal transplant recipients with chronic vascular rejection</TI>
<SO>Nephrology Dialysis Transplantation</SO>
<YR>1989</YR>
<VL>4</VL>
<NO>12</NO>
<PG>1070-5</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="2517328"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tatsioni-2005" MODIFIED="2016-04-04 14:47:39 +1000" MODIFIED_BY="Narelle Willis" NAME="Tatsioni 2005" TYPE="JOURNAL_ARTICLE">
<AU>Tatsioni A, Chung M, Sun Y, Kupelnick B, Lichtenstein AH, Perrone R, et al</AU>
<TI>Effects of fish oil supplementation on kidney transplantation: A systematic review and meta-analysis of randomized, controlled trials</TI>
<SO>Journal of the American Society of Nephrology</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>8</NO>
<PG>2462-70</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="15958723"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Vandenbroecke-1991" MODIFIED="2016-04-04 14:47:45 +1000" MODIFIED_BY="Narelle Willis" NAME="Vandenbroecke 1991" TYPE="JOURNAL_ARTICLE">
<AU>Vandenbroecke C, Caillat-Zucman S, Legendre C, Noel LH, Kreis H, Woodrow D, et al</AU>
<TI>Differential in situ expression of cytokines in renal allograft rejection</TI>
<SO>Transplantation</SO>
<YR>1991</YR>
<VL>51</VL>
<NO>3</NO>
<PG>602-9</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="1900962"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Wang-2006" MODIFIED="2016-04-04 14:47:49 +1000" MODIFIED_BY="Narelle Willis" NAME="Wang 2006" TYPE="JOURNAL_ARTICLE">
<AU>Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, et al</AU>
<TI>n-3 fatty acids from fish or fish oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2006</YR>
<VL>84</VL>
<NO>1</NO>
<PG>5-17</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="16825676"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Yard-1994" MODIFIED="2016-04-04 14:48:04 +1000" MODIFIED_BY="Narelle Willis" NAME="Yard 1994" TYPE="JOURNAL_ARTICLE">
<AU>Yard BA, Kooymans-Couthino M, Paape ME, Bruijn JA, Daha MR, van Es LA, et al</AU>
<TI>Analysis of cytokine production by graft-infiltrating cells isolated from rejecting renal allografts</TI>
<SO>Transplantation</SO>
<YR>1994</YR>
<VL>57</VL>
<NO>1</NO>
<PG>153-5</PG>
<IDENTIFIERS><IDENTIFIER TYPE="MEDLINE" VALUE="8291102"/></IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2016-04-04 12:01:56 +1000" MODIFIED_BY="Narelle Willis">
<REFERENCE ID="REF-Lim-2007a" MODIFIED="2016-04-04 11:59:53 +1000" MODIFIED_BY="Narelle Willis" NAME="Lim 2007a" TYPE="COCHRANE_REVIEW">
<AU>Lim AK, Manley KJ, Roberts MA, Fraenkel MB</AU>
<TI>Fish oil for kidney transplant recipients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2016-04-04 11:59:37 +1000" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-04-04 11:59:37 +1000" MODIFIED_BY="Narelle Willis" TYPE="DOI" VALUE="10.1002/14651858.CD005282.pub2"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Lim-2007b" MODIFIED="2016-04-04 12:01:56 +1000" MODIFIED_BY="Narelle Willis" NAME="Lim 2007b" TYPE="OTHER">
<AU>Lim AK, Manley KJ, Roberts MA, Fraenkel MB</AU>
<TI>Fish oil treatment for kidney transplant recipients: a meta-analysis of randomized controlled trials</TI>
<SO>Transplantation</SO>
<YR>2007</YR>
<VL>83</VL>
<NO>7</NO>
<PG>831-8</PG>
<IDENTIFIERS MODIFIED="2016-04-04 11:56:41 +1000" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-04-04 11:56:41 +1000" MODIFIED_BY="Narelle Willis" TYPE="MEDLINE" VALUE="17460552"/></IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Manley-2005" MODIFIED="2016-04-04 12:01:23 +1000" MODIFIED_BY="Narelle Willis" NAME="Manley 2005" TYPE="COCHRANE_PROTOCOL">
<AU>Manley K, Fraenkel M, Lim A, Roberts MA</AU>
<TI>Fish oil for kidney transplant recipients</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2016-04-04 12:01:17 +1000" MODIFIED_BY="Narelle Willis"><IDENTIFIER MODIFIED="2016-04-04 12:01:17 +1000" MODIFIED_BY="Narelle Willis" TYPE="DOI" VALUE="10.1002/14651858.CD005282"/></IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2014-03-04 10:46:35 +1100" MODIFIED_BY="Gail Y Higgins"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2016-08-11 10:32:13 +1000" MODIFIED_BY="Narelle S Willis" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2016-08-11 10:17:53 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Bennett-_x0028_high_x0029_-1995">
<CHAR_METHODS MODIFIED="2016-03-21 16:56:51 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: double blind RCT</LI>
<LI>Time frame: 6 months</LI>
<LI>Follow-up period: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-24 14:50:07 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre (3 kidney transplant centres)</LI>
<LI>18 to 70 years, clinically stable kidney transplants (16 week open-label baseline evaluation period)</LI>
<LI>Number: treatment group (18); control group (25)</LI>
<LI>Mean age ± SD (years): not reported</LI>
<LI>Sex (M/F): not reported</LI>
<LI>Exclusion criteria: MI/arrhythmia &lt; 6 months; liver disease; malignancy &lt; 2 years; investigational drug use &lt; 3 months; severe gastrointestinal malabsorption; severe COPD; pregnancy; lactation; active infection; acute rejection &lt; 2 weeks prior to period 2</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-14 16:40:56 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>18 g MaxEPA (EPA 180 mg/g, DHA 120 mg/g) daily</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Corn oil 18 g</LI>
</UL>
<P>Co-interventions: not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-21 17:01:44 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Patient survival</LI>
<LI>Graft survival</LI>
<LI>Acute rejection</LI>
<LI>Kidney function (GFR and CrCl)</LI>
<LI>HDL/LDL cholesterol</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-08-11 10:17:53 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>
<LINK REF="STD-Bennett-_x0028_high_x0029_-1995" TYPE="STUDY">Bennett (high) 1995</LINK> is the same study as <LINK REF="STD-Bennett-_x0028_low_x0029_-1995" TYPE="STUDY">Bennett (low) 1995</LINK>
</LI>
<LI>The high dose arm is analysed compared to half of the control group for continuous outcomes. Dichotomous outcomes analysed together (see <LINK REF="STD-Bennett-_x0028_low_x0029_-1995" TYPE="STUDY">Bennett (low) 1995</LINK>)</LI>
<LI>Results for low and high dose corn oil were combined (n = 50) in the published report</LI>
<LI>Exclusions post randomisation but pre intervention: none</LI>
<LI>Unpublished data provided by triallists</LI>
<UL>
<LI>Stroke and myocardial infarction: no events</LI>
</UL>
<LI>Completeness of follow-up: 90/133 patients evaluated (similar number of patients in both groups)</LI>
<LI>Rate of non-compliant drop-outs not reported (although mentioned)</LI>
<LI>Results for low and high dose corn oil were combined (n = 50) in the published report</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-04 14:51:00 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Bennett-_x0028_low_x0029_-1995">
<CHAR_METHODS MODIFIED="2016-03-21 17:01:35 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: double blind RCT</LI>
<LI>Time frame: 6 months</LI>
<LI>Follow-up period: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-24 10:46:28 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: USA</LI>
<LI>Setting: multicentre (3 kidney transplant centres)</LI>
<LI>18 to 70 years, clinically stable kidney transplants (16 week open-label baseline evaluation period)</LI>
<LI>Number: treatment group (22); control group (25)</LI>
<LI>Mean age ± SD (years): not reported</LI>
<LI>Sex (M/F): not reported</LI>
<LI>Exclusion criteria: myocardial infarct/arrhythmia &lt; 6 months; liver disease; malignancy &lt; 2 years; investigational drug use &lt; 3 months; severe gastrointestinal malabsorption; severe COPD; pregnancy; lactation; active infection; acute rejection &lt; 2 weeks prior to period 2</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-14 16:40:56 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>9 g MaxEPA (EPA 180 mg/g, DHA 120 mg/g) daily</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Corn oil 9 g</LI>
</UL>
<P>Co-interventions: not reported</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-21 17:01:55 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Patient survival</LI>
<LI>Graft survival</LI>
<LI>Acute rejection</LI>
<LI>Kidney function (GFR and CrCl)</LI>
<LI>HDL/LDL cholesterol</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-04 14:51:00 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>
<LINK REF="STD-Bennett-_x0028_high_x0029_-1995" TYPE="STUDY">Bennett (high) 1995</LINK> is the same study as <LINK REF="STD-Bennett-_x0028_low_x0029_-1995" TYPE="STUDY">Bennett (low) 1995</LINK>
</LI>
<LI>The high dose arm is analysed compared to half of the control group for continuous outcomes. Dichotomous outcomes analysed together</LI>
<LI>Results for low and high dose corn oil were combined (n = 50) in the published report</LI>
<LI>Exclusions post randomisation but pre intervention: none</LI>
<LI>Unpublished data provided by triallists</LI>
<UL>
<LI>Stroke and myocardial infarction: no events</LI>
</UL>
<LI>Completeness of follow-up: 90/133 patients evaluated (similar number of patients in both groups)</LI>
<LI>Rate of non-compliant drop-outs not reported (although mentioned)</LI>
<LI>Results for low and high dose corn oil were combined (n = 50) in the published report.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-04 10:46:28 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Berthoux-1992">
<CHAR_METHODS MODIFIED="2016-03-21 17:08:25 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: RCT (non-placebo)</LI>
<LI>Time frame: 12 months</LI>
<LI>Follow-up period: 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-21 17:12:10 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: France</LI>
<LI>Setting: single-centre university hospital</LI>
<LI>Cadaveric donor kidney transplant recipients</LI>
<LI>Number: treatment group (14); control group (15)</LI>
<LI>Mean age ± SD (years): treatment group (46.0 ± 13.9); control group (42.9 ± 10.7)</LI>
<LI>Sex (M/F): treatment group (6/8); control group (11/4)</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-04-04 10:46:28 +1000" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>9 g fish oil (MaxEPA 3 g 3 times/d) daily (day 3 to 365)</LI>
</UL>
<P>Control group</P>
<UL>
<LI>None</LI>
</UL>
<P>Co-interventions: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-24 16:32:15 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Patient survival</LI>
<LI>Graft survival</LI>
<LI>BP (data not shown)</LI>
<LI>Kidney function (SCr, CrCl, GFR)</LI>
<LI>Lipids (TC, TG)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-03-24 08:04:37 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre intervention: none</LI>
<LI>Additional data requested from authors: no unpublished data provided</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-08-11 10:31:15 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Busnach-1998">
<CHAR_METHODS MODIFIED="2016-03-21 17:21:56 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: double blind placebo controlled RCT</LI>
<LI>Time frame: 12 months</LI>
<LI>Follow-up period: 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-21 17:13:27 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: Italy</LI>
<LI>Setting: single centre</LI>
<LI>All kidney transplant recipients</LI>
<LI>Number: treatment group (21); control group (21)</LI>
<LI>Mean age ± SD (years): treatment group (44 ± 2.6); control group (39 ± 2.1)</LI>
<LI>Sex (M/F): treatment group (10/11); control group (14/7)</LI>
<LI>Exclusion criteria: significant lipid disorders, on hypolipaemic drugs in last 3/12 pre-transplant</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-14 16:49:44 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>6 g/d fish oil (Esapent) (85% EPA, DHA) for 1 month, 3 g/d to completion</LI>
</UL>
<P>Control group</P>
<UL>
<LI>6 g/d olive oil similar schedule to treatment group</LI>
</UL>
<P>Co-interventions: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-24 16:32:20 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Patient survival</LI>
<LI>Graft failure</LI>
<LI>Acute rejection</LI>
<LI>Compliance</LI>
<LI>Kidney function (SCr)</LI>
<LI>BP (not reported/no longer available)</LI>
<LI>Lipids</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-08-11 10:31:15 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre intervention: none</LI>
<LI>Additional data requested: unpublished data provided by triallists</LI>
<UL>
<LI>Acute rejection: not all rejection episodes were biopsy proven</LI>
<LI>CSA toxicity: only looked at when biopsy was performed (retrospective)</LI>
<LI>Compliance: no withdrawals for side-effects; adverse effects not specifically considered</LI>
<LI>Method of randomisation: centrally processed by sponsor by means of sealed envelopes; active drug and placebo capsules prepared by sponsor</LI>
</UL>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-24 10:46:29 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Castro-1997">
<CHAR_METHODS MODIFIED="2016-03-21 17:28:09 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: RCT of fish oil versus statin (non-placebo, open-label)</LI>
<LI>Time frame: 3 months</LI>
<LI>Follow-up: 3 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-24 10:46:29 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Portugal</LI>
<LI>Setting: single centre</LI>
<LI>&gt; 1 year post-transplant, stable kidney function, persistent elevated cholesterol after a 12-week lipid lowering diet (AHA, Step 2)</LI>
<LI>Number: treatment group (18); control group (25)</LI>
<LI>Mean age ± SD (years): treatment group (43.4 ± 11.7); control group (45.6 ± 9.4)</LI>
<LI>Sex (M/F): treatment group (6/12); control group (11/14)</LI>
<LI>Exclusion criteria: non-compliance (13 patients excluded pre-randomisation); diet-normalised patients excluded</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-21 17:36:25 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Fish oil 6 g/d (30% EPA; 20% DHA)</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Simvastatin 10 mg/d</LI>
</UL>
<P>Co-interventions: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-21 17:28:57 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Lipids: TC, TG, LDL, HDL</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-03-21 17:36:15 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Exclusions post randomisation but pre intervention: none</LI>
<LI>Additional data requested: none</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-04 14:20:21 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Hernandez-2002">
<CHAR_METHODS MODIFIED="2016-03-21 17:42:31 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: double blind placebo controlled RCT</LI>
<LI>Time frame: 3 months</LI>
<LI>Follow-up period: 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-21 17:43:58 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: Spain</LI>
<LI>Setting: single centre</LI>
<LI>Consecutive recipients of 1st cadaveric kidney graft, 18 to 70 years, no fish oil or immunosuppressive treatment &lt; 6 months, no haemorrhagic disorders</LI>
<LI>Number: treatment group (46); control group (40)</LI>
<LI>Mean age ± SD (years): treatment group (46.8 ± 12.1); control group (45.3 ± 14.5)</LI>
<LI>Sex (M/F): treatment group (26/19); control group (30/10)</LI>
<LI>Exclusion criteria: investigational drug &lt; 3 months; acute liver disease; malignancy &lt; 2 years; fish or iodine allergy; pregnancy or lactation</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-14 16:52:00 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>6 g/d fish oil (Epaleo) 21% EPA; 11% DHA</LI>
</UL>
<P>Control group</P>
<UL>
<LI>6 g/d soy oil</LI>
</UL>
<P>Co-interventions: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-24 16:32:26 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Patient survival</LI>
<LI>Graft survival</LI>
<LI>Acute rejection</LI>
<LI>CNI toxicity</LI>
<LI>Adverse effects</LI>
<LI>Compliance</LI>
<LI>Kidney function (SCr, CrCl, GFR)</LI>
<LI>BP</LI>
<LI>Lipids</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-04 14:20:21 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Exclusions post randomisation but pre intervention: 1 patient (post-op thrombosis, graft loss)</LI>
<LI>Additional data requested: unpublished data provided by triallists</LI>
<UL>
<LI>Nature of loss to follow-up: 12 patients at 12 months (fish oil: allograft loss (6), acute rejection (5), CAN (1); control: allograft loss (6), acute rejection (4), CAN (2)).</LI>
<LI>These figures were used for graft survival analysis rather than deriving numbers from percentages in publication. In publication, 5 patients lost grafts (fish oil (3), control (2)). We have assumed that these occurred in the intervention period of the initial 3 months and the remainder of the graft losses occurred from 4 to 12 months. Therefore, we have adjusted the patient numbers to 42/38 for fish oil/control respectively for the analysis of continuous outcomes.</LI>
<LI>Patients with rejection: 36 (fish oil (20), control (16))</LI>
<LI>CNI toxicity: all biopsy proven</LI>
<LI>Adverse effects: fishy aftertaste 70%</LI>
<LI>Compliance: no patient drop-out</LI>
<LI>HDL (LDL calculated using Frederickson formula)</LI>
<LI>Systolic and diastolic BP</LI>
</UL>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-08-11 10:32:13 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Homan-van-der-Heide-1990a">
<CHAR_METHODS MODIFIED="2016-03-21 17:50:28 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Study design: double blind placebo controlled RCT</LI>
<LI>Time frame: 1 month</LI>
<LI>Follow-up period: 1 month</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-21 17:52:30 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: Netherlands</LI>
<LI>Setting: single centre (unclear)</LI>
<LI>Inclusion criteria: not reported</LI>
<LI>Number: treatment group (14); control group (17)</LI>
<LI>Median age, range (years): treatment group (49, 28 to 63); control group (47, 22 to 64)</LI>
<LI>Sex (M/F): not reported</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-24 08:04:03 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>6 g/d fish oil (Kortman Intradal) EPA 30%; DHA 20%</LI>
</UL>
<P>Control group</P>
<UL>
<LI>6 g/d coconut oil</LI>
</UL>
<P>Co-interventions: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-24 14:54:27 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Patient survival</LI>
<LI>Graft failure</LI>
<LI>Acute rejection (not defined whether biopsy proven, data not used)</LI>
<LI>Adverse effects</LI>
<LI>BP (MAP)</LI>
<LI>Kidney function (SCr, CrCl, GFR)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-08-11 10:32:13 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre intervention: none</LI>
<LI>Additional data requested: no unpublished data provided</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-04-04 10:46:57 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Homan-van-der-Heide-1990b">
<CHAR_METHODS MODIFIED="2016-03-24 10:44:01 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: double blind placebo controlled RCT</LI>
<LI>Time frame: 3 months</LI>
<LI>Follow-up period: 3 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-24 14:54:38 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Netherlands</LI>
<LI>Setting: single centre (unclear)</LI>
<LI>Patients &gt; 9 months post-transplant, stable kidney function and CSA dosage &gt; 3 months</LI>
<LI>Number: treatment group (11); control group (10)</LI>
<LI>Median age, range (years): treatment group (40, 27 to 66); control group (37, 17 to 62)</LI>
<LI>Sex (M/F): treatment group (5/6); control group (6/4)</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-24 10:47:50 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>6 g/d fish oil (Super EPA) EPA 30%; DHA 20%</LI>
</UL>
<P>Control group</P>
<UL>
<LI>6 g/d corn oil</LI>
</UL>
<P>Co-interventions: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-24 14:54:50 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Patient survival</LI>
<LI>Graft failure</LI>
<LI>Acute rejection</LI>
<LI>Compliance</LI>
<LI>BP (MAP)</LI>
<LI>Kidney function (SCr, CrCl, GFR)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-04-04 10:46:57 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Exclusions post randomisation but pre intervention: none</LI>
<LI>Additional data requested: no unpublished data provided</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-08-11 10:31:31 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Homan-van-der-Heide-1992">
<CHAR_METHODS MODIFIED="2016-03-24 10:50:13 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: double blind placebo controlled RCT</LI>
<LI>Time frame: 1 month</LI>
<LI>Follow-up period: 1 month</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-24 10:51:48 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Netherlands</LI>
<LI>Setting: single centre</LI>
<LI>Consecutive first cadaveric kidney transplants</LI>
<LI>Number: treatment group (40); control group (48)</LI>
<LI>Median age, range (years): treatment group (48, 17 to 68); control group (44, 19 to 68)</LI>
<LI>Sex (M/F): treatment group (26/14); control group (28/20)</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-24 10:51:53 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>6 g/d fish oil (Kortman Intradal) EPA 30%; DHA 20%</LI>
</UL>
<P>Control group</P>
<UL>
<LI>6 g/d coconut oil</LI>
</UL>
<P>Co-interventions: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-24 14:55:12 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Patient survival</LI>
<LI>Graft survival</LI>
<LI>Acute rejection</LI>
<LI>Adverse effects</LI>
<LI>Compliance</LI>
<LI>Kidney function (SCr, CrCl)</LI>
<LI>BP (MAP)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-08-11 10:31:31 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre intervention: none</LI>
<LI>Additional data requested: no unpublished data provided</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-08-11 10:31:38 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Homan-van-der-Heide-1993">
<CHAR_METHODS MODIFIED="2016-03-24 11:01:25 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: double blind placebo control RCT (blinding ceased at 3 months)</LI>
<LI>Time frame: 12 months</LI>
<LI>Follow-up period: 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-24 11:02:49 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Netherlands</LI>
<LI>Setting: single centre</LI>
<LI>First cadaveric kidney transplant</LI>
<LI>Number: treatment group (33); control group (33)</LI>
<LI>Median age, range (years): treatment group (41, 17 to 69); control group (47, 19 to 67)</LI>
<LI>Sex (M/F): treatment group (21/12); control group (19/14)</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-24 11:02:53 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>6 g/d fish oil (Kortman Intradal) EPA 30%; DHA 20%</LI>
</UL>
<P>Control group</P>
<UL>
<LI>6 g/d coconut oil</LI>
</UL>
<P>Co-interventions: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-24 14:55:24 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Patient survival</LI>
<LI>Graft survival</LI>
<LI>Acute rejection</LI>
<LI>Adverse effects</LI>
<LI>Compliance</LI>
<LI>Kidney function (GFR)</LI>
<LI>BP (MAP)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-08-11 10:31:38 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre intervention: none</LI>
<LI>Additional data requested: no unpublished data provided</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-08-11 10:31:55 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Kooijmans_x002d_Coutinho-1996">
<CHAR_METHODS MODIFIED="2016-03-24 11:10:10 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: double blind placebo controlled RCT</LI>
<LI>Time frame: 12 months (May 1990 to November 1991)</LI>
<LI>Follow-up period: 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-04-04 14:20:38 +1000" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Country: Netherlands</LI>
<LI>Setting: single centre, University hospital</LI>
<LI>First cadaveric kidney transplant recipients</LI>
<LI>Number: treatment group (25); control group (25)</LI>
<LI>Median age, range (years): treatment group (43.5, 22 to 71); control group (47.0, 27 to 68)</LI>
<LI>Sex (M/F): treatment group (13/12); control group (17/12)</LI>
<LI>Exclusion criteria: fish/iodine allergy; non-steroidal anti-inflammatory treatment; diabetes; previous non-compliance</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-24 11:29:45 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Fish oil 6 g/d (Kortman Intradal) EPA 30%; DHA 20%</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Coconut oil 6 g/d</LI>
</UL>
<P>Co-interventions: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-24 14:55:33 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Patient survival</LI>
<LI>Graft survival</LI>
<LI>Acute rejection</LI>
<LI>Cardiovascular events</LI>
<LI>Adverse effects</LI>
<LI>Compliance</LI>
<LI>Kidney function (CrCl, GFR)</LI>
<LI>BP (MAP)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-08-11 10:31:55 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre intervention: none</LI>
<LI>Additional data requested: no unpublished data provided</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-08-11 10:31:56 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Maachi-1995">
<CHAR_METHODS MODIFIED="2016-03-24 13:21:21 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: RCT</LI>
<LI>Time frame: 12 months</LI>
<LI>Follow-up period: 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-24 13:20:15 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: France</LI>
<LI>Setting: single centre, University hospital</LI>
<LI>Consecutive cadaveric kidney transplant recipients</LI>
<LI>Number: treatment group (40); control group (40)</LI>
<LI>Mean age ± SD (years): treatment group (44.7 ± 12.7); control group (42.8 ± 11.2)</LI>
<LI>Sex (M/F): treatment group (30/10); control group (30/10)</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-24 13:21:08 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Fish oil 8 g/d (Maxepa) EPA 18%; DHA 12%</LI>
</UL>
<P>Control group</P>
<UL>
<LI>No placebo</LI>
</UL>
<P>Co-interventions: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-24 13:22:14 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Patient survival</LI>
<LI>Graft failure</LI>
<LI>Acute rejection</LI>
<LI>Adverse effects</LI>
<LI>Compliance</LI>
<LI>Kidney function (SCr, CrCl, GFR)</LI>
<LI>Hypertension (number of medications to maintain set BP goal)</LI>
<LI>Lipids (TC,TG)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-08-11 10:31:56 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre intervention: 1 patient failed to received fish oil</LI>
<LI>Additional data requested: no unpublished data provided</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-24 14:56:14 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Rodriguez-1997">
<CHAR_METHODS MODIFIED="2016-03-24 14:02:33 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: parallel RCT</LI>
<LI>Time frame: 6 months</LI>
<LI>Follow-up period: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-24 14:56:14 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Spain</LI>
<LI>Setting: single centre</LI>
<LI>Clinically stable kidney transplants with hyperlipidaemia after 3 months dietary intervention, TC &gt; 240 mg/dL (6.2 mmol/L)</LI>
<LI>Number: treatment group (18); control group (16)</LI>
<LI>Mean age ± SD (years): treatment group (43.8 ± 9.4); control group (42.7 ± 12.5)</LI>
<LI>Sex (M/F): treatment group (13/5); control group (11/5)</LI>
<LI>Exclusion criteria: diabetes; nephrotic syndrome; abnormal liver function; SCr &gt; 3 mg/dL (229 &#956;mol/L)</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-24 13:50:43 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Fish oil 2 g/d (Beromegan) EPA 18%; DHA 12%</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Lovastatin 20 mg/d</LI>
</UL>
<P>Co-interventions: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-24 13:50:35 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Lipids (TC, TG, LDL, HDL)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-03-24 14:02:19 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre intervention: none</LI>
<LI>Additional data requested from authors: none</LI>
<LI>Paper in Spanish. Translation obtained from Spanish speaking person</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-24 14:56:40 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Santos-2000">
<CHAR_METHODS MODIFIED="2016-03-24 14:24:17 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: placebo controlled RCT</LI>
<LI>Time frame: 12 months</LI>
<LI>Follow-up period: 12 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-24 14:56:27 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Portugal</LI>
<LI>Setting: single centre</LI>
<LI>First cadaveric kidney transplant with delayed graft function (urine output &lt; 1000 mL/d and no improvement in SCr)</LI>
<LI>Number: treatment group (15); control group (15)</LI>
<LI>Mean age ± SD (years): treatment group (37.4 ± 10.9); control group (37.8 ± 11.8)</LI>
<LI>Sex (M/F): treatment group (7/8); control group (9/6)</LI>
<LI>Exclusion criteria: primary non-function; diabetes</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-24 14:25:32 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Fish oil 6 g/d EPA 30%; DHA 20%</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Placebo; not specified</LI>
</UL>
<P>Co-interventions: low sodium diet advised</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-24 14:56:40 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Patient survival</LI>
<LI>Graft survival</LI>
<LI>Acute rejection</LI>
<LI>Adverse effects</LI>
<LI>Compliance</LI>
<LI>Kidney function (SCr, CrCl, GFR)</LI>
<LI>BP (systolic, diastolic)</LI>
<LI>Lipids (TC, LDL, HDL, TG)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-03-24 14:26:31 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre intervention: none</LI>
<LI>Additional data requested from authors: no unpublished data provided</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-08-11 10:31:59 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Schut-1992a">
<CHAR_METHODS MODIFIED="2016-03-24 14:37:48 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: double blind cross-over RCT</LI>
<LI>Time frame: 4 months (first period of randomisation) (1979 to 1988)</LI>
<LI>Follow-up period: 8 months (2 periods of crossover)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-24 14:56:55 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Netherlands</LI>
<LI>Setting: single centre</LI>
<LI>Cadaveric kidney transplant stable for at least 1 year</LI>
<LI>Number: 10</LI>
<LI>Mean age ± SD: 53 ± 14 years</LI>
<LI>Sex (M/F): 4/6</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-24 14:42:21 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Fish oil 6 g/d (SuperEPA) EPA 30%; DHA 20%</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Corn oil 6 g/d</LI>
</UL>
<P>Co-interventions: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-24 14:56:47 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>BP (MAP)</LI>
<LI>Kidney function (GFR)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-08-11 10:31:59 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Same study as <LINK REF="STD-Schut-1992b" TYPE="STUDY">Schut 1992b</LINK>
</LI>
<LI>Data for patients receiving CSA only</LI>
<LI>Exclusions post randomisation but pre intervention: none</LI>
<LI>Additional data requested: no unpublished data provided</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-03-24 16:32:28 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Schut-1992b">
<CHAR_METHODS MODIFIED="2016-03-24 14:43:27 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: double blind cross-over RCT</LI>
<LI>Time frame: 4 months (first period of randomisation) (1979 to 1988)</LI>
<LI>Follow-up period: 8 months (2 periods of crossover)</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-24 14:57:07 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: Netherlands</LI>
<LI>Setting: single centre</LI>
<LI>Cadaveric kidney transplant stable for at least 1 year</LI>
<LI>Number: 10</LI>
<LI>Mean age ± SD: 51 ± 14 years</LI>
<LI>Sex (M/F): 9/1</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-24 14:43:27 +1100" MODIFIED_BY="Narelle S Willis">
<P>Treatment group</P>
<UL>
<LI>Fish oil 6 g/d (SuperEPA) EPA 30%; DHA 20%</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Corn oil 6 g/d</LI>
</UL>
<P>Co-interventions: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-24 16:32:28 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>BP (MAP)</LI>
<LI>Kidney function (GFR)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-03-24 14:57:16 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Same study as <LINK REF="STD-Schut-1992a" TYPE="STUDY">Schut 1992a</LINK>
</LI>
<LI>Data from CSA and prednisone group only</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2016-08-11 10:32:02 +1000" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Yoa-1994">
<CHAR_METHODS MODIFIED="2016-03-24 14:46:23 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Study design: double blind placebo controlled RCT</LI>
<LI>Time frame: 6 months</LI>
<LI>Follow-up period: 6 months</LI>
</UL>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-24 14:47:18 +1100" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Country: France</LI>
<LI>Setting: university hospital</LI>
<LI>All kidney transplant patients stable for at least 3 months</LI>
<LI>Number: treatment group (12); control group (11)</LI>
<LI>Mean age ± SD (years): treatment group (38.5 ± 11.01); control group (37 ± 14.15)</LI>
<LI>Sex (M/F): treatment group (6/6); control group (7/4)</LI>
<LI>Exclusion criteria: not reported</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-14 16:56:21 +1100" MODIFIED_BY="Narelle Willis">
<P>Treatment group</P>
<UL>
<LI>Fish oil 6 g/d (MaxEPA) EPA 18%; DHA 12%</LI>
</UL>
<P>Control group</P>
<UL>
<LI>Olive oil 6 g/d</LI>
</UL>
<P>Co-interventions: none</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-03-14 16:56:13 +1100" MODIFIED_BY="Narelle Willis">
<UL>
<LI>Lipids</LI>
<LI>Kidney function (CrCl)</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-08-11 10:32:02 +1000" MODIFIED_BY="Narelle S Willis">
<UL>
<LI>Exclusions post randomisation but pre intervention: none</LI>
<LI>Additional data requested: none</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AHA - American Heart Association; BP - blood pressure; CAN - chronic allograft nephropathy; CNI - calcineurin inhibitor; COPD - chronic obstructive pulmonary disease; CrCl - creatinine clearance; CSA - cyclosporin A; DHA - docosahexaenoic acid; EPA - eicosapentaenoic acid; GFR - glomerular filtration rate; HDL - high density lipoprotein; LDL - low density lipoprotein; MAP - mean arterial pressure; M/F - male/female; MI - myocardial infarction; RCT - randomised controlled trial; SCr - serum creatinine; SD - standard deviation; TC - total cholesterol; TG - triglycerides</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2016-03-24 16:36:25 +1100" MODIFIED_BY="Narelle S Willis" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-A_x002d_Echevarria-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Non-interventional, non-RCT, cross-sectional dietary assessment study, examining dietary influences on the plasma profile of fatty acids.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-24 16:35:02 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Alexander-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-24 16:35:02 +1100" MODIFIED_BY="Narelle S Willis">
<P>This RCT has dual therapy (arginine + canola oil) in the intervention arm. Fish oil is not used, although canola oil does contain small amounts of omega-3. Arginine alone may have impact on outcome measures.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:11 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Alexander-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:11 +1100" MODIFIED_BY="Narelle Willis">
<P>Dual intervention with arginine and fish oil. Arginine alone may have impact on outcome measure</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:12 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Alexander-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:12 +1100" MODIFIED_BY="Narelle Willis">
<P>Dual intervention with arginine and fish oil</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:13 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Arnadottir-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:13 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, review article on treatment of hyperlipidaemia in kidney transplant recipients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:13 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Balasubramaniam-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:13 +1100" MODIFIED_BY="Narelle Willis">
<P>A conference abstract looking at treatment of donors, not recipients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:21 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Bellomo-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:21 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, conference paper on nutritional support in ICU patients with kidney failure</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:23 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Bennett-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:23 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, review article on arachidonic acid metabolism in transplant-associated acute kidney failure</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:24 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Bloomgarden-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:24 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, review article</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:26 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Butani-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:26 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, case report on the effect of fish oil in post-transplantation IgA nephropathy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:27 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Clark-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:27 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, review article on the treatment of lupus nephritis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:28 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Davis-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:28 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, review article on kidney disease and liver transplantation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:30 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-de-Mattos-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:30 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, review article on immunosuppressive medications</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:31 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Donadio-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:31 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, review article on IgA nephropathy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:32 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Donadio-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:32 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, review article on IgA nephropathy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:33 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Endres-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:33 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, review article on n-3 fatty acids</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:34 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Endres-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:34 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, review article on n-3 PUFA and human cytokine synthesis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:35 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Farbakhsh-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:35 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, review article on dyslipidaemia in CKD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:35 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Gerster-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:35 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, review article on fish oil in enteral nutrition</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-24 16:35:28 +1100" MODIFIED_BY="Narelle S Willis" STUDY_ID="STD-Grekas-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-24 16:35:28 +1100" MODIFIED_BY="Narelle S Willis">
<P>Non-RCT. There is no control group in this clinical trial of dyslipidaemia, where treatment consists of statin + fish oil</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:42 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Grimble-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:42 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, review article on stress proteins</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:43 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Hansen-1995a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:43 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, cohort study in stable transplants looking at the effects of fish oil on kidney haemodynamics</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:44 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Hansen-1995b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:44 +1100" MODIFIED_BY="Narelle Willis">
<P>No control group - All patients and "controls" received fish oil. No randomisation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:44 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Hejaili-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:44 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, review article on lupus nephritis</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:45 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Homan-van-der-Heide-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:45 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT. Journal note/commentary on another trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:46 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Julian-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:46 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, conference paper on IgA nephropathy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:48 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Kasiske-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:48 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, K/DOQI practice guidelines on treatment of dyslipidaemia in CKD</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:49 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Kasiske-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:49 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, K/DOQI practice guidelines on treatment of dyslipidaemia in kidney transplantation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:50 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Kho-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:50 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, study examining effects of dopamine infusion and fish oil administration on urinary prostaglandins</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:54 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Kobashigawa-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:54 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT. Review article on hyperlipidaemia in solid organ transplantation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:55 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Levi-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:55 +1100" MODIFIED_BY="Narelle Willis">
<P>Fish oil versus corn oil crossover trial, which did not include any of the outcome measures examined in the review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:56 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Maes-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:56 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, short survey on IgA nephropathy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:58 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Mathis-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:58 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, review article on drug-related dyslipidaemia after kidney transplantation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:58 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Naber-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:58 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, conference paper on lipids in artificial nutrition</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:19:59 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Nakamura-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:19:59 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, uncontrolled cohort study on the effects of fish oil on hyperlipidaemia post transplantation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:20:03 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Ramezani--2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:20:03 +1100" MODIFIED_BY="Narelle Willis">
<P>Immunosuppression protocol could not be determined (in relation of CNI exposure) and the lipid data presented represents change in values rather than absolute numbers. No further information was available from study authors. Authors contacted 24 July 2015 - no reply as of 10 Feb 2016</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:20:05 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Rodicio-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:20:05 +1100" MODIFIED_BY="Narelle Willis">
<P>No fish oil intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:20:06 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Romo-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:20:06 +1100" MODIFIED_BY="Narelle Willis">
<P>Abstract only available. All patients received omega-3, with the control group receiving placebo and intervention group receiving atorvastatin. Unclear if all patients on CNI</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:20:08 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Schiele-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:20:08 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, review article on IgA nephropathy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:20:08 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Shah-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:20:08 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, no fish oil intervention</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:20:10 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Shihab-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:20:10 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, review article on cyclosporine nephropathy</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:20:11 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Singer-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:20:11 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT study of parenteral fish oil given to donors and recipients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:20:15 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Soylu-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:20:15 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, conference paper on paediatric kidney transplant experience</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:20:18 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Urakaze-1989">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:20:18 +1100" MODIFIED_BY="Narelle Willis">
<P>Not all patients were on CNI (separate data for patients on CNI not provided)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:20:19 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Wierzbicki-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:20:19 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, review article on lipid lowering in transplantation</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:20:20 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Young-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:20:20 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-kidney transplant patients. Conference paper</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:20:23 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Zak-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:20:23 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, non-transplant patients, trial on fish oil in diabetic patients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2016-03-14 16:20:24 +1100" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-Zolotarski-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2016-03-14 16:20:24 +1100" MODIFIED_BY="Narelle Willis">
<P>Non-RCT, conference paper on effects of parenteral fish oil given to donors and kidney transplant recipients</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>CKD - chronic kidney disease; CNI - calcineurin inhibitor; ICU - intensive care unit; RCT - randomised controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2016-04-04 14:21:59 +1000" MODIFIED_BY="Narelle Willis" STUDY_ID="STD-NCT01744067">
<CHAR_METHODS MODIFIED="2016-03-31 15:25:39 +1100" MODIFIED_BY="Narelle S Willis">
<P>Allocation: randomised<BR/>Endpoint classification: safety/efficacy study<BR/>Intervention model: parallel assignment<BR/>Masking: double blind (subject, caregiver, investigator, outcomes assessor)<BR/>Primary purpose: treatment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2016-03-24 18:24:39 +1100" MODIFIED_BY="Narelle S Willis">
<P>Inclusion criteria</P>
<UL>
<LI>Patients over the age of 18 who have received a kidney transplant. Patients with a functioning kidney transplant, defined as eGFR&gt;30 ml/min. Signed informed consent.</LI>
</UL>
<P>Exclusion criteria</P>
<UL>
<LI>Patients participating in clinical trials with other investigational drugs. Patients who received a deceased donor kidney from a donor &gt;75 years. Patients with a history of an allergic reaction or significant sensitivity to the study drug or drugs similar to the study drug.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2016-03-24 18:40:56 +1100" MODIFIED_BY="Narelle S Willis">
<P>Active comparator</P>
<P>Omega-3 fatty acids 2,7 g omega-3 fatty acids / day: Omacor 1 g 1 capsule by mouth 3 times a day for 44 weeks.</P>
<P>Placebo comparator</P>
<P>Placebo: 1 capsule containing 1 g of olive oil by mouth 3 times a day for 44 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2016-04-04 14:21:59 +1000" MODIFIED_BY="Narelle Willis">
<P>Primary outcome measures</P>
<P>Glomerular filtration rate. Time frame: 44 weeks. Iohexol clearance<BR/>
<BR/>Secondary outcome measures</P>
<P>Proteinuria. Time frame: 44 weeks. Both ACR and FEPR<BR/>Inflammation in the renal transplant. Time frame: 44 weeks. Degree of total inflammation in renal transplant biopsies, scores by PI and rescored by two pathologists.<BR/>Fibrosis in the renal transplant. Time frame: 44 weeks. As for inflammation<BR/>Blood pressure. Time frame: 44 weeks.<BR/>Heart rate variability. Time frame: 44 weeks.<BR/>Flow mediated dilation. Time frame: 44 weeks.<BR/>Pulse wave velocity and augmentation index. Time frame: 44 weeks.<BR/>Blood glucose. Time frame: 44 weeks. HbA1c and oral glucose tolerance test<BR/>Lipids. Time frame: 44 weeks. Total, LDL and HDL cholesterol, triglyceride and ratios<BR/>Body composition. Time frame: 44 weeks. Visceral fat volume and weight, visceral to subcutaneous fat ratio.<BR/>Bone mineral density. Time frame: 44 weeks. Regular BMD in the lumbar spine, hips, femur and arms and also selected to trabecular bone.<BR/>Body mass index. Time frame: 44 weeks.<BR/>Vitamin D levels. Time frame: 44 weeks.<BR/>Fatty acid composition in plasma and renal tissue. Time frame: 44 weeks.<BR/>Tacrolimus pharmacokinetics. Time frame: 12 weeks. Substudy of 15 patients, where we study tacrolimus trough levels, Tmax and AUC at the end of the ORENTRA trial, after a minimum of 4 weeks wash-out and again after 4 weeks of 2.7 g omega-3 fatty acid supplementation<BR/>
</P>
<P>Other outcomes<BR/>Incidence of post-transplant complications. Time frame: 44 weeks + 8 weeks.<BR/>Adverse events. Time frame: 44 weeks + 8 weeks.<BR/>Adverse reactions. Time frame: 44 weeks.<BR/>Frequency of clinically significant safety laboratory variables [Time Frame: 44 weeks]. Especially INR and tacrolimus trough concentrations. Follow-up by local nephrologist plus five Telephone Controls during follow-up.<BR/>Quality of life. Time frame: 44 weeks. The participants fill out SF-36 at baseline and the 1 year post transplant control for both safety reasons and measurement of differences between the groups with regards to quality of life.<BR/>Food questionnaire. Time frame: 44 weeks. Two specially designed food questionnaires to obtain data on dietary habits in general and type and amount of fish consumed<BR/>Comorbidity, concomitant medication and life-style factor interview. Time frame: 44 weeks.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2016-03-01 14:55:43 +1100" MODIFIED_BY="Gail Y Higgins"/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2016-03-01 14:55:43 +1100" MODIFIED_BY="Gail Y Higgins" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2016-03-31 16:31:54 +1100" MODIFIED_BY="Narelle S Willis">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2016-03-24 14:48:28 +1100" MODIFIED_BY="Narelle S Willis" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 16:54:20 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bennett-_x0028_high_x0029_-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 16:59:52 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bennett-_x0028_low_x0029_-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 17:06:35 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Berthoux-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 17:15:51 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Busnach-1998">
<DESCRIPTION>
<P>Central randomisation (sponsor)<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 17:28:19 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Castro-1997">
<DESCRIPTION>
<P>Not reported<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 17:41:31 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hernandez-2002">
<DESCRIPTION>
<P>Central (method not specified)<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 17:55:48 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Homan-van-der-Heide-1990a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 08:31:10 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Homan-van-der-Heide-1990b">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 10:53:19 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Homan-van-der-Heide-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 13:17:34 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Homan-van-der-Heide-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 11:31:41 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Kooijmans_x002d_Coutinho-1996">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 13:23:58 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Maachi-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 14:02:04 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Rodriguez-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 14:23:29 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Santos-2000">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 14:29:54 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Schut-1992a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 14:30:03 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Schut-1992b">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 14:48:28 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Yoa-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2016-03-24 14:48:15 +1100" MODIFIED_BY="Narelle S Willis" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 16:56:26 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bennett-_x0028_high_x0029_-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 16:59:52 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bennett-_x0028_low_x0029_-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 17:06:40 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Berthoux-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 17:15:47 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Busnach-1998">
<DESCRIPTION>
<P>Closed envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 17:27:04 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Castro-1997">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 17:40:33 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hernandez-2002">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 17:54:08 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Homan-van-der-Heide-1990a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 08:31:15 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Homan-van-der-Heide-1990b">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 10:52:41 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Homan-van-der-Heide-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 10:56:50 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Homan-van-der-Heide-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 11:30:51 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Kooijmans_x002d_Coutinho-1996">
<DESCRIPTION>
<P>Sealed envelope</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 13:24:12 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Maachi-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-14 16:17:45 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Rodriguez-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 14:23:33 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Santos-2000">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 14:29:23 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Schut-1992a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 14:30:03 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Schut-1992b">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 14:48:15 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Yoa-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2016-03-31 16:15:24 +1100" MODIFIED_BY="Narelle S Willis" NO="9">
<NAME>Intention-to-treat analysis</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 16:54:30 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Bennett-_x0028_high_x0029_-1995">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 16:59:56 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Bennett-_x0028_low_x0029_-1995">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 17:06:46 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Berthoux-1992">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 17:14:17 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Busnach-1998">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 17:39:43 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Castro-1997">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 17:40:48 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Hernandez-2002">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 17:55:37 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Homan-van-der-Heide-1990a">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 08:30:28 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Homan-van-der-Heide-1990b">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 10:52:47 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Homan-van-der-Heide-1992">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 10:56:57 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Homan-van-der-Heide-1993">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 11:31:31 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Kooijmans_x002d_Coutinho-1996">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 13:23:12 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Maachi-1995">
<DESCRIPTION>
<P>No</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 14:01:28 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Rodriguez-1997">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 14:23:12 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Santos-2000">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 14:29:29 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Schut-1992a">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-31 16:15:24 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Schut-1992b">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 14:47:57 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Yoa-1994">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2016-03-21 16:54:05 +1100" MODIFIED_BY="Narelle Willis" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2016-03-31 16:31:54 +1100" MODIFIED_BY="Narelle S Willis" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-21 16:54:57 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Bennett-_x0028_high_x0029_-1995">
<DESCRIPTION>
<P>Participants blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-21 16:59:58 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Bennett-_x0028_low_x0029_-1995">
<DESCRIPTION>
<P>Participants blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-21 17:07:06 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Berthoux-1992">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-21 17:14:44 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Busnach-1998">
<DESCRIPTION>
<P>Participants and investigators blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-21 17:26:41 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Castro-1997">
<DESCRIPTION>
<P>Open-label study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-21 17:41:07 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Hernandez-2002">
<DESCRIPTION>
<P>Participants and investigators blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-21 17:55:22 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Homan-van-der-Heide-1990a">
<DESCRIPTION>
<P>Participants blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-31 16:27:24 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Homan-van-der-Heide-1990b">
<DESCRIPTION>
<P>Participants blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-31 16:29:13 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Homan-van-der-Heide-1992">
<DESCRIPTION>
<P>Participants blinded; placebo flavour matched</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-31 16:30:37 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Homan-van-der-Heide-1993">
<DESCRIPTION>
<P>Participants blinded; placebo flavour matched</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-31 16:31:54 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Kooijmans_x002d_Coutinho-1996">
<DESCRIPTION>
<P>Only first 3 months then code broken</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-24 13:23:21 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Maachi-1995">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-24 14:01:35 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Rodriguez-1997">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-24 14:23:16 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Santos-2000">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-24 14:29:10 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Schut-1992a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-24 14:30:03 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Schut-1992b">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2016-03-24 14:48:02 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Yoa-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2016-03-24 14:52:47 +1100" MODIFIED_BY="Narelle S Willis" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-21 16:55:12 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bennett-_x0028_high_x0029_-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-21 16:59:52 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Bennett-_x0028_low_x0029_-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-21 17:07:14 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Berthoux-1992">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-24 14:52:47 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Busnach-1998">
<DESCRIPTION>
<P>Outcome assessors and data analysis blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-21 17:26:53 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Castro-1997">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-21 17:41:15 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Hernandez-2002">
<DESCRIPTION>
<P>Outcomes assessors blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-21 17:54:50 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Homan-van-der-Heide-1990a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-24 08:30:40 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Homan-van-der-Heide-1990b">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-24 10:52:56 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Homan-van-der-Heide-1992">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-24 10:57:43 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Homan-van-der-Heide-1993">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-24 11:31:23 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Kooijmans_x002d_Coutinho-1996">
<DESCRIPTION>
<P>Yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-24 13:23:29 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Maachi-1995">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-24 14:01:39 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Rodriguez-1997">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-24 14:23:19 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Santos-2000">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-24 14:29:14 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Schut-1992a">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-24 14:30:03 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Schut-1992b">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2016-03-24 14:48:09 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Yoa-1994">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2016-03-31 16:19:44 +1100" MODIFIED_BY="Narelle S Willis" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-21 16:55:36 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Bennett-_x0028_high_x0029_-1995">
<DESCRIPTION>
<P>Loss to follow-up: 43 (32%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-21 17:00:01 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Bennett-_x0028_low_x0029_-1995">
<DESCRIPTION>
<P>Loss to follow-up: 43 (32%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-21 17:07:29 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Berthoux-1992">
<DESCRIPTION>
<P>Loss to follow-up: 3 (9%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-21 17:15:26 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Busnach-1998">
<DESCRIPTION>
<P>No losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-21 17:27:21 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Castro-1997">
<DESCRIPTION>
<P>No losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-21 17:46:16 +1100" MODIFIED_BY="Narelle Willis" RESULT="UNKNOWN" STUDY_ID="STD-Hernandez-2002">
<DESCRIPTION>
<P>12/86 (14%) lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-21 17:55:17 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Homan-van-der-Heide-1990a">
<DESCRIPTION>
<P>No losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-24 08:29:44 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Homan-van-der-Heide-1990b">
<DESCRIPTION>
<P>Loss to follow-up: 3 (14%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-24 10:49:54 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Homan-van-der-Heide-1992">
<DESCRIPTION>
<P>No loss to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-24 10:56:38 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Homan-van-der-Heide-1993">
<DESCRIPTION>
<P>Loss to follow-up: 6 (9%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-24 11:32:24 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Kooijmans_x002d_Coutinho-1996">
<DESCRIPTION>
<P>No losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-24 13:18:13 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Maachi-1995">
<DESCRIPTION>
<P>Loss to follow-up: 2 (2%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-24 13:51:03 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Rodriguez-1997">
<DESCRIPTION>
<P>Loss to follow-up: 2 (6%)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-31 16:19:12 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Santos-2000">
<DESCRIPTION>
<P>No losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-31 16:19:24 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Schut-1992a">
<DESCRIPTION>
<P>No losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-31 16:16:41 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Schut-1992b">
<DESCRIPTION>
<P>No losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2016-03-31 16:19:44 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Yoa-1994">
<DESCRIPTION>
<P>No losses to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2016-03-31 16:19:52 +1100" MODIFIED_BY="Narelle S Willis" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-31 16:16:20 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Bennett-_x0028_high_x0029_-1995">
<DESCRIPTION>
<P>Outcomes relevant to our review were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 17:19:04 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Bennett-_x0028_low_x0029_-1995">
<DESCRIPTION>
<P>Outcomes relevant to our review were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 16:32:18 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Berthoux-1992">
<DESCRIPTION>
<P>BP reported but no data available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 16:32:23 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Busnach-1998">
<DESCRIPTION>
<P>All relevant outcomes reported; BP not reported but data no longer available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 17:38:26 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Castro-1997">
<DESCRIPTION>
<P>Only lipids were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 17:41:58 +1100" MODIFIED_BY="Narelle Willis" RESULT="YES" STUDY_ID="STD-Hernandez-2002">
<DESCRIPTION>
<P>Outcomes relevant to this review reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-21 17:56:52 +1100" MODIFIED_BY="Narelle Willis" RESULT="NO" STUDY_ID="STD-Homan-van-der-Heide-1990a">
<DESCRIPTION>
<P>Unable to use acute rejection data; median data reported for some continuous outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 10:58:26 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Homan-van-der-Heide-1990b">
<DESCRIPTION>
<P>Median data reported for some continuous outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 10:58:39 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Homan-van-der-Heide-1992">
<DESCRIPTION>
<P>Median data reported for some continuous outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 10:59:25 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Homan-van-der-Heide-1993">
<DESCRIPTION>
<P>Median data reported for some continuous outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 11:32:21 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Kooijmans_x002d_Coutinho-1996">
<DESCRIPTION>
<P>Outcomes relevant to this review were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 13:23:52 +1100" MODIFIED_BY="Narelle S Willis" RESULT="UNKNOWN" STUDY_ID="STD-Maachi-1995">
<DESCRIPTION>
<P>Outcomes relevant to this review were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 14:01:57 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Rodriguez-1997">
<DESCRIPTION>
<P>Only lipid results reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-31 16:19:05 +1100" MODIFIED_BY="Narelle S Willis" RESULT="YES" STUDY_ID="STD-Santos-2000">
<DESCRIPTION>
<P>Outcomes relevant to this review were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-24 14:29:46 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Schut-1992a">
<DESCRIPTION>
<P>Only BP and GFR reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-31 16:15:44 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Schut-1992b">
<DESCRIPTION>
<P>Only BP and GFR reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2016-03-31 16:19:52 +1100" MODIFIED_BY="Narelle S Willis" RESULT="NO" STUDY_ID="STD-Yoa-1994">
<DESCRIPTION>
<P>Only lipids and CrCl reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2016-03-21 16:54:05 +1100" MODIFIED_BY="Narelle Willis" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2016-08-11 10:42:37 +1000" MODIFIED_BY="Narelle S Willis">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NO="1">
<TITLE>Summary of reported outcome measures</TITLE>
<TABLE COLS="10" ROWS="16">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Patient survival</P>
</TH>
<TH>
<P>Graft survival</P>
</TH>
<TH>
<P>Acute rejection</P>
</TH>
<TH>
<P>CNI toxicity</P>
</TH>
<TH>
<P>Adverse effects</P>
</TH>
<TH>
<P>Compliance</P>
</TH>
<TH>
<P>Kidney function</P>
</TH>
<TH>
<P>Blood pressure</P>
</TH>
<TH>
<P>Lipid profile</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bennett-_x0028_high_x0029_-1995" TYPE="STUDY">Bennett (high) 1995</LINK>; <LINK REF="STD-Bennett-_x0028_low_x0029_-1995" TYPE="STUDY">Bennett (low) 1995</LINK>
</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>X</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Berthoux-1992" TYPE="STUDY">Berthoux 1992</LINK>
</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Busnach-1998" TYPE="STUDY">Busnach 1998</LINK>
</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Castro-1997" TYPE="STUDY">Castro 1997</LINK>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>X</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hernandez-2002" TYPE="STUDY">Hernandez 2002</LINK>
</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Homan-van-der-Heide-1990a" TYPE="STUDY">Homan van der Heide 1990a</LINK>
</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Homan-van-der-Heide-1990b" TYPE="STUDY">Homan van der Heide 1990b</LINK>
</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Homan-van-der-Heide-1992" TYPE="STUDY">Homan van der Heide 1992</LINK>
</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Homan-van-der-Heide-1993" TYPE="STUDY">Homan van der Heide 1993</LINK>
</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kooijmans_x002d_Coutinho-1996" TYPE="STUDY">Kooijmans-Coutinho 1996</LINK>
</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Maachi-1995" TYPE="STUDY">Maachi 1995</LINK>
</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>X</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rodriguez-1997" TYPE="STUDY">Rodriguez 1997</LINK>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>X</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Santos-2000" TYPE="STUDY">Santos 2000</LINK>
</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Schut-1992a" TYPE="STUDY">Schut 1992a</LINK>; <LINK REF="STD-Schut-1992b" TYPE="STUDY">Schut 1992b</LINK>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Yoa-1994" TYPE="STUDY">Yoa 1994</LINK>
</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>X</P>
</TD>
<TD>
<P>-</P>
</TD>
<TD>
<P>X</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CNI - calcineurin inhibitor </P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2016-03-24 16:46:17 +1100" MODIFIED_BY="Narelle S Willis" NO="2">
<TITLE MODIFIED="2016-03-21 16:36:56 +1100" MODIFIED_BY="Narelle Willis">Fish oil versus control: adverse effects</TITLE>
<TABLE COLS="6" ROWS="11">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Fishy taste</P>
</TH>
<TH>
<P>GI upset</P>
</TH>
<TH>
<P>Breath</P>
</TH>
<TH>
<P>Bleeding</P>
</TH>
<TH>
<P>Other</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Bennett-_x0028_high_x0029_-1995" TYPE="STUDY">Bennett (high) 1995</LINK>; <LINK REF="STD-Bennett-_x0028_low_x0029_-1995" TYPE="STUDY">Bennett (low) 1995</LINK>
</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Berthoux-1992" TYPE="STUDY">Berthoux 1992</LINK>
</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Hernandez-2002" TYPE="STUDY">Hernandez 2002</LINK>
</P>
</TD>
<TD>
<P>Yes (70%)</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Homan-van-der-Heide-1990a" TYPE="STUDY">Homan van der Heide 1990a</LINK>
</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Homan-van-der-Heide-1992" TYPE="STUDY">Homan van der Heide 1992</LINK>
</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Homan-van-der-Heide-1993" TYPE="STUDY">Homan van der Heide 1993</LINK>
</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>"Pyrosis"<BR/>Swallowing problems</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Kooijmans_x002d_Coutinho-1996" TYPE="STUDY">Kooijmans-Coutinho 1996</LINK>
</P>
</TD>
<TD>
<P>Yes (1 patient in control group)</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Maachi-1995" TYPE="STUDY">Maachi 1995</LINK>
</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Rodriguez-1997" TYPE="STUDY">Rodriguez 1997</LINK>
</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Yes</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Santos-2000" TYPE="STUDY">Santos 2000</LINK>
</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>GI - gastrointestinal</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2016-08-11 10:42:37 +1000" MODIFIED_BY="Narelle S Willis" NO="3">
<TITLE MODIFIED="2016-03-21 16:43:53 +1100" MODIFIED_BY="Narelle Willis">Short-course fish oil versus control/miscellaneous</TITLE>
<TABLE COLS="7" ROWS="4">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Serum creatinine:<BR/>median (range)</P>
</TH>
<TH>
<P>Creatinine clearance:<BR/>median (range)</P>
</TH>
<TH>
<P>GFR:<BR/>median (range)</P>
</TH>
<TH>
<P>Blood pressure (MAP):<BR/>median (range)</P>
</TH>
<TH>
<P>Lipids</P>
</TH>
<TH>
<P>Other</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Homan-van-der-Heide-1990a" TYPE="STUDY">Homan van der Heide 1990a</LINK>
</P>
</TD>
<TD>
<P>Fish oil: 170 (93 to 224)<BR/>Control: 172 (101 to 540)<BR/>P = NS</P>
</TD>
<TD>
<P>Fish oil: 51 (35 to 75)</P>
<P>Control: 48 (10 to 88)</P>
<P>P = NS</P>
</TD>
<TD>
<P>Fish oil: 44 (26 to 60)</P>
<P>Control: 40 (10 to 80)</P>
<P>P = NS</P>
</TD>
<TD>
<P>Fish oil: 106 (82 to 137)</P>
<P>Control: 107 (80 to 132)</P>
<P>P = NS</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Homan-van-der-Heide-1990b" TYPE="STUDY">Homan van der Heide 1990b</LINK>
</P>
</TD>
<TD>
<P>Fish oil: 120 (88 to 159)</P>
<P>Control: 147 (106 to 189)</P>
<P>P &lt; 0.05</P>
</TD>
<TD>
<P>Fish oil: 88.4 (57.7 to 158.6)</P>
<P>Control: 79.5 (52.3 to 113.3)</P>
<P>P &lt; 0.05</P>
</TD>
<TD>
<P>Fish oil: 68 (29 to 93)</P>
<P>Control: 60 (32 to 84)</P>
<P/>
<P>Per cent change</P>
<P>Fish oil: 20.3 (8.9 to 33.3)</P>
<P>Control: -2.6 (-38 to -7.2)</P>
<P>P &lt; 0.01</P>
</TD>
<TD>
<P>Fish oil: 98 (76 to 106)</P>
<P>Control: 109 (103 to 116)</P>
<P/>
<P>Per cent change</P>
<P>Fish oil: -8.6 (-23.8 to 0)</P>
<P>Control: 0.9 (-6.9 to 9.4)</P>
<P>P &lt; 0.01</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Homan-van-der-Heide-1992" TYPE="STUDY">Homan van der Heide 1992</LINK>
</P>
</TD>
<TD>
<P>Fish oil: 163 (93 to 406)</P>
<P>Control: 200 (100 to 850)</P>
<P>P = NS</P>
</TD>
<TD>
<P>Fish oil: 53 (22 to 80)</P>
<P>Control: 49 (12 to 88)</P>
<P>P = NS</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Fish oil: 105 (76 to 137)</P>
<P>Control: 108 (76 to 142)</P>
<P>P = NS</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Rejecting patients</P>
<P>SCr median (range)</P>
<P>Fish oil: 183 (127 to 406)</P>
<P>Control: 283 (132 to 860)</P>
<P>P &lt; 0.05</P>
<P/>
<P>CrCl median (range)</P>
<P>Fish oil: 43 (22 to 69)</P>
<P>Control: 27 (12 to 50)</P>
<P>P &lt; 0.05</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CrCl - creatinine clearance; NS - not significant; SCr - serum creatinine</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2016-03-24 16:45:12 +1100" MODIFIED_BY="Narelle S Willis" NO="4">
<TITLE MODIFIED="2016-03-21 16:44:01 +1100" MODIFIED_BY="Narelle Willis">Long-course fish oil versus control/miscellaneous</TITLE>
<TABLE COLS="7" ROWS="2">
<TR>
<TH>
<P>Study ID</P>
</TH>
<TH>
<P>Serum creatinine</P>
</TH>
<TH>
<P>Creatinine clearance</P>
</TH>
<TH>
<P>GFR (median)</P>
</TH>
<TH>
<P>Mean arterial pressure (range)</P>
</TH>
<TH>
<P>Lipids</P>
</TH>
<TH>
<P>Other</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Homan-van-der-Heide-1993" TYPE="STUDY">Homan van der Heide 1993</LINK>
</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>Fish oil: 53 mL/min</P>
<P>Control: 40 mL/min </P>
<P>P = 0.038</P>
</TD>
<TD>
<P>Fish oil: 103 (80 to 141)<BR/>Control: 118 (98 to 131)<BR/>P = 0.0011</P>
</TD>
<TD>
<P>Not reported</P>
</TD>
<TD>
<P>-</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<COMPARISON ID="CMP-001" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NO="1">
<NAME>Fish oil versus control</NAME>
<DICH_OUTCOME CHI2="1.5393729412813806" CI_END="8.098154592072405" CI_START="0.3372077680790828" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.65250132694413" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.9083860631020856" LOG_CI_START="-0.47210242931709945" LOG_EFFECT_SIZE="0.218141816892493" METHOD="MH" NO="1" P_CHI2="0.46315839027250694" P_Q="1.0" P_Z="0.5356406535887697" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="316" TOTAL_2="329" WEIGHT="100.0" Z="0.6194185710047804">
<NAME>All-cause mortality</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="4" TAU2="0.0" TOTAL_1="112" TOTAL_2="117" WEIGHT="0.0" Z="0.0">
<NAME>Short-course</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="42853" O_E="0.0" SE="0.0" STUDY_ID="STD-Hernandez-2002" TOTAL_1="46" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="42854" O_E="0.0" SE="0.0" STUDY_ID="STD-Homan-van-der-Heide-1990a" TOTAL_1="14" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="42855" O_E="0.0" SE="0.0" STUDY_ID="STD-Homan-van-der-Heide-1990b" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="42856" O_E="0.0" SE="0.0" STUDY_ID="STD-Homan-van-der-Heide-1992" TOTAL_1="40" TOTAL_2="48" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.5393729412813806" CI_END="8.098154592072405" CI_START="0.3372077680790828" DF="2" EFFECT_SIZE="1.65250132694413" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.9083860631020856" LOG_CI_START="-0.47210242931709945" LOG_EFFECT_SIZE="0.218141816892493" NO="2" P_CHI2="0.46315839027250694" P_Z="0.5356406535887697" STUDIES="8" TAU2="0.0" TOTAL_1="204" TOTAL_2="212" WEIGHT="100.0" Z="0.6194185710047804">
<NAME>Long-course</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Bennett-_x0028_low_x0029_-1995" TOTAL_1="40" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="2" O_E="0.0" SE="0.0" STUDY_ID="STD-Berthoux-1992" TOTAL_1="17" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="98.2719903161007" CI_START="0.25439598729592483" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9924297519668148" LOG_CI_START="-0.5944897432947772" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="3" O_E="0.0" SE="1.5195693169746844" STUDY_ID="STD-Busnach-1998" TOTAL_1="21" TOTAL_2="21" VAR="2.309090909090909" WEIGHT="28.477361877680554"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="4" O_E="0.0" SE="0.0" STUDY_ID="STD-Yoa-1994" TOTAL_1="12" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.897117532359623" CI_START="0.014069831258787349" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8974686016417053" LOG_CI_START="-1.8517111110810305" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="5" O_E="0.0" SE="1.6148817719123905" STUDY_ID="STD-Homan-van-der-Heide-1993" TOTAL_1="33" TOTAL_2="33" VAR="2.607843137254902" WEIGHT="25.21502021623198"/>
<DICH_DATA CI_END="20.6706293264143" CI_START="0.1935112829336326" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.3153536991153598" LOG_CI_START="-0.7132937077873972" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="6" O_E="0.0" SE="1.1916375287812984" STUDY_ID="STD-Kooijmans_x002d_Coutinho-1996" TOTAL_1="25" TOTAL_2="25" VAR="1.42" WEIGHT="46.307617906087465"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7" O_E="0.0" SE="0.0" STUDY_ID="STD-Maachi-1995" TOTAL_1="41" TOTAL_2="42" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="8" O_E="0.0" SE="0.0" STUDY_ID="STD-Santos-2000" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.098402762370669" CI_END="1.634148660028353" CI_START="0.5107742329306333" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="0.913608793915976" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.2132915621677927" LOG_CI_START="-0.2917710197451532" LOG_EFFECT_SIZE="-0.03923972878868021" METHOD="MH" MODIFIED="2016-03-31 17:10:22 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.9104295866094784" P_Q="0.6702789472196236" P_Z="0.7607087541107348" Q="0.18127601235186958" RANDOM="YES" SCALE="50.0" SORT_BY="USER" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="313" TOTAL_2="327" WEIGHT="100.0" Z="0.30455020008664574">
<NAME>Graft loss</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="4.7533208093407533E-4" CI_END="4.16632707520141" CI_START="0.32746564616153184" DF="1" EFFECT_SIZE="1.1680449425433572" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.6197533609980294" LOG_CI_START="-0.4848342543441072" LOG_EFFECT_SIZE="0.067459553326961" NO="1" P_CHI2="0.9826058098410717" P_Z="0.8107966131387652" STUDIES="4" TAU2="0.0" TOTAL_1="112" TOTAL_2="117" WEIGHT="20.906919637776642" Z="0.23939847432211045">
<NAME>Short-course</NAME>
<DICH_DATA CI_END="4.872682094067326" CI_START="0.2758758693008727" EFFECT_SIZE="1.1594202898550725" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.6877680778503953" LOG_CI_START="-0.5592862853410187" LOG_EFFECT_SIZE="0.06424089625468829" ORDER="42865" O_E="0.0" SE="0.7325259059572915" STUDY_ID="STD-Hernandez-2002" TOTAL_1="46" TOTAL_2="40" VAR="0.5365942028985506" WEIGHT="16.402861454120057"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="42866" O_E="0.0" SE="0.0" STUDY_ID="STD-Homan-van-der-Heide-1990a" TOTAL_1="14" TOTAL_2="17" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="42867" O_E="0.0" SE="0.0" STUDY_ID="STD-Homan-van-der-Heide-1990b" TOTAL_1="12" TOTAL_2="12" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="18.5818413840133" CI_START="0.07749501086791587" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2690887485860998" LOG_CI_START="-1.1107262564908502" LOG_EFFECT_SIZE="0.07918124604762482" ORDER="42868" O_E="0.0" SE="1.3979151142564654" STUDY_ID="STD-Homan-van-der-Heide-1992" TOTAL_1="40" TOTAL_2="48" VAR="1.9541666666666668" WEIGHT="4.504058183656586"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.9213838865466735" CI_END="1.646299274078183" CI_START="0.44524951013219993" DF="4" EFFECT_SIZE="0.8561623358419286" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="18" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.21650878668814388" LOG_CI_START="-0.35139654967942846" LOG_EFFECT_SIZE="-0.0674438814956423" NO="2" P_CHI2="0.7502157876238151" P_Z="0.6415542465439017" STUDIES="8" TAU2="0.0" TOTAL_1="201" TOTAL_2="210" WEIGHT="79.09308036222336" Z="0.46552680612069086">
<NAME>Long-course</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Santos-2000" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.09371827394474" CI_START="0.17220963689612723" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8508739365322062" LOG_CI_START="-0.7639425489700256" LOG_EFFECT_SIZE="0.043465693781090345" ORDER="2" O_E="0.0" SE="0.9485511970545312" STUDY_ID="STD-Busnach-1998" TOTAL_1="19" TOTAL_2="21" VAR="0.899749373433584" WEIGHT="9.782368987532971"/>
<DICH_DATA CI_END="2.1196042620943962" CI_START="0.02948663631117787" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.32625478412131476" LOG_CI_START="-1.5303747667772396" LOG_EFFECT_SIZE="-0.6020599913279624" ORDER="3" O_E="0.0" SE="1.0905933886623096" STUDY_ID="STD-Homan-van-der-Heide-1993" TOTAL_1="33" TOTAL_2="33" VAR="1.1893939393939394" WEIGHT="7.400138907479086"/>
<DICH_DATA CI_END="5.096292470222609" CI_START="0.32037330253759905" EFFECT_SIZE="1.2777777777777777" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7072543436913086" LOG_CI_START="-0.4943436818627349" LOG_EFFECT_SIZE="0.10645533091428677" ORDER="3" O_E="0.0" SE="0.7058246282165999" STUDY_ID="STD-Kooijmans_x002d_Coutinho-1996" TOTAL_1="24" TOTAL_2="23" VAR="0.49818840579710144" WEIGHT="17.6673729553104"/>
<DICH_DATA CI_END="3.275944064524516" CI_START="0.32032762194149644" EFFECT_SIZE="1.024390243902439" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.515336477741697" LOG_CI_START="-0.4944056103853671" LOG_EFFECT_SIZE="0.010465433678164979" ORDER="4" O_E="0.0" SE="0.5931275008697853" STUDY_ID="STD-Maachi-1995" TOTAL_1="41" TOTAL_2="42" VAR="0.35180023228803714" WEIGHT="25.01897258561933"/>
<DICH_DATA CI_END="2.4926512716376488" CI_START="0.1756894479923939" EFFECT_SIZE="0.6617647058823529" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.39666152383183684" LOG_CI_START="-0.755254321693622" LOG_EFFECT_SIZE="-0.17929639893089266" ORDER="5" O_E="0.0" SE="0.6766410697370518" STUDY_ID="STD-Berthoux-1992" TOTAL_1="17" TOTAL_2="15" VAR="0.4578431372549019" WEIGHT="19.22422692628157"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="42869" O_E="0.0" SE="0.0" STUDY_ID="STD-Bennett-_x0028_low_x0029_-1995" TOTAL_1="40" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="42876" O_E="0.0" SE="0.0" STUDY_ID="STD-Yoa-1994" TOTAL_1="12" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.352773388060037" CI_END="1.2498789932283325" CI_START="0.8028660181492299" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0017411693953682" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="84" I2="0.0" I2_Q="22.986299915233136" ID="CMP-001.03" LOG_CI_END="0.09686796891440907" LOG_CI_START="-0.09535692350506819" LOG_EFFECT_SIZE="7.555227046704698E-4" METHOD="MH" MODIFIED="2016-03-31 17:10:30 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.49921370772262474" P_Q="0.2544929548955909" P_Z="0.9877075383960053" Q="1.2984702707431632" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="235" TOTAL_2="247" WEIGHT="100.0" Z="0.015406925419678983">
<NAME>Acute rejection</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.0152575002000335" CI_END="1.7879344764513188" CI_START="0.8159662721772725" DF="2" EFFECT_SIZE="1.2078469396604876" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="30" I2="0.7570992887270742" ID="CMP-001.03.01" LOG_CI_END="0.2523515988910776" LOG_CI_START="-0.08832779236136591" LOG_EFFECT_SIZE="0.0820119032648558" NO="1" P_CHI2="0.36508377796973757" P_Z="0.34535057584234974" STUDIES="3" TAU2="0.0012234496910087098" TOTAL_1="97" TOTAL_2="100" WEIGHT="32.33838074459523" Z="0.9436460251485635">
<NAME>Short-course</NAME>
<DICH_DATA CI_END="1.8333077176761912" CI_START="0.6734100824052845" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.2632353666929816" LOG_CI_START="-0.1717203855716313" LOG_EFFECT_SIZE="0.04575749056067514" ORDER="42877" O_E="0.0" SE="0.2554951619459315" STUDY_ID="STD-Hernandez-2002" TOTAL_1="45" TOTAL_2="40" VAR="0.06527777777777777" WEIGHT="19.531207570412736"/>
<DICH_DATA CI_END="3.773467029338969" CI_START="0.010600331124930263" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.5767405596967805" LOG_CI_START="-1.974680568368818" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="42878" O_E="0.0" SE="1.4987174003640065" STUDY_ID="STD-Homan-van-der-Heide-1990b" TOTAL_1="12" TOTAL_2="12" VAR="2.2461538461538457" WEIGHT="0.5676164300571814"/>
<DICH_DATA CI_END="2.823679337243296" CI_START="0.7968326892941858" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="12" LOG_CI_END="0.4508153758171137" LOG_CI_START="-0.09863285770575124" LOG_EFFECT_SIZE="0.17609125905568124" ORDER="42879" O_E="0.0" SE="0.3227486121839514" STUDY_ID="STD-Homan-van-der-Heide-1992" TOTAL_1="40" TOTAL_2="48" VAR="0.10416666666666667" WEIGHT="12.239556744125313"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.0353349423102323" CI_END="1.1988440856187697" CI_START="0.699960636539797" DF="4" EFFECT_SIZE="0.916047853161441" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="54" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.0787627050685053" LOG_CI_START="-0.15492638257751196" LOG_EFFECT_SIZE="-0.03808183875450331" NO="2" P_CHI2="0.5519297722742718" P_Z="0.5229600802236614" STUDIES="5" TAU2="0.0" TOTAL_1="138" TOTAL_2="147" WEIGHT="67.66161925540477" Z="0.6387891978674533">
<NAME>Long-course</NAME>
<DICH_DATA CI_END="8.48670433962606" CI_START="0.18411151578645032" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9287390724599617" LOG_CI_START="-0.7349190464438489" LOG_EFFECT_SIZE="0.09691001300805642" ORDER="1" O_E="0.0" SE="0.9772410142846032" STUDY_ID="STD-Bennett-_x0028_low_x0029_-1995" TOTAL_1="40" TOTAL_2="50" VAR="0.955" WEIGHT="1.3350301858775429"/>
<DICH_DATA CI_END="1.4091439853743117" CI_START="0.4475219309847385" EFFECT_SIZE="0.7941176470588235" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.148955371291534" LOG_CI_START="-0.3491856770580697" LOG_EFFECT_SIZE="-0.10011515288326783" ORDER="2" O_E="0.0" SE="0.2926105176385151" STUDY_ID="STD-Berthoux-1992" TOTAL_1="17" TOTAL_2="15" VAR="0.08562091503267975" WEIGHT="14.890682107595202"/>
<DICH_DATA CI_END="2.353850331232768" CI_START="0.7899840136639179" EFFECT_SIZE="1.3636363636363635" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.3717788449193998" LOG_CI_START="-0.10238169712448746" LOG_EFFECT_SIZE="0.13469857389745618" ORDER="3" O_E="0.0" SE="0.27852424952911653" STUDY_ID="STD-Kooijmans_x002d_Coutinho-1996" TOTAL_1="25" TOTAL_2="25" VAR="0.07757575757575758" WEIGHT="16.434951682785453"/>
<DICH_DATA CI_END="1.223445057621876" CI_START="0.5489418864947241" EFFECT_SIZE="0.8195121951219512" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" LOG_CI_END="0.0875844708619709" LOG_CI_START="-0.2604736295217538" LOG_EFFECT_SIZE="-0.08644457932989147" ORDER="4" O_E="0.0" SE="0.20445105108078357" STUDY_ID="STD-Maachi-1995" TOTAL_1="41" TOTAL_2="42" VAR="0.04180023228803717" WEIGHT="30.50111824086521"/>
<DICH_DATA CI_END="1.892323407364669" CI_START="0.23486706485515438" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.2769953614690809" LOG_CI_START="-0.6291778795804434" LOG_EFFECT_SIZE="-0.17609125905568127" ORDER="5" O_E="0.0" SE="0.5322906474223771" STUDY_ID="STD-Santos-2000" TOTAL_1="15" TOTAL_2="15" VAR="0.2833333333333333" WEIGHT="4.499837038281365"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2016-03-31 17:06:05 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="5.0" SORT_BY="USER" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="NO" TOTAL_1="45" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>CNI toxicity</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="12" EVENTS_2="9" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="45" TOTAL_2="40" WEIGHT="0.0" Z="0.0">
<NAME>Short-course</NAME>
<DICH_DATA CI_END="2.5141338756446774" CI_START="0.5587068917808745" EFFECT_SIZE="1.1851851851851851" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.4003883998040853" LOG_CI_START="-0.25281597148224805" LOG_EFFECT_SIZE="0.07378621416091864" ORDER="1" O_E="0.0" SE="0.3836954811073779" STUDY_ID="STD-Hernandez-2002" TOTAL_1="45" TOTAL_2="40" VAR="0.1472222222222222" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Long-course</NAME>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="6.015746915401721" CI_END="20.071774720666596" CI_START="-11.574044716237548" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="4.248865002214523" ESTIMABLE="YES" I2="16.884801333665994" I2_Q="56.90856982417619" ID="CMP-001.05" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NO="5" P_CHI2="0.3046897438937427" P_Q="0.12766705061659978" P_Z="0.5986786878214267" Q="2.3206470426248327" RANDOM="YES" SCALE="500.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="66.89610210781807" TOTALS="YES" TOTAL_1="139" TOTAL_2="136" UNITS="ng/mL" WEIGHT="100.0" Z="0.526301579652054">
<NAME>CNI levels</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="13.992422068142112" CI_START="-52.1924220681421" DF="0" EFFECT_SIZE="-19.099999999999994" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" NO="1" P_CHI2="1.0" P_Z="0.25795613629663927" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="38" WEIGHT="18.516890428132" Z="1.1312351821099789">
<NAME>Short-course</NAME>
<CONT_DATA CI_END="13.992422068142112" CI_START="-52.1924220681421" EFFECT_SIZE="-19.099999999999994" ESTIMABLE="YES" MEAN_1="239.1" MEAN_2="258.2" ORDER="1" SD_1="87.1" SD_2="63.0" SE="16.88419906139649" STUDY_ID="STD-Hernandez-2002" TOTAL_1="42" TOTAL_2="38" WEIGHT="18.516890428132"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="3.6950998727768884" CI_END="23.63767394391924" CI_START="-5.600112125439223" DF="4" EFFECT_SIZE="9.018780909240007" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" NO="2" P_CHI2="0.44883910613488065" P_Z="0.22660389846096685" STUDIES="5" TAU2="0.0" TOTAL_1="97" TOTAL_2="98" WEIGHT="81.483109571868" Z="1.2091535059894962">
<NAME>Long-course</NAME>
<CONT_DATA CI_END="88.62913770968558" CI_START="-49.2291377096856" EFFECT_SIZE="19.69999999999999" ESTIMABLE="YES" MEAN_1="438.2" MEAN_2="418.5" ORDER="1" SD_1="160.0" SD_2="133.0" SE="35.16857363369421" STUDY_ID="STD-Maachi-1995" TOTAL_1="35" TOTAL_2="35" WEIGHT="4.9990862915837555"/>
<CONT_DATA CI_END="17.41481554178964" CI_START="-26.61481554178963" EFFECT_SIZE="-4.599999999999994" ESTIMABLE="YES" MEAN_1="109.0" MEAN_2="113.6" ORDER="1" SD_1="37.6" SD_2="31.6" SE="11.232255141135086" STUDY_ID="STD-Kooijmans_x002d_Coutinho-1996" TOTAL_1="20" TOTAL_2="18" WEIGHT="33.75864342844387"/>
<CONT_DATA CI_END="42.54668602267724" CI_START="-2.5466860226772425" EFFECT_SIZE="20.0" ESTIMABLE="YES" MEAN_1="171.0" MEAN_2="151.0" ORDER="2" SD_1="31.0" SD_2="32.0" SE="11.50362261782493" STUDY_ID="STD-Santos-2000" TOTAL_1="15" TOTAL_2="15" WEIGHT="32.71319887567717"/>
<CONT_DATA CI_END="103.6182216484923" CI_START="-239.6182216484923" EFFECT_SIZE="-68.0" ESTIMABLE="YES" MEAN_1="462.0" MEAN_2="530.0" ORDER="2" SD_1="193.0" SD_2="217.0" SE="87.56192613853872" STUDY_ID="STD-Berthoux-1992" TOTAL_1="11" TOTAL_2="11" WEIGHT="0.8427001666848031"/>
<CONT_DATA CI_END="75.73360970764267" CI_START="-23.733609707642678" EFFECT_SIZE="26.0" ESTIMABLE="YES" MEAN_1="252.0" MEAN_2="226.0" ORDER="42887" SD_1="59.0" SD_2="90.0" SE="25.374756934277897" STUDY_ID="STD-Busnach-1998" TOTAL_1="16" TOTAL_2="19" WEIGHT="9.169480809478403"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.9288646137780445" CI_END="9.37452876729083" CI_START="0.10749134843544518" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.003833023038674" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.9719494461161404" LOG_CI_START="-0.968626489031616" LOG_EFFECT_SIZE="0.0016614785422622929" METHOD="MH" MODIFIED="2016-03-31 17:33:08 +1100" MODIFIED_BY="Narelle S Willis" NO="6" P_CHI2="0.33515827877058535" P_Q="1.0" P_Z="0.9973221797077424" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="98" TOTAL_2="108" WEIGHT="99.99999999999999" Z="0.0033561563296128465">
<NAME>Myocardial infarction</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9288646137780445" CI_END="9.37452876729083" CI_START="0.10749134843544518" DF="1" EFFECT_SIZE="1.003833023038674" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.9719494461161404" LOG_CI_START="-0.968626489031616" LOG_EFFECT_SIZE="0.0016614785422622929" NO="1" P_CHI2="0.33515827877058535" P_Z="0.9973221797077424" STUDIES="3" TAU2="0.0" TOTAL_1="98" TOTAL_2="108" WEIGHT="99.99999999999999" Z="0.0033561563296128465">
<NAME>Long-course</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Bennett-_x0028_low_x0029_-1995" TOTAL_1="40" TOTAL_2="50" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="7.897117532359623" CI_START="0.014069831258787349" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8974686016417053" LOG_CI_START="-1.8517111110810305" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="2" O_E="0.0" SE="1.6148817719123905" STUDY_ID="STD-Homan-van-der-Heide-1993" TOTAL_1="33" TOTAL_2="33" VAR="2.607843137254902" WEIGHT="49.82588508415554"/>
<DICH_DATA CI_END="70.29633525231901" CI_START="0.12802943379190032" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8469326846047245" LOG_CI_START="-0.8926901751653995" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="42894" O_E="0.0" SE="1.6092680291808414" STUDY_ID="STD-Kooijmans_x002d_Coutinho-1996" TOTAL_1="25" TOTAL_2="25" VAR="2.58974358974359" WEIGHT="50.17411491584445"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.9313951998344949" CI_END="9.37394147487303" CI_START="0.10813949889401593" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0068233875683472" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.9719222377249381" LOG_CI_START="-0.9660156472263454" LOG_EFFECT_SIZE="0.0029532952492964297" METHOD="MH" MODIFIED="2016-03-31 17:33:08 +1100" MODIFIED_BY="Narelle S Willis" NO="7" P_CHI2="0.3345007988631552" P_Q="1.0" P_Z="0.9952336867758921" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="69" TOTAL_2="69" WEIGHT="100.0" Z="0.00597372327491265">
<NAME>Cardiovascular death</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9313951998344949" CI_END="9.37394147487303" CI_START="0.10813949889401593" DF="1" EFFECT_SIZE="1.0068233875683472" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.9719222377249381" LOG_CI_START="-0.9660156472263454" LOG_EFFECT_SIZE="0.0029532952492964297" NO="1" P_CHI2="0.3345007988631552" P_Z="0.9952336867758921" STUDIES="3" TAU2="0.0" TOTAL_1="69" TOTAL_2="69" WEIGHT="100.0" Z="0.00597372327491265">
<NAME>Long-course</NAME>
<DICH_DATA CI_END="69.69936418378434" CI_START="0.12912599857107263" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8432288163658224" LOG_CI_START="-0.8889863069264972" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="1" O_E="0.0" SE="1.6049166881048922" STUDY_ID="STD-Busnach-1998" TOTAL_1="21" TOTAL_2="21" VAR="2.5757575757575757" WEIGHT="50.309491059147184"/>
<DICH_DATA CI_END="7.897117532359623" CI_START="0.014069831258787349" EFFECT_SIZE="0.3333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8974686016417053" LOG_CI_START="-1.8517111110810305" LOG_EFFECT_SIZE="-0.47712125471966244" ORDER="2" O_E="0.0" SE="1.6148817719123905" STUDY_ID="STD-Homan-van-der-Heide-1993" TOTAL_1="33" TOTAL_2="33" VAR="2.607843137254902" WEIGHT="49.690508940852816"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="3" O_E="0.0" SE="0.0" STUDY_ID="STD-Santos-2000" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7417712263626653" CI_END="6.2626308738165015" CI_START="0.56334913766918" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="1.878309799342193" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.7967568146728977" LOG_CI_START="-0.24922236613042262" LOG_EFFECT_SIZE="0.27376722427123756" METHOD="MH" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NO="8" P_CHI2="0.9460795311740787" P_Q="0.7486400947446257" P_Z="0.30490369384184" Q="0.10267734719241908" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="209" TOTAL_2="203" WEIGHT="100.0" Z="1.025974339770381">
<NAME>Compliance</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="67.05568402675195" CI_START="0.13421680996363317" DF="0" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-001.08.01" LOG_CI_END="1.8264355970545303" LOG_CI_START="-0.8721930876152056" LOG_EFFECT_SIZE="0.47712125471966244" NO="1" P_CHI2="1.0" P_Z="0.4882790296766242" STUDIES="2" TAU2="0.0" TOTAL_1="57" TOTAL_2="52" WEIGHT="15.023108927584552" Z="0.6930486441661347">
<NAME>Short-course</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="1" O_E="0.0" SE="0.0" STUDY_ID="STD-Hernandez-2002" TOTAL_1="45" TOTAL_2="40" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="67.05568402675195" CI_START="0.13421680996363317" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8264355970545303" LOG_CI_START="-0.8721930876152056" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="2" O_E="0.0" SE="1.585187847802434" STUDY_ID="STD-Homan-van-der-Heide-1990b" TOTAL_1="12" TOTAL_2="12" VAR="2.5128205128205123" WEIGHT="15.023108927584552"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.6393774635875478" CI_END="6.384915321105241" CI_START="0.468249342570501" DF="3" EFFECT_SIZE="1.729084266736543" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-001.08.02" LOG_CI_END="0.8051551418781199" LOG_CI_START="-0.3295228237086334" LOG_EFFECT_SIZE="0.2378161590847432" NO="2" P_CHI2="0.8873615541514155" P_Z="0.41131924984849544" STUDIES="6" TAU2="0.0" TOTAL_1="152" TOTAL_2="151" WEIGHT="84.97689107241544" Z="0.8215742631552981">
<NAME>Long-course</NAME>
<DICH_DATA CI_END="60.93381569300773" CI_START="0.11670221256022738" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.7848583746209683" LOG_CI_START="-0.9329209100764063" LOG_EFFECT_SIZE="0.4259687322722811" ORDER="1" O_E="0.0" SE="1.596437005055668" STUDY_ID="STD-Berthoux-1992" TOTAL_1="17" TOTAL_2="15" VAR="2.548611111111111" WEIGHT="14.81213674184819"/>
<DICH_DATA CI_END="69.69936418378434" CI_START="0.12912599857107263" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8432288163658224" LOG_CI_START="-0.8889863069264972" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="2" O_E="0.0" SE="1.6049166881048922" STUDY_ID="STD-Busnach-1998" TOTAL_1="21" TOTAL_2="21" VAR="2.5757575757575757" WEIGHT="14.656028437951262"/>
<DICH_DATA CI_END="71.07405779123665" CI_START="0.12662848132908622" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8517111110810305" LOG_CI_START="-0.8974686016417053" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="3" O_E="0.0" SE="1.6148817719123905" STUDY_ID="STD-Homan-van-der-Heide-1993" TOTAL_1="33" TOTAL_2="33" VAR="2.607843137254902" WEIGHT="14.475708197429647"/>
<DICH_DATA CI_END="6.553055387930549" CI_START="0.15260057191669785" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8164438387284481" LOG_CI_START="-0.8164438387284481" LOG_EFFECT_SIZE="0.0" ORDER="4" O_E="0.0" SE="0.9591663046625438" STUDY_ID="STD-Kooijmans_x002d_Coutinho-1996" TOTAL_1="25" TOTAL_2="25" VAR="0.9199999999999999" WEIGHT="41.033017695186345"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="5" O_E="0.0" SE="0.0" STUDY_ID="STD-Maachi-1995" TOTAL_1="41" TOTAL_2="42" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="6" O_E="0.0" SE="0.0" STUDY_ID="STD-Santos-2000" TOTAL_1="15" TOTAL_2="15" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="33.96051143516416" CI_END="-1.5253276191897598" CI_START="-59.7410144510961" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="MD" EFFECT_SIZE="-30.63317103514293" ESTIMABLE="YES" I2="88.22161436633068" I2_Q="56.64954671683973" ID="CMP-001.09" MODIFIED="2016-03-31 17:33:08 +1100" MODIFIED_BY="Narelle S Willis" NO="9" P_CHI2="7.592214700258282E-7" P_Q="0.12881069701881243" P_Z="0.039143872581068155" Q="2.3067809544414972" RANDOM="YES" SCALE="200.0" SORT_BY="USER" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="835.4422010428831" TOTALS="YES" TOTAL_1="119" TOTAL_2="118" UNITS="µmol/L" WEIGHT="100.0" Z="2.0626712567867385">
<NAME>Serum creatinine</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="8.626638722858942" CI_START="-26.30663872285895" DF="0" EFFECT_SIZE="-8.840000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-001.09.01" NO="1" P_CHI2="1.0" P_Z="0.32122055166428687" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="38" WEIGHT="24.108424785655334" Z="0.9919528249392994">
<NAME>Short-course</NAME>
<CONT_DATA CI_END="8.626638722858942" CI_START="-26.30663872285895" EFFECT_SIZE="-8.840000000000003" ESTIMABLE="YES" MEAN_1="132.6" MEAN_2="141.44" ORDER="42906" SD_1="44.2" SD_2="35.36" SE="8.911714123643884" STUDY_ID="STD-Hernandez-2002" TOTAL_1="42" TOTAL_2="38" WEIGHT="24.108424785655334"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="16.72902387539999" CI_END="-4.9396048944008655" CI_START="-69.88871575115385" DF="3" EFFECT_SIZE="-37.41416032277736" ESTIMABLE="YES" I2="82.06709475493369" ID="CMP-001.09.02" NO="2" P_CHI2="8.034700048147325E-4" P_Z="0.023940168203305544" STUDIES="4" TAU2="778.2148456570246" TOTAL_1="77" TOTAL_2="80" WEIGHT="75.89157521434467" Z="2.258088087031193">
<NAME>Long-course</NAME>
<CONT_DATA CI_END="26.939850532520293" CI_START="-26.939850532520293" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="128.18" MEAN_2="128.18" ORDER="1" SD_1="30.94" SD_2="43.32" SE="13.745074269230656" STUDY_ID="STD-Santos-2000" TOTAL_1="15" TOTAL_2="15" WEIGHT="21.53115549121446"/>
<CONT_DATA CI_END="-46.44682420125591" CI_START="-63.1731757987441" EFFECT_SIZE="-54.81" ESTIMABLE="YES" MEAN_1="111.38" MEAN_2="166.19" ORDER="2" SD_1="5.3" SD_2="17.68" SE="4.26700483514583" STUDY_ID="STD-Busnach-1998" TOTAL_1="16" TOTAL_2="19" WEIGHT="25.83713008045756"/>
<CONT_DATA CI_END="-2.2215287140253146" CI_START="-63.37847128597471" EFFECT_SIZE="-32.80000000000001" ESTIMABLE="YES" MEAN_1="152.7" MEAN_2="185.5" ORDER="3" SD_1="35.5" SD_2="85.2" SE="15.601547542288417" STUDY_ID="STD-Maachi-1995" TOTAL_1="35" TOTAL_2="35" WEIGHT="20.443846718530715"/>
<CONT_DATA CI_END="-9.192448599652892" CI_START="-179.8075514003471" EFFECT_SIZE="-94.5" ESTIMABLE="YES" MEAN_1="152.7" MEAN_2="247.2" ORDER="4" SD_1="40.7" SD_2="138.5" SE="43.5250607017487" STUDY_ID="STD-Berthoux-1992" TOTAL_1="11" TOTAL_2="11" WEIGHT="8.079442924141937"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.8697510709770317" CI_END="4.451438691294369" CI_START="-5.667981143355657" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6082712260306438" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.10" MODIFIED="2016-03-31 17:33:08 +1100" MODIFIED_BY="Narelle S Willis" NO="10" P_CHI2="0.8967841630491645" P_Q="0.5788713441716795" P_Z="0.8137243556410328" Q="0.3080630080091602" RANDOM="YES" SCALE="50.0" SORT_BY="USER" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="175" TOTAL_2="178" UNITS="mL/min" WEIGHT="100.0" Z="0.23562411982748133">
<NAME>Creatinine clearance</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours fish oil</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.232147032534055E-33" CI_END="8.33312261777504" CI_START="-15.733122617775045" DF="0" EFFECT_SIZE="-3.7000000000000024" ESTIMABLE="YES" I2="100.00000000000001" ID="CMP-001.10.01" NO="1" P_CHI2="0.0" P_Z="0.5467357256046783" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="38" WEIGHT="17.68050041912324" Z="0.6026587589231344">
<NAME>Short-course</NAME>
<CONT_DATA CI_END="8.33312261777504" CI_START="-15.733122617775045" EFFECT_SIZE="-3.700000000000003" ESTIMABLE="YES" MEAN_1="61.0" MEAN_2="64.7" ORDER="42911" SD_1="35.0" SD_2="18.0" SE="6.1394610884132454" STUDY_ID="STD-Hernandez-2002" TOTAL_1="42" TOTAL_2="38" WEIGHT="17.68050041912324"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.5616880629678715" CI_END="5.632428376549829" CI_START="-5.520893953452871" DF="6" EFFECT_SIZE="0.05576721154847894" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.02" NO="2" P_CHI2="0.8615009249871508" P_Z="0.9843625829459333" STUDIES="7" TAU2="0.0" TOTAL_1="133" TOTAL_2="140" WEIGHT="82.31949958087675" Z="0.01959985068470956">
<NAME>Long-course</NAME>
<CONT_DATA CI_END="21.37276499964832" CI_START="-13.772764999648327" EFFECT_SIZE="3.799999999999997" ESTIMABLE="YES" MEAN_1="74.2" MEAN_2="70.4" ORDER="1" SD_1="28.8" SD_2="19.4" SE="8.965861178195135" STUDY_ID="STD-Santos-2000" TOTAL_1="15" TOTAL_2="15" WEIGHT="8.29031504536981"/>
<CONT_DATA CI_END="22.49156678241243" CI_START="-12.49156678241243" EFFECT_SIZE="5.0" ESTIMABLE="YES" MEAN_1="70.0" MEAN_2="65.0" ORDER="2" SD_1="32.1" SD_2="22.5" SE="8.924432755083092" STUDY_ID="STD-Kooijmans_x002d_Coutinho-1996" TOTAL_1="20" TOTAL_2="18" WEIGHT="8.367463222828592"/>
<CONT_DATA CI_END="10.047949909906812" CI_START="-9.247949909906815" EFFECT_SIZE="0.3999999999999986" ESTIMABLE="YES" MEAN_1="49.0" MEAN_2="48.6" ORDER="3" SD_1="17.2" SD_2="23.5" SE="4.922513875769458" STUDY_ID="STD-Maachi-1995" TOTAL_1="35" TOTAL_2="35" WEIGHT="27.503068924268426"/>
<CONT_DATA CI_END="28.451212674986483" CI_START="-9.451212674986483" EFFECT_SIZE="9.5" ESTIMABLE="YES" MEAN_1="53.2" MEAN_2="43.7" ORDER="4" SD_1="13.9" SD_2="28.9" SE="9.669163731819172" STUDY_ID="STD-Berthoux-1992" TOTAL_1="11" TOTAL_2="11" WEIGHT="7.12815650536915"/>
<CONT_DATA CI_END="8.674882673742665" CI_START="-20.674882673742665" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="61.0" MEAN_2="67.0" ORDER="42912" SD_1="15.0" SD_2="33.0" SE="7.487322618933954" STUDY_ID="STD-Bennett-_x0028_high_x0029_-1995" TOTAL_1="18" TOTAL_2="25" WEIGHT="11.887812916764085"/>
<CONT_DATA CI_END="13.442177893193513" CI_START="-21.442177893193513" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="63.0" MEAN_2="67.0" ORDER="42913" SD_1="28.0" SD_2="33.0" SE="8.89923387918104" STUDY_ID="STD-Bennett-_x0028_low_x0029_-1995" TOTAL_1="22" TOTAL_2="25" WEIGHT="8.414916563262478"/>
<CONT_DATA CI_END="11.48795389269805" CI_START="-19.407953892698067" EFFECT_SIZE="-3.960000000000008" ESTIMABLE="YES" MEAN_1="60.16" MEAN_2="64.12" ORDER="42918" SD_1="18.3" SD_2="19.4" SE="7.88175395800614" STUDY_ID="STD-Yoa-1994" TOTAL_1="12" TOTAL_2="11" WEIGHT="10.727766403014213"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="10.623064697309099" CI_END="7.262963699565144" CI_START="-2.903670039442207" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="MD" EFFECT_SIZE="2.1796468300614684" ESTIMABLE="YES" I2="24.69216532187308" I2_Q="0.0" ID="CMP-001.11" MODIFIED="2016-03-31 17:33:08 +1100" MODIFIED_BY="Narelle S Willis" NO="11" P_CHI2="0.2239848427202703" P_Q="0.9831187791630529" P_Z="0.40068307810194614" Q="4.4770547070392143E-4" RANDOM="YES" SCALE="50.0" SORT_BY="USER" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="14.472937486205439" TOTALS="YES" TOTAL_1="167" TOTAL_2="176" UNITS="mL/min" WEIGHT="100.0" Z="0.8404019256730865">
<NAME>Glomerular filtration rate</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours fish oil</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="13.532769969756194" CI_START="-9.532769969756194" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.11.01" NO="1" P_CHI2="1.0" P_Z="0.7339357907956424" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="38" WEIGHT="13.700869348992518" Z="0.3398947502950132">
<NAME>Short-course</NAME>
<CONT_DATA CI_END="13.532769969756194" CI_START="-9.532769969756194" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="61.0" MEAN_2="59.0" ORDER="42919" SD_1="35.0" SD_2="14.4" SE="5.884174434186144" STUDY_ID="STD-Hernandez-2002" TOTAL_1="42" TOTAL_2="38" WEIGHT="13.700869348992518"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="10.590196630043465" CI_END="7.803295323842841" CI_START="-4.083423425949897" DF="7" EFFECT_SIZE="1.8599359489464715" ESTIMABLE="YES" I2="33.90113286337281" ID="CMP-001.11.02" NO="2" P_CHI2="0.1575202914039181" P_Z="0.5396396035122413" STUDIES="8" TAU2="23.733643782135783" TOTAL_1="125" TOTAL_2="138" WEIGHT="86.29913065100749" Z="0.613358076390926">
<NAME>Long-course</NAME>
<CONT_DATA CI_END="25.748036593287303" CI_START="-17.548036593287314" EFFECT_SIZE="4.099999999999994" ESTIMABLE="YES" MEAN_1="92.6" MEAN_2="88.5" ORDER="1" SD_1="37.6" SD_2="20.4" SE="11.045119585892525" STUDY_ID="STD-Santos-2000" TOTAL_1="15" TOTAL_2="15" WEIGHT="4.929111197182155"/>
<CONT_DATA CI_END="16.34774887822355" CI_START="-12.547748878223553" EFFECT_SIZE="1.8999999999999986" ESTIMABLE="YES" MEAN_1="54.4" MEAN_2="52.5" ORDER="2" SD_1="21.6" SD_2="18.9" SE="7.371435899937729" STUDY_ID="STD-Kooijmans_x002d_Coutinho-1996" TOTAL_1="14" TOTAL_2="17" WEIGHT="9.775529342830852"/>
<CONT_DATA CI_END="14.65467421394756" CI_START="-0.45467421394755725" EFFECT_SIZE="7.100000000000001" ESTIMABLE="YES" MEAN_1="50.1" MEAN_2="43.0" ORDER="3" SD_1="18.0" SD_2="14.0" SE="3.854496446637726" STUDY_ID="STD-Maachi-1995" TOTAL_1="35" TOTAL_2="35" WEIGHT="22.934270476183535"/>
<CONT_DATA CI_END="24.361337986606408" CI_START="1.6386620133935939" EFFECT_SIZE="13.0" ESTIMABLE="YES" MEAN_1="42.0" MEAN_2="29.0" ORDER="4" SD_1="15.1" SD_2="11.9" SE="5.796707529435841" STUDY_ID="STD-Berthoux-1992" TOTAL_1="11" TOTAL_2="11" WEIGHT="13.992041900900576"/>
<CONT_DATA CI_END="9.141993325915513" CI_START="-17.141993325915514" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="54.0" MEAN_2="58.0" ORDER="42920" SD_1="24.0" SD_2="18.0" SE="6.705221845696084" STUDY_ID="STD-Bennett-_x0028_high_x0029_-1995" TOTAL_1="18" TOTAL_2="25" WEIGHT="11.318033806400218"/>
<CONT_DATA CI_END="14.663122986512576" CI_START="-12.663122986512576" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="59.0" MEAN_2="58.0" ORDER="42921" SD_1="28.0" SD_2="18.0" SE="6.971109211335283" STUDY_ID="STD-Bennett-_x0028_low_x0029_-1995" TOTAL_1="22" TOTAL_2="25" WEIGHT="10.665474069155875"/>
<CONT_DATA CI_END="7.635124828955373" CI_START="-29.635124828955373" EFFECT_SIZE="-11.0" ESTIMABLE="YES" MEAN_1="46.0" MEAN_2="57.0" ORDER="42926" SD_1="14.0" SD_2="16.0" SE="9.50789145920377" STUDY_ID="STD-Schut-1992a" TOTAL_1="5" TOTAL_2="5" WEIGHT="6.414085576376874"/>
<CONT_DATA CI_END="4.880873352692532" CI_START="-32.88087335269253" EFFECT_SIZE="-14.0" ESTIMABLE="YES" MEAN_1="56.0" MEAN_2="70.0" ORDER="42927" SD_1="20.0" SD_2="8.0" SE="9.633275663033837" STUDY_ID="STD-Schut-1992b" TOTAL_1="5" TOTAL_2="5" WEIGHT="6.270584281977399"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="8.716922904084852" CI_END="10.831723966303544" CI_START="-5.931234235698289" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="2.450244865302628" ESTIMABLE="YES" I2="65.58418569247452" I2_Q="79.49581568987671" ID="CMP-001.12" MODIFIED="2016-03-31 17:33:08 +1100" MODIFIED_BY="Narelle S Willis" NO="12" P_CHI2="0.03330129857968689" P_Q="0.027216169782942723" P_Z="0.5666605171725176" Q="4.87705331202218" RANDOM="YES" SCALE="50.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="46.791229124753144" TOTALS="YES" TOTAL_1="97" TOTAL_2="103" UNITS="mm Hg" WEIGHT="100.0" Z="0.5729766347235591">
<NAME>Systolic blood pressure</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.4597721453259274" CI_START="-13.459772145325928" DF="0" EFFECT_SIZE="-6.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.12.01" NO="1" P_CHI2="1.0" P_Z="0.11492750154803137" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="38" WEIGHT="29.843139183982935" Z="1.576426689467809">
<NAME>Short-course</NAME>
<CONT_DATA CI_END="1.4597721453259274" CI_START="-13.459772145325928" EFFECT_SIZE="-6.0" ESTIMABLE="YES" MEAN_1="146.0" MEAN_2="152.0" ORDER="42928" SD_1="17.0" SD_2="17.0" SE="3.806076134136983" STUDY_ID="STD-Hernandez-2002" TOTAL_1="42" TOTAL_2="38" WEIGHT="29.843139183982935"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.937967576886882" CI_END="13.530907786232152" CI_START="-1.5933256320749267" DF="2" EFFECT_SIZE="5.968791077078613" ESTIMABLE="YES" I2="31.925729346569835" ID="CMP-001.12.02" NO="2" P_CHI2="0.23015931151935298" P_Z="0.12186257622604527" STUDIES="3" TAU2="14.559382338392567" TOTAL_1="55" TOTAL_2="65" WEIGHT="70.15686081601707" Z="1.547002776108648">
<NAME>Long-course</NAME>
<CONT_DATA CI_END="14.616696090174365" CI_START="-12.616696090174365" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="134.0" MEAN_2="133.0" ORDER="1" SD_1="18.0" SD_2="20.0" SE="6.947421584060281" STUDY_ID="STD-Santos-2000" TOTAL_1="15" TOTAL_2="15" WEIGHT="19.23786861374749"/>
<CONT_DATA CI_END="11.433667304852678" CI_START="-5.433667304852678" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="137.0" MEAN_2="134.0" ORDER="42929" SD_1="10.0" SD_2="18.0" SE="4.302970550161314" STUDY_ID="STD-Bennett-_x0028_high_x0029_-1995" TOTAL_1="18" TOTAL_2="25" WEIGHT="28.001857982851018"/>
<CONT_DATA CI_END="25.260066362799797" CI_START="2.7399336372002043" EFFECT_SIZE="14.0" ESTIMABLE="YES" MEAN_1="148.0" MEAN_2="134.0" ORDER="42930" SD_1="21.0" SD_2="18.0" SE="5.745037384165098" STUDY_ID="STD-Bennett-_x0028_low_x0029_-1995" TOTAL_1="22" TOTAL_2="25" WEIGHT="22.91713421941856"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.905634230997045" CI_END="-1.4505201576617646" CI_START="-7.601737826914293" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.526128992288029" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.13" MODIFIED="2016-03-31 17:33:08 +1100" MODIFIED_BY="Narelle S Willis" NO="13" P_CHI2="0.4064046603868886" P_Q="0.8162507453328406" P_Z="0.003922559880227061" Q="0.05399575950536088" RANDOM="YES" SCALE="20.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="97" TOTAL_2="103" UNITS="mm Hg" WEIGHT="100.0" Z="2.884323166975517">
<NAME>Diastolic blood pressure</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0401120592630138" CI_START="-9.040112059263013" DF="0" EFFECT_SIZE="-4.0" ESTIMABLE="YES" I2="0.0" ID="CMP-001.13.01" NO="1" P_CHI2="1.0" P_Z="0.11982884628371589" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="38" WEIGHT="37.23761132673338" Z="1.5554923870693846">
<NAME>Short-course</NAME>
<CONT_DATA CI_END="1.0401120592630138" CI_START="-9.040112059263013" EFFECT_SIZE="-4.0" ESTIMABLE="YES" MEAN_1="85.0" MEAN_2="89.0" ORDER="1" SD_1="12.0" SD_2="11.0" SE="2.5715329970442182" STUDY_ID="STD-Hernandez-2002" TOTAL_1="42" TOTAL_2="38" WEIGHT="37.23761132673338"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.8389380754164266" CI_END="0.20847881697811488" CI_START="-9.901055351124027" DF="2" EFFECT_SIZE="-4.846288267072956" ESTIMABLE="YES" I2="29.55112274836667" ID="CMP-001.13.02" NO="2" P_CHI2="0.24184271549128777" P_Z="0.060227123051090785" STUDIES="3" TAU2="6.168562923551156" TOTAL_1="55" TOTAL_2="65" WEIGHT="62.76238867326663" Z="1.8791272286574967">
<NAME>Long-course</NAME>
<CONT_DATA CI_END="17.41616853740286" CI_START="-13.416168537402863" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="80.0" MEAN_2="78.0" ORDER="1" SD_1="28.0" SD_2="12.0" SE="7.8655366420014" STUDY_ID="STD-Santos-2000" TOTAL_1="15" TOTAL_2="15" WEIGHT="3.9802403700085085"/>
<CONT_DATA CI_END="2.1092902472266983" CI_START="-8.1092902472267" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="82.0" MEAN_2="85.0" ORDER="42933" SD_1="8.0" SD_2="9.0" SE="2.6068286394689535" STUDY_ID="STD-Bennett-_x0028_high_x0029_-1995" TOTAL_1="18" TOTAL_2="25" WEIGHT="36.23606667790611"/>
<CONT_DATA CI_END="-2.5226768806425186" CI_START="-15.477323119357482" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="76.0" MEAN_2="85.0" ORDER="42934" SD_1="13.0" SD_2="9.0" SE="3.3048174203453633" STUDY_ID="STD-Bennett-_x0028_low_x0029_-1995" TOTAL_1="22" TOTAL_2="25" WEIGHT="22.54608162535201"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.8014693073882966" CI_END="0.5285941205749305" CI_START="-7.432417079720976" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.4519114795730226" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.14" MODIFIED="2016-03-31 17:33:08 +1100" MODIFIED_BY="Narelle S Willis" NO="14" P_CHI2="0.6146153953569427" P_Q="0.45518028144296707" P_Z="0.0891894113870115" Q="0.5577204290797679" RANDOM="YES" SCALE="100.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="72" TOTAL_2="66" UNITS="mm Hg" WEIGHT="100.0" Z="1.6996891494216266">
<NAME>Mean arterial pressure</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.4549685324060073" CI_START="-9.854968532406012" DF="0" EFFECT_SIZE="-4.700000000000003" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.01" NO="1" P_CHI2="1.0" P_Z="0.07394056249953902" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="38" WEIGHT="59.6244576137025" Z="1.786980981441368">
<NAME>Short-course</NAME>
<CONT_DATA CI_END="0.4549685324060073" CI_START="-9.854968532406012" EFFECT_SIZE="-4.700000000000003" ESTIMABLE="YES" MEAN_1="105.3" MEAN_2="110.0" ORDER="42936" SD_1="11.8" SD_2="11.7" SE="2.6301343152566803" STUDY_ID="STD-Hernandez-2002" TOTAL_1="42" TOTAL_2="38" WEIGHT="59.6244576137025"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.2437488783085284" CI_END="4.655593241039509" CI_START="-7.873194458698689" DF="2" EFFECT_SIZE="-1.6088006088295899" ESTIMABLE="YES" I2="0.0" ID="CMP-001.14.02" NO="2" P_CHI2="0.5369373577342123" P_Z="0.6147172546434654" STUDIES="3" TAU2="0.0" TOTAL_1="30" TOTAL_2="28" WEIGHT="40.375542386297504" Z="0.5033513740005344">
<NAME>Long-course</NAME>
<CONT_DATA CI_END="5.184544674067173" CI_START="-9.184544674067173" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="104.3" MEAN_2="106.3" ORDER="1" SD_1="10.8" SD_2="11.7" SE="3.665651374585423" STUDY_ID="STD-Kooijmans_x002d_Coutinho-1996" TOTAL_1="20" TOTAL_2="18" WEIGHT="30.695730930925706"/>
<CONT_DATA CI_END="10.635490710700356" CI_START="-16.635490710700356" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="103.0" MEAN_2="106.0" ORDER="2" SD_1="11.0" SD_2="11.0" SE="6.957010852370434" STUDY_ID="STD-Schut-1992a" TOTAL_1="5" TOTAL_2="5" WEIGHT="8.521870589232412"/>
<CONT_DATA CI_END="55.99091282911585" CI_START="-17.99091282911585" EFFECT_SIZE="19.0" ESTIMABLE="YES" MEAN_1="102.0" MEAN_2="83.0" ORDER="42939" SD_1="10.0" SD_2="41.0" SE="18.873261509341727" STUDY_ID="STD-Schut-1992b" TOTAL_1="5" TOTAL_2="5" WEIGHT="1.1579408661393842"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="6.716060109275178" CI_END="0.14192603913155977" CI_START="-0.364431169891541" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.1112525653799906" ESTIMABLE="YES" I2="25.551589493745336" I2_Q="76.68989340216244" ID="CMP-001.15" MODIFIED="2016-03-31 17:33:08 +1100" MODIFIED_BY="Narelle S Willis" NO="15" P_CHI2="0.2426283013973809" P_Q="0.03833768816565575" P_Z="0.38909831391841343" Q="4.289984671682147" RANDOM="YES" SCALE="2.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.02545415628593709" TOTALS="YES" TOTAL_1="131" TOTAL_2="129" UNITS="mmol/L" WEIGHT="100.0" Z="0.8612537451699298">
<NAME>Total cholesterol</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.0030384154770253247" CI_START="-0.8769615845229755" DF="0" EFFECT_SIZE="-0.4400000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-001.15.01" NO="1" P_CHI2="1.0" P_Z="0.048428084942688875" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="38" WEIGHT="22.201502666096246" Z="1.9735926080071262">
<NAME>Short-course</NAME>
<CONT_DATA CI_END="-0.0030384154770253247" CI_START="-0.8769615845229755" EFFECT_SIZE="-0.4400000000000004" ESTIMABLE="YES" MEAN_1="6.06" MEAN_2="6.5" ORDER="42940" SD_1="0.88" SD_2="1.09" SE="0.22294368058274144" STUDY_ID="STD-Hernandez-2002" TOTAL_1="42" TOTAL_2="38" WEIGHT="22.201502666096246"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="2.4260754375930316" CI_END="0.23732694499419874" CI_START="-0.11969734009507901" DF="4" EFFECT_SIZE="0.05881480244955987" ESTIMABLE="YES" I2="0.0" ID="CMP-001.15.02" NO="2" P_CHI2="0.657920281059864" P_Z="0.5184388157383764" STUDIES="5" TAU2="0.0" TOTAL_1="89" TOTAL_2="91" WEIGHT="77.79849733390375" Z="0.6457538009222525">
<NAME>Long-course</NAME>
<CONT_DATA CI_END="0.566716359379199" CI_START="-0.9867163593791989" EFFECT_SIZE="-0.20999999999999996" ESTIMABLE="YES" MEAN_1="5.43" MEAN_2="5.64" ORDER="1" SD_1="1.06" SD_2="1.11" SE="0.3962911387687929" STUDY_ID="STD-Santos-2000" TOTAL_1="15" TOTAL_2="15" WEIGHT="9.143089990463892"/>
<CONT_DATA CI_END="0.3172912421478391" CI_START="-0.07729124214783886" EFFECT_SIZE="0.1200000000000001" ESTIMABLE="YES" MEAN_1="5.89" MEAN_2="5.77" ORDER="2" SD_1="0.31" SD_2="0.28" SE="0.1006606466772079" STUDY_ID="STD-Busnach-1998" TOTAL_1="16" TOTAL_2="19" WEIGHT="46.88887737548426"/>
<CONT_DATA CI_END="0.5033958168198112" CI_START="-0.7233958168198118" EFFECT_SIZE="-0.11000000000000032" ESTIMABLE="YES" MEAN_1="6.01" MEAN_2="6.12" ORDER="3" SD_1="1.2" SD_2="1.41" SE="0.3129628001627578" STUDY_ID="STD-Maachi-1995" TOTAL_1="35" TOTAL_2="35" WEIGHT="13.52206805290367"/>
<CONT_DATA CI_END="0.9431114344181697" CI_START="-1.6631114344181703" EFFECT_SIZE="-0.3600000000000003" ESTIMABLE="YES" MEAN_1="6.76" MEAN_2="7.12" ORDER="4" SD_1="1.2" SD_2="1.85" SE="0.6648649897125389" STUDY_ID="STD-Berthoux-1992" TOTAL_1="11" TOTAL_2="11" WEIGHT="3.569246709365025"/>
<CONT_DATA CI_END="0.6383909238820777" CI_START="-1.6183909238820782" EFFECT_SIZE="-0.4900000000000002" ESTIMABLE="YES" MEAN_1="5.59" MEAN_2="6.08" ORDER="4" SD_1="1.73" SD_2="0.95" SE="0.575720234036279" STUDY_ID="STD-Yoa-1994" TOTAL_1="12" TOTAL_2="11" WEIGHT="4.675215205686904"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="30.583671289735182" CI_END="1.2170458752513484" CI_START="-0.619464621730168" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="0.29879062676059026" ESTIMABLE="YES" I2="93.46056272625694" I2_Q="0.0" ID="CMP-001.16" MODIFIED="2016-03-31 18:30:07 +1100" MODIFIED_BY="Narelle S Willis" NO="16" P_CHI2="2.2847756220301108E-7" P_Q="1.0" P_Z="0.5236353136968049" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.601027866120125" TOTALS="SUB" TOTAL_1="55" TOTAL_2="65" UNITS="mmol/L" WEIGHT="100.0" Z="0.637751723533765">
<NAME>LDL cholesterol</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-001.16.01" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="0" TAU2="0.0" TOTAL_1="0" TOTAL_2="0" WEIGHT="0.0" Z="0.0">
<NAME>Short-course</NAME>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="30.583671289735182" CI_END="1.2170458752513484" CI_START="-0.619464621730168" DF="2" EFFECT_SIZE="0.29879062676059026" ESTIMABLE="YES" I2="93.46056272625694" ID="CMP-001.16.02" MODIFIED="2016-03-31 18:04:46 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="2.2847756220301108E-7" P_Z="0.5236353136968049" STUDIES="3" TAU2="0.601027866120125" TOTAL_1="55" TOTAL_2="65" WEIGHT="100.0" Z="0.637751723533765">
<NAME>Long-course</NAME>
<CONT_DATA CI_END="1.432470814032372" CI_START="0.8075291859676272" EFFECT_SIZE="1.1199999999999997" ESTIMABLE="YES" MEAN_1="4.84" MEAN_2="3.72" MODIFIED="2016-03-31 18:04:46 +1100" MODIFIED_BY="Narelle S Willis" ORDER="1" SD_1="0.47" SD_2="0.62" SE="0.15942681421551738" STUDY_ID="STD-Bennett-_x0028_low_x0029_-1995" TOTAL_1="22" TOTAL_2="25" WEIGHT="35.03869036207824"/>
<CONT_DATA CI_END="0.4713641043371256" CI_START="-0.9313641043371256" EFFECT_SIZE="-0.22999999999999998" ESTIMABLE="YES" MEAN_1="3.39" MEAN_2="3.62" ORDER="3" SD_1="0.98" SD_2="0.98" SE="0.3578454042367085" STUDY_ID="STD-Santos-2000" TOTAL_1="15" TOTAL_2="15" WEIGHT="30.106117842587874"/>
<CONT_DATA CI_END="0.26212507163337395" CI_START="-0.4021250716333745" EFFECT_SIZE="-0.07000000000000028" ESTIMABLE="YES" MEAN_1="3.65" MEAN_2="3.72" ORDER="42946" SD_1="0.49" SD_2="0.62" SE="0.16945468092941218" STUDY_ID="STD-Bennett-_x0028_high_x0029_-1995" TOTAL_1="18" TOTAL_2="25" WEIGHT="34.85519179533388"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="12.097132438901658" CI_END="0.1866198937067394" CI_START="-0.012230799908449885" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="0.08719454689914476" ESTIMABLE="YES" I2="58.66789071498363" I2_Q="65.30630015787781" ID="CMP-001.17" MODIFIED="2016-03-31 18:30:45 +1100" MODIFIED_BY="Narelle S Willis" NO="17" P_CHI2="0.03348086864825772" P_Q="0.08955438397483495" P_Z="0.08564001376841637" Q="2.88236770523357" RANDOM="YES" SCALE="1.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.007500064891039182" TOTALS="YES" TOTAL_1="125" TOTAL_2="133" UNITS="mmol/L" WEIGHT="99.99999999999999" Z="1.7188591949428158">
<NAME>HDL cholesterol</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours fish oil</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.13048253970833393" CI_START="-0.29048253970833404" DF="0" EFFECT_SIZE="-0.08000000000000007" ESTIMABLE="YES" I2="0.0" ID="CMP-001.17.01" MODIFIED="2016-03-31 18:05:53 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="1.0" P_Z="0.45630726415261424" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="38" WEIGHT="13.520512385633586" Z="0.7449412145087118">
<NAME>Short-course</NAME>
<CONT_DATA CI_END="0.13048253970833393" CI_START="-0.29048253970833404" EFFECT_SIZE="-0.08000000000000007" ESTIMABLE="YES" MEAN_1="1.5" MEAN_2="1.58" MODIFIED="2016-03-31 18:05:53 +1100" MODIFIED_BY="Narelle S Willis" ORDER="42949" SD_1="0.52" SD_2="0.44" SE="0.10739102420686983" STUDY_ID="STD-Hernandez-2002" TOTAL_1="42" TOTAL_2="38" WEIGHT="13.520512385633586"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="7.528961734152977" CI_END="0.20784811885474846" CI_START="0.028509977590602045" DF="4" EFFECT_SIZE="0.11817904822267526" ESTIMABLE="YES" I2="46.87182454580495" ID="CMP-001.17.02" NO="2" P_CHI2="0.11043906662895253" P_Z="0.009790901840749966" STUDIES="5" TAU2="0.004315503964092358" TOTAL_1="83" TOTAL_2="95" WEIGHT="86.4794876143664" Z="2.583127901415057">
<NAME>Long-course</NAME>
<CONT_DATA CI_END="0.36183436574799455" CI_START="-0.16183436574799437" EFFECT_SIZE="0.10000000000000009" ESTIMABLE="YES" MEAN_1="1.29" MEAN_2="1.19" ORDER="1" SD_1="0.39" SD_2="0.34" SE="0.13359141688995843" STUDY_ID="STD-Santos-2000" TOTAL_1="15" TOTAL_2="15" WEIGHT="10.152572084028717"/>
<CONT_DATA CI_END="0.24391073057304913" CI_START="0.13608926942695077" EFFECT_SIZE="0.18999999999999995" ESTIMABLE="YES" MEAN_1="1.53" MEAN_2="1.34" ORDER="2" SD_1="0.1" SD_2="0.05" SE="0.027505980211009046" STUDY_ID="STD-Busnach-1998" TOTAL_1="16" TOTAL_2="19" WEIGHT="31.166963753127607"/>
<CONT_DATA CI_END="0.8254884593897487" CI_START="-0.40548845938974876" EFFECT_SIZE="0.20999999999999996" ESTIMABLE="YES" MEAN_1="1.66" MEAN_2="1.45" ORDER="3" SD_1="1.0" SD_2="0.41" SE="0.3140304945624732" STUDY_ID="STD-Yoa-1994" TOTAL_1="12" TOTAL_2="11" WEIGHT="2.425048244250873"/>
<CONT_DATA CI_END="0.1324390462638922" CI_START="-0.1324390462638922" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="1.34" MEAN_2="1.34" ORDER="42950" SD_1="0.21" SD_2="0.23" SE="0.0675721836261046" STUDY_ID="STD-Bennett-_x0028_high_x0029_-1995" TOTAL_1="18" TOTAL_2="25" WEIGHT="21.32712873318315"/>
<CONT_DATA CI_END="0.2417781818462842" CI_START="-0.02177818184628444" EFFECT_SIZE="0.10999999999999988" ESTIMABLE="YES" MEAN_1="1.45" MEAN_2="1.34" ORDER="42951" SD_1="0.23" SD_2="0.23" SE="0.06723500170703839" STUDY_ID="STD-Bennett-_x0028_low_x0029_-1995" TOTAL_1="22" TOTAL_2="25" WEIGHT="21.407774799776057"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="18.34917880529816" CI_END="0.05049965557083502" CI_START="-0.5762762051012089" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.26288827476518695" ESTIMABLE="YES" I2="72.75082414829215" I2_Q="0.0" ID="CMP-001.18" MODIFIED="2016-03-31 18:31:11 +1100" MODIFIED_BY="Narelle S Willis" NO="18" P_CHI2="0.0025391751786609795" P_Q="0.44460679183395935" P_Z="0.10014865867009802" Q="0.5843644770325276" RANDOM="YES" SCALE="2.0" SORT_BY="USER" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0966483248246249" TOTALS="YES" TOTAL_1="131" TOTAL_2="129" UNITS="mmol/L" WEIGHT="100.00000000000003" Z="1.644133358758174">
<NAME>Triglycerides</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.3067259757560689" CI_START="-0.4867259757560691" DF="0" EFFECT_SIZE="-0.09000000000000008" ESTIMABLE="YES" I2="0.0" ID="CMP-001.18.01" NO="1" P_CHI2="1.0" P_Z="0.6565862759270259" STUDIES="1" TAU2="0.0" TOTAL_1="42" TOTAL_2="38" WEIGHT="18.577462307043106" Z="0.4446312300888117">
<NAME>Short-course</NAME>
<CONT_DATA CI_END="0.3067259757560689" CI_START="-0.4867259757560691" EFFECT_SIZE="-0.09000000000000008" ESTIMABLE="YES" MEAN_1="1.88" MEAN_2="1.97" ORDER="42955" SD_1="0.93" SD_2="0.88" SE="0.20241493154231038" STUDY_ID="STD-Hernandez-2002" TOTAL_1="42" TOTAL_2="38" WEIGHT="18.577462307043106"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="15.370397536888325" CI_END="0.0662791905480547" CI_START="-0.6679025677118731" DF="4" EFFECT_SIZE="-0.3008116885819092" ESTIMABLE="YES" I2="73.97594961093125" ID="CMP-001.18.02" MODIFIED="2016-03-31 18:27:48 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.003991551540803662" P_Z="0.10825468391472917" STUDIES="5" TAU2="0.11278101444280332" TOTAL_1="89" TOTAL_2="91" WEIGHT="81.42253769295692" Z="1.6060875093017153">
<NAME>Long-course</NAME>
<CONT_DATA CI_END="0.7172374648211325" CI_START="-0.15723746482113243" EFFECT_SIZE="0.28" ESTIMABLE="YES" MEAN_1="1.86" MEAN_2="1.58" MODIFIED="2016-03-31 18:27:47 +1100" MODIFIED_BY="Narelle S Willis" ORDER="1" SD_1="0.52" SD_2="0.69" SE="0.22308443842336173" STUDY_ID="STD-Santos-2000" TOTAL_1="15" TOTAL_2="15" WEIGHT="17.461550483238597"/>
<CONT_DATA CI_END="-0.39212712272202" CI_START="-0.64787287727798" EFFECT_SIZE="-0.52" ESTIMABLE="YES" MEAN_1="1.35" MEAN_2="1.87" MODIFIED="2016-03-31 18:27:48 +1100" MODIFIED_BY="Narelle S Willis" ORDER="2" SD_1="0.14" SD_2="0.24" SE="0.06524246276290022" STUDY_ID="STD-Busnach-1998" TOTAL_1="16" TOTAL_2="19" WEIGHT="25.33705171757712"/>
<CONT_DATA CI_END="0.4503224689554728" CI_START="-1.8903224689554723" EFFECT_SIZE="-0.7199999999999998" ESTIMABLE="YES" MEAN_1="1.87" MEAN_2="2.59" ORDER="3" SD_1="1.08" SD_2="1.66" SE="0.5971142726023676" STUDY_ID="STD-Berthoux-1992" TOTAL_1="11" TOTAL_2="11" WEIGHT="5.641367736736702"/>
<CONT_DATA CI_END="-0.23008251110411865" CI_START="-1.0899174888958811" EFFECT_SIZE="-0.6599999999999999" ESTIMABLE="YES" MEAN_1="1.34" MEAN_2="2.0" ORDER="42958" SD_1="0.62" SD_2="1.14" SE="0.2193496882019341" STUDY_ID="STD-Maachi-1995" TOTAL_1="35" TOTAL_2="35" WEIGHT="17.660863919975682"/>
<CONT_DATA CI_END="0.47935403448346625" CI_START="-0.5593540344834659" EFFECT_SIZE="-0.039999999999999813" ESTIMABLE="YES" MEAN_1="1.34" MEAN_2="1.38" ORDER="42960" SD_1="0.74" SD_2="0.52" SE="0.26498141730157515" STUDY_ID="STD-Yoa-1994" TOTAL_1="12" TOTAL_2="11" WEIGHT="15.321703835428814"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NO="2">
<NAME>Fish oil versus statins</NAME>
<CONT_OUTCOME CHI2="0.055377627378713656" CI_END="0.8168422708859585" CI_START="-0.09608362879934507" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.3603793210433067" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2016-03-31 17:33:42 +1100" MODIFIED_BY="Narelle S Willis" NO="1" P_CHI2="0.8139568708905932" P_Q="0.8139568708905932" P_Z="0.12176696831145047" Q="0.055377627378713656" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="40" UNITS="mmol/L" WEIGHT="100.0" Z="1.5473993897234364">
<NAME>Total cholesterol</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Statin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours statin</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.9300167415396706" CI_START="-0.3100167415396714" DF="0" EFFECT_SIZE="0.3099999999999996" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.01" NO="1" P_CHI2="1.0" P_Z="0.32710808253628376" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="25" WEIGHT="54.2006172333573" Z="0.9799555310371247">
<NAME>Fish oil (3 g) versus simvastatin (10 mg)</NAME>
<CONT_DATA CI_END="0.9300167415396706" CI_START="-0.3100167415396714" EFFECT_SIZE="0.3099999999999996" ESTIMABLE="YES" MEAN_1="6.21" MEAN_2="5.9" ORDER="42961" SD_1="0.8" SD_2="1.27" SE="0.3163408850521152" STUDY_ID="STD-Castro-1997" TOTAL_1="18" TOTAL_2="25" WEIGHT="54.2006172333573"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.0944903180104424" CI_START="-0.2544903180104424" DF="0" EFFECT_SIZE="0.41999999999999993" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.02" NO="2" P_CHI2="1.0" P_Z="0.22229257789321466" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="15" WEIGHT="45.799382766642694" Z="1.2204546922704356">
<NAME>Fish oil (0.6 g) versus lovastatin (20 mg)</NAME>
<CONT_DATA CI_END="1.0944903180104424" CI_START="-0.2544903180104424" EFFECT_SIZE="0.41999999999999993" ESTIMABLE="YES" MEAN_1="6.14" MEAN_2="5.72" ORDER="42962" SD_1="0.95" SD_2="0.99" SE="0.3441340368143169" STUDY_ID="STD-Rodriguez-1997" TOTAL_1="17" TOTAL_2="15" WEIGHT="45.799382766642694"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.07133270608379888" CI_END="0.882359767514479" CI_START="-0.05857146513630873" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.4118941511890851" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2016-03-31 18:32:50 +1100" MODIFIED_BY="Narelle S Willis" NO="2" P_CHI2="0.7894061597041149" P_Q="0.7894061597041149" P_Z="0.08617032756182463" Q="0.07133270608379882" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="40" UNITS="mmol/L" WEIGHT="100.0" Z="1.715954734543112">
<NAME>LDL cholesterol</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Statin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours statin</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="3.747725180495319E-32" CI_END="0.9320105352973154" CI_START="-0.192010535297316" DF="0" EFFECT_SIZE="0.3699999999999997" ESTIMABLE="YES" I2="100.0" ID="CMP-002.02.01" NO="1" P_CHI2="0.0" P_Z="0.19693139931870962" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="25" WEIGHT="70.07560629351043" Z="1.2903435589444603">
<NAME>Fish oil (3 g) versus simvastatin (10 mg)</NAME>
<CONT_DATA CI_END="0.9320105352973154" CI_START="-0.19201053529731604" EFFECT_SIZE="0.36999999999999966" ESTIMABLE="YES" MEAN_1="4.09" MEAN_2="3.72" ORDER="42965" SD_1="0.77" SD_2="1.11" SE="0.28674533804211866" STUDY_ID="STD-Castro-1997" TOTAL_1="18" TOTAL_2="25" WEIGHT="70.07560629351043"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="1.3700331843324647" CI_START="-0.350033184332465" DF="0" EFFECT_SIZE="0.5099999999999998" ESTIMABLE="YES" I2="0.0" ID="CMP-002.02.02" NO="2" P_CHI2="1.0" P_Z="0.2451301427586654" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="15" WEIGHT="29.92439370648956" Z="1.1622593759463786">
<NAME>Fish oil (0.6 g) versus lovastatin (20 mg)</NAME>
<CONT_DATA CI_END="1.3700331843324647" CI_START="-0.3500331843324651" EFFECT_SIZE="0.5099999999999998" ESTIMABLE="YES" MEAN_1="2.53" MEAN_2="2.02" ORDER="42966" SD_1="1.37" SD_2="1.11" SE="0.438800504048185" STUDY_ID="STD-Rodriguez-1997" TOTAL_1="17" TOTAL_2="15" WEIGHT="29.92439370648956"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.784224947787234" CI_END="0.02218450144113779" CI_START="-0.38937099381586526" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.18359324618736375" ESTIMABLE="YES" I2="43.95325537622466" I2_Q="43.95325537622466" ID="CMP-002.03" MODIFIED="2016-03-31 18:32:51 +1100" MODIFIED_BY="Narelle S Willis" NO="3" P_CHI2="0.18163151534363564" P_Q="0.18163151534363564" P_Z="0.08034910706799497" Q="1.784224947787234" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.009691692810457557" TOTALS="YES" TOTAL_1="35" TOTAL_2="40" UNITS="mmol/L" WEIGHT="100.0" Z="1.748664053713206">
<NAME>HDL cholesterol</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Statin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours fish oil</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.1352651642167758" CI_START="-0.2952651642167755" DF="0" EFFECT_SIZE="-0.07999999999999985" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.01" NO="1" P_CHI2="1.0" P_Z="0.4663745308761026" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="25" WEIGHT="50.66988276792199" Z="0.7283905843924969">
<NAME>Fish oil (3 g) versus simvastatin (10 mg)</NAME>
<CONT_DATA CI_END="0.1352651642167758" CI_START="-0.2952651642167755" EFFECT_SIZE="-0.07999999999999985" ESTIMABLE="YES" MEAN_1="1.37" MEAN_2="1.45" ORDER="42967" SD_1="0.31" SD_2="0.41" SE="0.10983118359049442" STUDY_ID="STD-Castro-1997" TOTAL_1="18" TOTAL_2="25" WEIGHT="50.66988276792199"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-0.06952604371727755" CI_START="-0.5104739562827225" DF="0" EFFECT_SIZE="-0.29000000000000004" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.02" NO="2" P_CHI2="1.0" P_Z="0.009936395961839376" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="15" WEIGHT="49.33011723207802" Z="2.578034907613974">
<NAME>Fish oil (0.6 g) versus lovastatin (20 mg)</NAME>
<CONT_DATA CI_END="-0.06952604371727755" CI_START="-0.5104739562827225" EFFECT_SIZE="-0.29000000000000004" ESTIMABLE="YES" MEAN_1="1.27" MEAN_2="1.56" ORDER="42968" SD_1="0.29" SD_2="0.34" SE="0.11248877939686286" STUDY_ID="STD-Rodriguez-1997" TOTAL_1="17" TOTAL_2="15" WEIGHT="49.33011723207802"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.38929691588552146" CI_END="0.5498041296512973" CI_START="-0.184916112591299" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="0.18244400852999917" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" MODIFIED="2016-03-31 18:32:51 +1100" MODIFIED_BY="Narelle S Willis" NO="4" P_CHI2="0.5326695675502846" P_Q="0.5326695675502846" P_Z="0.3303608480747706" Q="0.38929691588552146" RANDOM="YES" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="35" TOTAL_2="40" UNITS="mmol/L" WEIGHT="100.0" Z="0.9733873258274726">
<NAME>Triglycerides</NAME>
<GROUP_LABEL_1>Fish oil</GROUP_LABEL_1>
<GROUP_LABEL_2>Statin</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours fish oil</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours statin</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.674249586428558" CI_START="-0.1742495864285581" DF="0" EFFECT_SIZE="0.25" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.01" NO="1" P_CHI2="1.0" P_Z="0.24810712239702204" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="25" WEIGHT="74.97926241851822" Z="1.1549592782396878">
<NAME>Fish oil (3 g) versus simvastatin (10 mg)</NAME>
<CONT_DATA CI_END="0.674249586428558" CI_START="-0.1742495864285581" EFFECT_SIZE="0.25" ESTIMABLE="YES" MEAN_1="1.76" MEAN_2="1.51" ORDER="42963" SD_1="0.81" SD_2="0.51" SE="0.21645784809056937" STUDY_ID="STD-Castro-1997" TOTAL_1="18" TOTAL_2="25" WEIGHT="74.97926241851822"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.7144157052725157" CI_START="-0.7544157052725158" DF="0" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" I2="0.0" ID="CMP-002.04.02" NO="2" P_CHI2="1.0" P_Z="0.9574332959572038" STUDIES="1" TAU2="0.0" TOTAL_1="17" TOTAL_2="15" WEIGHT="25.020737581481786" Z="0.053374784075805745">
<NAME>Fish oil (0.6 g) versus lovastatin (20 mg)</NAME>
<CONT_DATA CI_END="0.7144157052725157" CI_START="-0.7544157052725158" EFFECT_SIZE="-0.020000000000000018" ESTIMABLE="YES" MEAN_1="2.23" MEAN_2="2.25" ORDER="42964" SD_1="1.02" SD_2="1.09" SE="0.374708775806848" STUDY_ID="STD-Rodriguez-1997" TOTAL_1="17" TOTAL_2="15" WEIGHT="25.020737581481786"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAu4AAAG2CAYAAAAgKAPNAABVK0lEQVR42u2dD2SW3///PyTJZCJJ
kkSSJIkkkySSJB+JJJO3RJIkiSRJZmQyMzMmSSaRvCVJJJkkkcxM5kMyySQmSZLz8zx+5/6e++y6
znWu+77b7m2PB5ftvq/7/L2uc87zel2vc85/jMd//vMfDg4ODo4ZPJoNrgkHBwdH84wL//E7ZwAA
mHmhTF4AACCrL/4PnTMAAOId0Q4A0Pzjwn/onAEAEO+IdgCA5h8XEO4AAAh3hDsAAMIdAAAQ7gAA
gHAHAEC4I9wBABDuAACAcAcAAIQ7AAAg3AEAAOEO08Pw8DCVAIBwB/prAJhJ4f7jxw9z6tQp09LS
YhYtWmQOHz5svn37Vjmv/w8cOGAWL15sf3PkyBEzMTGRfD5rZ6gFCxbM6YFpcHDQrFmzxtbntm3b
zPv37yvnJicnZ8UuiiEqCwDMD+Fe77jg+Pnzp1m3bl3pfpIHlvryTH8NMIeF+9mzZ01vb6/58+eP
PS5evGg7ace1a9fM1atXK+fv3LljLl++nHw+5N9//42en+28efPGbN++3Xz8+NHWx927d82GDRsq
5x89elRVv4gLADroZku73nFB/P792xw6dCgzjaJ+Euq7T+ivAeawcF+6dKntOP3O1n9a37NnjxkZ
Gak6v2/fvuTzPkpn8+bN5vv379HMvn792ixfvtxs3bq1aqBobW211p1z587Z7xTPqlWrrFXH59ev
X2bTpk2ZHVhWPEKWn69fv9r/NZgonAYX8eXLF3s+pUM8evSouXHjRu7569evm+7u7lIXL7U+/DC3
b982y5Yts+fPnDkzpY40EOucLGa7du0y4+PjuWlmvR14/PixWbhwoX17orp+8eIFLQ1gjgj3escF
oX7l06dPmWkU9ZOzbVxIqdeqrcwL+mjV/enTp82SJUvMypUr7dsJP/z//ve/yhsP9cPr1683Dx8+
9Af8KW9zY2MGAMwi4R6izk2do0Mdh9+Bu+9Sz/v09fUVWtuVT3ViivPz58+VcLdu3bLfaYBQJ9bZ
2WnP6XVuV1dXVRw3b960nVTYWcbiOXbsmHnw4IH9/969e3aQ0u/d5/b29qT6W716ddS/UBYoDXrq
QFVPEtCNrA8XZsuWLVaM6zeqC1nQHKqvnp6eirVM8fnly0ozvH80WDx58sT+//TpU7N27VpaGsAc
Ee71jgvi2bNnuWkU9ZOzfVxIEe6xPlp57ejosOfkgtTW1lYVXgYwvaVwfbj6c//6hOkXjRkAMIuF
u155XrlypUqghfjfFZ33UWcjq0VRZn3rr1AHFw4STiiOjo5a64o7r7+ygrg4/HLH4pH1Q529OHHi
hLUI6RDHjx+3HV0KKruErCwgsoaEvqErVqywdezy2t/fX1Xf9daHC/Pq1avKZ/mrqo4cGzdutAOx
PyjL8hNLM7x/NEjcv3+f1gUwD4R72XGhKI2ifnK2jwspwj3WR+utgt9Hv337tvBa+XPHwt8WjRkA
MEuFu14JapKRnsizOoOsDrrovEMdqSYg1TKQKL7YBNedO3daa4KQFUKvELPii8Wj/OnBQuh1qiZK
uY5Ug0vRA4efnjp6TUJ11mzX0Weh30jMN7I+9DnspMtcs6JBR2jQdVYj+boCwNwU7rWMCykitkw/
OdvGhRThHuujw7rUb8M45TqkhynVm4wxYfxl6goAZqFwV6es14LhygBZbi+hq0zsvEN+3UVuIXkd
XlEHowmf6kRd5+pe0YbxFcUjv06V33XMep0rP07fElKEyu5bStThFs3wj+WrlvrIG+RiA2ys08/7
TgOH6n7v3r3mwoULtDSAOSbcax0XitIo20/OtnEhRbjX00frTYAm8w4MDNhyyX0oFj8iHWCOCXdZ
VGT9yLIeSJTpNZ5DE2g06Sj1vEO+3epIaxlI1OnKMhNDnan8AsPJQn58RfEoj//880/F8uNei8Ys
QSHhBC0NSHoV7JBLij85V4OXG1waVR8K4y+tplfQ/qCq8KGrjD9opgp3h9JiFQOAuSXc6xkXitIo
6idn+7gQ5tdNbE3to7Xijt9H60HBD6/f+nnOir9sXQHALBHuQ0ND9pWiZshnoUkzbpKMDj3h+64R
Recd8qdzk4rKDiSaZOSnoc/hIKGJNpp9H0648eMrikdvBSSstQyakP+5BhP3ujUF+X3rcGkoTt9F
6Pz587bO3Hnl16XXqPpQGH2WlUjnL126ZAcfP7zy5cIrfX+t5aw0VQ/yD3WDiaw9WllGaJJq3mty
AJh9wr3ecaEojaJ+craPC/7kfa2sIzedUFjH+mi59mgFMjc5dffu3VXh9UDiVpGRqFfd+efD/jql
rgBglgh3ve6LbQgksa1OQxZZHfv376+aRFR03u/IQp++MgOJVqORlUFpqBMMHwJkHdK58JVuGF8s
Hg1W/nJfbkLQhw8fSg2y6ug1edOl4YeXZerkyZP2nF7BqjNtdH0ojDp1+c4rH3pYCK+JWw5Sh1ZG
GBsbi6apgc9dYyE3GflV6hWsrq0T8QAw+4V7veNCShqxfnK2jQshzpih/lFGEfWPoXAv6qO1XKYe
GLQCmeYA+OFfvnxpjWFKQ0YUPQT558P+OqWuAGCWCHdACAAAwh2odwBAuAODAgAg3IF6BwCEO2RR
tIoNACDiEJD00QCAcAcAAIQ7AAAg3AEAEO4IdwAAhDsAACDcAQAA4Q4AAAh3AABAuAMAINwR7gAA
CHcoYnh4mEoAAIQ7AAD8XeH+9OlTu/NdEKByaHc27bh26tQp8/3796YYVKYrj6kD23Qs76Vtrd02
1yEPHjyo2jI8a9fDcPfDrHP+Vt2pdRDGOTg4WPiborwl3tTROOqpL20Zvnfv3qodZR3Pnz+3v3n2
7NmUc7r3zp49a3c8VF1qd0NtD1827yloV8hz587ZnReVlnayDes+9T5oxDUr2yZj9VhUF9r5UeER
7gh3AIB5J9y3bNliRkdHo525Bt4LFy6Y06dPN41wb4Y8TucAqDQkNn/+/Fn1/a9fv8zmzZuniKha
8izRLtHqi/eywn3r1q1T8lg2b42o73rqS7+5fv26FcMh//3vf+19dvDgwSnnjh49au7cuWP+/PlT
iefixYv2aGT5da+rnm/dumXTENqSfc2aNeb27dul66nomtX6faxNxuqxKN/qr5RnhDvCHQBgXgn3
oaEhs2fPnqTOXGKkpaWl6jtZE1tbW+33sv6F8UhYrF692ixYsGCKNfd///uftZxJKOrc+vXrqyyk
ZYV7LXl052UZXLp0qenp6ckVdI8fP7b5VFk2bdpkXrx44VfwFAtkUd28fv3aWktTBYjC3Lhxw/T3
91d9L6F49erVhgh3J95VzlqFu/Kn/DSDcK+3vnRv+nz+/NmsWrXK/i+R/OXLl6rzfr354lX3ViPL
f+XKFdPV1TXle4l3/35Kraeia1bP91ltsqgeU/Ktfkv9F8Id4Q4AMG+Eu17r+xa6os7cH4D7+vqs
MNfA/Pv3b/u6vbOzsyoeCfPx8fFMQSir5927d214HRLNErL1CPeyedQ5Wf10fmJiwuzYsSNX0PkP
HnIvkhtEXn5S6ubMmTP2vERM6oX8+PGjzaOPXDo+fPjQMOFeVmhn/VaWbnfdZ1K411pfui4dHR1T
xLGs8JcuXbL/X758eYobzIYNG+x1dlbwvyWWlM6nT58aVk9F16we4R62yZR6TMn3wMCA7b8Q7gh3
AIB5I9w1WI+MjBR25hIJN2/etGLTIRcb5xLgCMWsLwRSBgpZs2sV7rXkcfv27VXWvrdv3+YKOj1U
3L9/Pyk/tdRN6iArISrhKZR3PQBlieMUn+S/Jdxfvnxpjhw5kvub6fBxb0R9yTrvo7dHelMk9FAg
a7GP7h9dZz3kad6ILNmqi7J5LyLLsl9vPcWuWa3CPatNptRjSl2o3/LnKSDcEe4AAHNeuMsVIBSY
WYP8ypUrrZ+urMe+eAh/VyS8w+/kLqLX/vINlj9xGWHZiDyGk0pVF3l5kJVdnyXKi9wKaqmb1EG2
u7u7Yq2UKHKW/GayuAuJQCdaZ8riXmt96T7Q2yC5b/nXf9euXVW/2717d+bkSt3XSktvnHQvyGWn
keUPXXgaUU+xa5Yq3FPaZEo9puQ7ywUH4Y5wBwCY08LdF5NZnbkslPv27TPv379PCls0KPjfyUVH
r/z1yluDtlxGarEI15PH0HIZE+5OkD169Mi6W8jFJu93tdRN6iCrepIgUl71ECGLZTMKd1lbnUV0
JoV7PfXlP9hJhGeJU30fQ0uFxtyqakFvDeTaFSKBnDpPpMw1SxXuKW0ypR5T6yj1zQPCHeEOADAn
hHuexT0UAxpU//3336rvNUFzcnKyZuGuCaF+eAmqWoR7PXmUSPEF0Lt375LyIEES+10tdVNmkJXF
UlZkufrUIrZjv6l3cqqP3kzIXWQmhXut9aV7Sss6Crk1yb0jbCv6rO+du5UmoYa/Eb5luBHlV71q
DkWIXHt8n/5a7oOsa1ZWuOe1ydR6TMm34sfijnAHAJhXwl3CVX65RZ25BlRZDZ21Umjinibwucml
+uy/Ai8S7hqonXXQ+avWKtxrzWM4OVXn8vKgtwNaWSZL3OoBSKLETUqspW7KDLKa/CqrvtwxGinc
VT6VxZWzXuGuJQZl5Z5p4V62vpRvCX33VkViNmsVFyE3GDe5Um4h+p2bOKp45Krj+3g3ovzfvn2z
rmW9vb3mx48f9h7T2vR6cPB96mu5D7KuWS3CPatNptZjSr71kI2PO8IdAGBeCXetyiBRk9KZa8OT
nTt3Vn2nFSFkOZdLgaxr/gopRcJdAsNN5JMo1sTPeoR7LXkUWuFCyzbKnUJ14btH+OnITUZiyS1t
6Ytb+U0rnB+2bN2UKbOEm/KRF2ejN2CKxVV0zbSiTi2TU8vOcYhNvi1bXxLAEttubXO5poTrnDsk
nPWGxSHxuW7dOpueLPYS8/4qM40ov9DDwbFjx6zVWWlpGchwU6JaJymH16xW4R62ydR6TMm33gqw
qgzCfb7Drt3UHcwz4f7q1aspE8XmMxIVbn3pmeDEiRNcBOqC8ifQ1tZmH6YR7o1PO2UH4Gapk0a/
zWuW69RMu3b746OMElnoYV+rQyk/ehOWNb+l2ZjOugNomHAXei0+X588NTBpsqlbb13WUX/S6XSj
FXaAuqD8ceRap35rrnTQzZZ2yg7A863+mvXtxHTlS+PjoUOHMtPTxm+aPySXOLcil96i0/YA/pJw
l2tE1rbj8wGtZiMXAz15yz3i/PnzVUvXAUDzof4qdAtCuDcu7dQdgLUymIwfctfyXcscsd2j9TDQ
3t5u59Ro2VW9/c3KV5kdtlN2uk7Jm8Tn6dOnraujXChjrmMu3aydsGfLrt0p96DezMs9L+u3etDz
l7xNue/K1lfK/aYHS53TvaL8hhvK+Wlm1V3RPQPQNMIdAAAQ7o7UHYD11kPiSEJXosufc1C0e7Te
KLkN7fTW07fQ+vkqs8N26k7XRXnTJHa3uIAWLZBbVpFwD3fCnku7djsjV949o4Umyry1r6W+iu43
TXrXveHuE8WnB8NYmln7r+TVMwDCHQAAmlK4p+4A7FvJNbnYnx9UtHu0hHrW0qkpdZK3mV3qTtdF
eZNF1n9oCXfUzspvuBP2XNq1u+ja6D6R0NXbEFm7Dx8+bBcEaGR9Fd1vWjjCv2b63y3nm5dmWJZY
PQMg3AEAoKlXlSnaATgUWr6LTdHu0bHNs2rdYTt1p+uyeQs35ksVs3Nl1+6isuq7U6dO2b1LnLVb
16qR9VV0v2Vteli0H0n4XayeARDuAAAwa5aDTNkBuEhI5f02lq8yO2yn7nRdS97KCve5tGt3UXj5
6fvWbpUltmJLLfVVdL8VXbMU4R6rZwCEOwAANKVwT90B2F/yT64REnCOot2jtaxgiqtMmR22U3e6
Lsqb3Fh8IapVjMoK97m0a3dR+H379k15CJHLTCPrK+V+C11l8vZkSamLsJ4BEO4AANCUwj11B2Ct
3CHxKaGmnYa1XKCjaPdoub7INUFohaC8yalldthO3em6KG+aDKuN+dzE0d27d5cW7nNp1+6issov
XIdLU/dKbFfjWuor5X5Tui68dpX215zPSjOsu1g9AyDcAQCgaV1lUnYAlqBesWKFndSnpXTDCYmx
3aP1MKBJjBJH8lvX5MysfJXZYTt1p+uivAn586vcWp5QPtu17OQ9W3btrnXDKx+JZt0HLs0PHz40
tL5S7je3HKQOrSgzNjYWTTOsu6J7BgDhDgBABz0r02ZMaSwzvWs37QQA4Q4AAAh3yKDZdu2mnQAg
3AEAYI4K99iqIVAMu3ZzvwEg3AEAEO6zIm0AAEC4AwAg3BHuAAAIdwAAQLgDAMBfFu500gAAiHaE
OwDALBHudNQAAIh2xgMAgFki3CtfcHBwcHDM2MHDAwAAJAl3AKyVAEA7AgBAuAMgOABoRwAAgHAH
QHAA0I4AABDuAAgOANoRAAAg3AEQHAC0IwAAQLgDggMAaEcAAAh3AAQHAO0IAAAQ7gAIDgDaEgAA
fTLCHRAbAEB7AgCYDX0xvTIgNAAg2qY4ODg4OJpjR21UDiDcAQCAcQFgNtzPVAHQQQMAAOMCAMId
gA4aAAAYFwAQ7gB00AAAwLgACHcAOmgAAGBcAEC4A9BBAwAA4wIAwh3ooAEAgHGBcQEQ7gB00AAA
wLgAgHAHoIMGAADGBQCEO9BBAwAA4wIAwh2ADhoAABgXABDuAHTQAADAuAAIdwA6aAAAYFwAQLgD
0EEDAADjAgDCHYAOGgAAGBcA4Q5ABw0AAIwLAAh3ADpoAABgXABAuAMdNAAAMC4AINwB6KABAIBx
AQDhDkAHDQAAjAsA3M1ABw0AAIwLAAh3ADpoAABgXABAuAN4HXN4AAAAMB4Awh0A4Q4AAAh3AIQ7
QL3iHQAAAOEOCHcAhDsAACDcARDuAAh3AABAuAMg3AHhDgAACHcAhDsAHTQAADAuACDcAeigAQCA
cQEQ7u7m5uDg4OCYuQMAEO4AhcKdGxsAAJEBQJsCaHLhzk0NAIDQAJhr7Yg3WjAH72tuZAAAxDsA
wh0A4Q4AAAh3gBkW7wAIdwAAQLgDINwBEO4AAAh3AEC4AyDcAQAQ7gAIdwCEOwAAINwBaEsACPe/
zvDwMJXANQdAbADQlgCaX7g36kavN56ZCr9o0aKGln26O46fP3+adevWTfl+cnKy9BJZT58+Nfv3
7698/vHjhzl16pRpaWmx9XT48GHz7du3ynn9f+DAAbN48WL7myNHjpiJiYmmbwxlrrnK9/z5c3oQ
mPNig91sOTg4OJpnR22E+18cNGdq4P39+7c5dOhQZvqPHj2yQrsMW7ZsMaOjo5XPZ8+eNb29vebP
nz/2uHjxYlWc165dM1evXq2cv3Pnjrl8+fKcEkqqj61bt6IuYU4LdyyVAADNNR4kCXf9f+vWLbN6
9WqzYMECs3DhQvPkyZPK+V+/fpn29nZrYV2/fr159epVstXZ/04i7/Tp02bJkiVm5cqVZnBwcEoY
icLW1lZryT137lzVuZTwPo8fP7ZlUZk2bdpkXrx4kWlhakTey5QjL1+pA+muXbvMp0+fMn97/fp1
093dnXyzDA0NmT179lR9t3TpUlte/0HBt1br9yMjI1Xn9+3bF70hX79+bZYvX14lhmN1pDC3b982
y5Yts+fPnDlj3zL46IFC53Rfqk7Gx8dz08y65rHr4Mqp+gGYi6IZ0Q4A0HxjQrJwl2uAEz4S7RI0
jitXrpj79+/b/2XR3bBhQ03C/ebNm6ajo8OKQrlWtLW1VZ3v6+uzDxA6LzEocdzZ2ZkcPsR/AJE7
yNq1a3PzWm/ey5Qjlq8Unj17lptnWeIlOCWI9ZAhcRtD1nUJ5Bh6cJMAdiheX9i772I3o4S3wnz+
/DmpjhRGbwJ0T+o3EvnKq6Orq8v09PRUrP6KTw+XsTTD+iq6DgMDA1VpAswV4YxoBwBoznEhWbj7
1srwvIR6KNRqEe6yfEoEOt6+fVt1XkItTMcXU0XhQyQ23QNH0cBVb97LlCOWr3oH3xUrVljXFaE8
9Pf32wevPLZt21ZlPc9C8flx+A91se9i91dRHSmM/2ZHfverVq2qfN64cWPV9dD/ss6n3tMp10H1
ovoBQLgDAEBTCffY+SJRVms8Em7h+dClQW4MqeFDZEV1llv5ZNcj3IvSLlOOWL4aPfgqnxLzecjN
JO+hTHz9+tVOPpVV3OGXpew9klpH+hzmy0+jKA9F1zPlOih9ueIAINwBAGDeC/fwfJYYKxKHRQOQ
/Jzl3rN3715z4cKFhgn3WNmLyhHL198YfGP5iZ2TWD927NiUFWOy3GKKXGXKpBsT+7Vcj9h3Rdch
du8DINwBAKDphLuWHazFVebjx49V323fvr3KvUGuCP55TRDUcoZ5FIWP8f79+2he6817mXLE8lXv
4Ct3ke/fv1c+K8+aUJxHnsVdlnYtCal6CJHIleuKQ5NGNTm0TD6L6khhVDcOLUHpPxwofOgq40+g
TRXuseugBxcs7oBwBwCAWSXc5d8stwKhta3zJqf6k/206okmvPrn7969a1c9cRM8d+/eXXVeEw7d
BFAd+uwLwqLwIcqnVg4R4YRbCVb5QDvxV2/ey5Qjlq96B9/z58/biZwubU341NKOeciHW/76PlpJ
ZefOnebLly+ZYRS/Xz5N4oy5/GTls6iOFEafVdc6f+nSJTvx1g+v1XNceJXRX9c+K83wmhddh3fv
3uHjDgh3AACYXcJdFlWt4y1ho0mBvtDzf+fEj9wgJKIkisK4b9y4Ya3CWvVEK4GE57UeuCyrsp5K
PLsVQVLD+8gNQvl1S1w6kSYkaJWGs9LWm/cy5Yjlq8yAmvVbXauTJ0/adLWso8RxDK2aorL4aBJo
bIMAlUUPLq7+tHmTv0FTqkiI1ZHCPHz40PrnaxKpHkjCNNxykDq0oszY2Fg0zfCax66D0MReVpUB
hDv8bdjVGQAKhTuA0MotMTeX+SwstOSnxD3AfBHu+l5Ls053XtnJe3bu5D1bd9EGQLjDrEarqjSb
xWem71vNYVC9AMw34a6lb8PNzmbLOMJO3tPLbN1FGwDhDrMauQkdPHiwqfLUCAtUPag+NJ8DYL4J
d7mIFS2fm7fr8Zo1a+zEduEm+L9588Z+1pwZnS/KDzt5z56dvMvuog0ACHcAAIR7A4W70KRsfwOz
1J2htXzsgwcP7P/37t2zD+BuDo0++7sbx4Q7O3nPjp28y+6iDQAIdwAAhHuDhfvLly+tv3LW72O7
Ht++fdsuIytOnDhhjh49ag9x/PjxTP/5LMHNTt6zYyfvsrtoAwDCHQAA4d5g4S4k3CXgw+9jux6P
jo6azZs32//ldqH9EbRKlZBbS9a+EGUFNzt5N89O3mV30QYAhDsAAML9Lwh37Wfh9jEoszO0lqGV
+4YT7PJVlx+0+9yswr1sOdnJu/wu2gCAcAcAQLj/BeEuZIHVZNUyO0Nro7R//vmn4iLj3GXc53oF
Nzt5N89O3mV30QYAhDsAAML9Lwl3CTG5UJTZGVo7GmujOrdjs4S/VoDRBMlGCHd28m6enbzL7qIN
AAh3AACE+18S7iJrmcPYrsdDQ0NVy0C6iZMfPnxoiHBnJ+/itKdrJ++yu2gDAMIdAADhPovSBgAA
hDsAAMId4Q4AgHAHAACEOwAAINwBABDuCHcAAIQ7HTQAAMId4Q4AgHAHAACEOwAAINwBABDuCHcA
AIQ7AAAg3AEAAOE+uxgeHqYSuOYACHcAAGg+4f7/T2YeMzkgzFR4t2Ndo9KeiYHx/v370XSLzju0
nbh2wEuNY3JysuH30XRQ5pprt0Ftrw6AcAcAgBkR7s04IMxU+EbUx0wOhp8+fTK7du3KzUPReZ8t
W7aY0dHR5DgePXpktyCfy8JJ9bF161Z6FUC4AwBA8wn3I0eOVFkYHz9+bPbt22f///Xrl2lvbzeL
Fy8269evN69evcqMNysN/7s/f/6Y06dPmyVLlpiVK1eawcHBKWGuXbtmWltbTUtLizl37lzVuZTw
PirDwoULzYIFC8ymTZvMixcv/IqqshTXm/cy5cjLV5kBdu/evebDhw+5vy867xgaGjJ79uwpFcf1
69dNd3d3qRvz9evXZvny5VViOFZHCnP79m2zbNkye/7MmTPm58+fVb+5ePGiPaf7Ug8Y4+PjuWlm
XfPYdRCqF9UPAMIdAACaSrh//vzZbNu2zQpUCaS1a9dWrLBXrlyxLhNC1tYNGzbUJNxv3rxpOjo6
bBoTExOmra2t6nxfX5+5deuWPf/7928rjjs7O5PDh0iUPXnyxP4vdxCVKS+v9ea9TDli+UpBwrmn
pyc330Xnfc6ePWsFcpk4Dh06ZEWtRLceZCSgi25MCW/Vh+6zlDpSGL0JkBjXbyTylVdHV1eXzZ/O
6VB8eriMpRmWo+g6DAwMVKUJgHAHAIBpE+5FPu4SPxKoElC+YJFQlwAqGhCKxK8sn7LeO96+fVt1
XkItTMcXU0XhQ2RtdQ8cRQNZvXkvU45Yvop48+ZNlYU8zHfR+RA9rI2MjJSKY8WKFebOnTv2f5Wz
v7/fPtzFbkzfGp5SRwrjv9n58eOHWbVqVeXzxo0bq66H/pd1PpZmWI6i66B6Uf0AINwBAGDahXsK
ElQSQF+/fq18J8tkyoBQJH7DeCTcwvPhQ4XcGFLDh8iK6iy3V69erUu4F6VdphyxfMX4/v27fYD4
8uVLZrpF57OQm4kvoGuJQ+El5suIhqI60udQ2PvXwP9t1vmi65lyHZS+XHEAEO4AANCUwl2ri8jC
Ph3CPTyfJcbyhFlqueTnLPce+WtfuHChYcI9VvaicsTyFeP48ePmwYMHuXkoOp9FmNda4igqc1b4
ojrKE/u1XI/Yd0XXIXbvAyDcAQBgxoR7b2+v9TsOfXvXrVtXk6vMx48fq77bvn17lXuDXBH885og
qKUG8ygKH+P9+/fRvNab9zLliOUr4QLnujvVsuRnaHFPiUNvZGSZd6heNGm5jGgoqiOFUd04vn37
Zv3p/fChq4y/3GOqcI9dB/neY3EHhDsAADSdcNcEvh07dlQJI60oIuS/LLcCoZVn8ian+pP9tJSg
1sL2z9+9e9dOenQTPHfv3l11XhMO3QRQHfqs1UJSw4con1o5RChfvvVUglU+0E781Zv3MuWI5avR
A3KKj7v89cvEcf78eTtZ1JVPcyL00FcmD0V1pDD6rLrW+UuXLtlJsX54rWzjwit9PWDG0gyvedF1
ePfuHT7ugHAHAICZEe4xS6rW5faXg9T/Eq9Cq8zovISNJgX6Qs9Pz4kfuUFIREkUhfm5ceOGtdhq
RRJNhg3PX7582VpWZT1V+m5FkNTwPnKDUH6VH+XLiTQhsak0nJW23ryXKUcsX2UH2HqFu96sqCxl
4tD9cPLkSVu2pUuXWgFeSx5idaQwDx8+tL7zmkSqhwVZ3X3ccpA6tKLM2NhYNM3wmseug9CkW1aV
AYR7fbBjMXUNXCOoQbgDZKGVW3xLNyLn/9CSnxL3AHNVuNezo3ZqecIdi/9mPTQqbnYEn957tpbd
uMMdv7PCp8w3m27YwRsQ7lA3WlWl2awAM30faw6D6gVgrgv3+fAQPl+E+2zdEbyW3bjzdvx2/Pvv
v/at7my+t9jBG+EOkInchA4ePDhrrRJ/A9UHlg6Y78I9tqO2H7bWXar1vxZEWL16dcVlzc01cmg+
jVzq5JanTddieS4TNzuCN8+O4GV3447t+O3KtXnz5qpFFNjBGxDuAAAwp4V7bEftvIUJyuxSrf/l
DuDETjhJXMJby7S6RQG0gEIZ4R6Lmx3Bm2dH8LK7ceft+O3nNbS2s4M3INwBAGDWC/dad9T2f1Pr
LtVFOxxrGV5/M7ii3bLLxM2O4M2zI3jZ3bizdvz2kbVdSzqH5WYHb0C4AwDArBbuKWTtqO2HrXWX
6iJhGbrMFe2WXe+GgI2Ihx3By+0InkXRbtzh/iM+eiOUJXTZwRsQ7gAAMC+Ee9aO2mHYWnaprldY
NqNwD8+zI3htxNKLnZOvfJarDTt4A8IdAADmvHDP21E7L2yZXaqLhI0sp/K9dmhTtEYJd3YEb44d
wUXZ3bhjFnf5y0sEp9zr7OANCHcAAJgzwj22o3boL566S3UZcR1OTtWqHY0S7uwI3jw7gpfdjTu2
47d81MONG/PuB3bwBoQ7AADMKuFe647afpxldqku60ogYanVRrRcoSbKxpaKLRM3O4IXpz1dO4KX
3Y07tuO30s6yxrODNyDcAQBgVgv32YYEnr+qB8xPpmvHb3bwBoQ7AADCHeGeiCzB8ld262zLulnv
pEeYG0zHjt/s4A0IdwAAhDvCPZFnz57ZtcadC4VcFSTgAaZjx2928AaEOwAAwh3hDgAACHcAAIQ7
wh0AAOEOAAAIdwAAaJxwp5MGAEC0I9wBAGaJcKejBgBAtDMeAADMEuFe+YKDg4ODY8YOHh4AACBJ
uANgrQQA2hEAAMIdAMEBQDsCAACEOwCCA4B2BACAcAdAcADQjgAAAOEOgOAAoB0BAADCHRAcAEA7
AgBAuAMgOABoRwAAgHAHQHAA0I4AAOibEe6A4AAA2hEAAMIdAMEBQDuCmhgeHqYSuGYACHdAcABA
+Xak7wcHB+ddu5up8i1atKiheZ/ucvz8+dOsW7cu6bdPnz41+/fvryuOZiC8ZgcOHDDPnz+nUwGE
OwDCHWD6hfvWrVutmKLdzY7+bKauze/fv82hQ4eS09+yZYsZHR2tK45mvGYqk9oMAMIdAOEOMO3C
vb+/31y9ejX6+2vXrpnW1lbT0tJizp07V/l+zZo15uvXr/b/jx8/2nBv3ryxn798+WLP53Hx4kUb
3+LFi82uXbvM+Ph4Vfq3bt0yq1evNgsWLDALFy40T548mZKnJUuWmKVLl5qenp4peS6Kv5Fp+Tx+
/NjGobg2bdpkXrx48X8DtHfkXRf/uz9//pjTp0/btFeuXGnfjsQs7nnXKZav1H5Wdfjp06ek3w4N
DZk9e/bUFYd+8/r1a7N8+fIqoRwro8Lcvn3bLFu2zJ4/c+bMlIfSovvCTzPrmgmVTWUEQLgDINwB
plW4i23btuUK276+PitsJSJlMZV47OzstOeOHTtmHjx4YP+/d++edSvQ793n9vb2zHS7urqsAFac
OhTG/63Sl0uCy5OEtESnQ/m5cOGCDTsxMWF27NhRleeU+BuVVogv/OUusnbt2tzrUCTcb968aTo6
Oippt7W15Qr32HUqylcKz549S+6Tz549awV0PXHoNxLeKs/nz5+TyqgwsvTrWuo3EvnKS5n7Ikwz
K68DAwNV8QIg3AEQ7gDTJtxfvnxpjhw5kvl7CSEJGR8n+iTOTp06Zf8/ceKEOXr0qD3E8ePHM/3n
xcaNG82vX78qn/W/rKR++v6DRJin7du3W4u+4+3bt1XnU+JvVFohstbev38/6ToUCXdZff1yhGmn
XqeifDW6T9aD4MjISF1xZF2XojIqzKtXryqff/z4YVatWtWw+86hsqmMAAh3AIQ7wLQLdyHhLgEf
fi9LbegyIHcLIX/fzZs32//lfvH+/fuKUFq/fr11n8nChffxrdxFgjacMCgx558vE3+9aYXImu0s
v0UuSEVp+3nOSjv1OhXlq9F9stxQQoFdi3DPuoaxMupzmK5fh/Xed/51kLsNAMIdAOEOMCPCXb7H
zopYJIJ95PctNw4n2OUrLoukb+mMiaVaxHSRoC0Tf71pZSE/6UePHpm9e/daN5tGCfdY3ouuUyxf
je6Ti/JSq3CvJV6/Duu974ruYQCEO3BTI9wBpkW4C1liNVnV/16W9MnJydy4tUrIP//8U3GRce4y
7nMWijN0WfAt20UCSg8YelhwvHv3bkqeU+OvN60YegMRSyv87Cb4OuSm45dDD0R58RVdp1i+Gt0n
/y2Le1EZFUZlc3z79s1O7G3UfeeQfz0Wd0C4AyDcAWZUuGsFDrlShBM93QRJHfqs1Tgc3d3d1k+4
t7fXfpbwl3DTJMI8FIfCuTgV1l/bu0hAhRNGlZ8wz6nx15tWyIYNG+wKLiKc6Kp6kQ+1E4/+hFG9
8dAkWT/uu3fvmuvXr1fS3r17d27ei65TLF+N7pP1sCN//EYL96IyKow+q650/tKlS/bBsp77Lrxm
7uENH3dAuAMg3AFmVLiLcMlBcfnyZWu5lHVS4tKtuCG0LJ6/DKSbQPnhw4dontyyfDq0ssfY2Fiy
mBYStFoWUMskanWQ0Bc9Nf5GpOUjdxRNgnRLSzqxLLQCisK68E5A67cSkPptmPaNGzfsg5HSV9qx
vMeuUyxfZfrZ1FVl3OpCjRTuRWVUmIcPH5oVK1bYybjnz5+3Vvd67rvwmrmHU1aVAYQ7AMIdgHZU
A3pTEPOpn61pzVa0sotvCZ9r97mW5dSDEADCHQDhDkA7KkAWaE2ydOt5y4pa62TLZkprLiGXq+Hh
4Tl3n2uegcoGgHAHQLgD0I4S0EY+WuNc7gta1UYuERLVsz2tuYTcgA4ePDitacZcmBqFyvT8+XMu
MCDcARDuALQjAACEOwCCA4B2BAAACHcABAcA7QgAABDugOAAANoRAADCHQDBAUA7AgAAhDsAggOA
dgQAAAh3QHAAAO0IAADhDoDgAKAdAQAAwh0AwQFAOwIAQLgDIDgAgHYEAIBwB0BwANCOAAAA4Q6A
4ACgHQEAINwBEBwAtCMAAEC4AyA4AGhHAACAcAcEBwDQjgAAEO4ACA4A2hFMG8PDw1QC1wwQ7gAI
DgCItyN9Pzg4OCfaXb15nqnwixYtamjZZ+La3b9/Pyndp0+fmv3799cVRzNQ5podOHDAPH/+vK66
AYQ7AMIdgHZkv9+6dav5+fMnwn2Gwjeirmfyen369Mns2rUrKQ9btmwxo6OjdcUx2+41lVdtrNa6
AYQ7AMIdgHZU+b6/v99cvXo1+vtr166Z1tZW09LSYs6dO1f5fs2aNebr16/2/48fP9pwb968sZ+/
fPliz+eRF+eRI0eqLJSPHz82+/bts///+vXLtLe3m8WLF5v169ebV69eZeY5q7z+d3/+/DGnT582
S5YsMStXrrRvHVLLnBreR2VYuHChWbBggdm0aZN58eLF/w3a3tGIvJcpR16+yvS9e/fuNR8+fCj8
/dDQkNmzZ09dcej869evzfLly6vEcKyMCnP79m2zbNkye/7MmTNTHlQvXrxoz+m+0gPE+Ph4bppZ
1yxWj0LlVvlT6ya1XeXVR1F5bt26ZVavXm3zq3w/efJkyj2j+2vp0qWmp6eHcRjhDoBwB2gW4S62
bds2ZXB39PX12YFegvH3799WKHZ2dtpzx44dMw8ePLD/37t3z7oQ6Pfus0R2FrE4P3/+bPOjcxJY
a9eurVgir1y5Yl0qxKNHj8yGDRtqEu43b940HR0dNo2JiQnT1taWXOaU8CG+OJJLhMqUl9d6816m
HLF8pXD9+nUr7FL66rNnz1oBXU8cOi/hrfLoPkkpo8LImq37W7+RKFVeHF1dXTZ9ndOh+Pz7NivN
MJ9F9TgwMFCVZlHdpLarrLyllEfuO669K9/Kv0N1eeHChcr9tWPHDsZhhDsAwh2gmYT7y5cvraU7
6/cSPRrEfZwwkdg4deqU/f/EiRPm6NGj9hDHjx/P9J8vitOJMQlUCTBf8Eioh+FqEe6yTsp673j7
9m1ymVPCh8gi6h44iq5NvXkvU45YvoqQBdi3Ehf11XoYGxkZqSsOnfcfMFPKqDD+m5kfP36YVatW
VT5v3Lixqj71v6zzsTTDfBbVo8qt8qfWTWq7yspbveXZvn27teqn3tuAcAdAuANMs3AXEu4S8OH3
ssaF7gF6xS5kCd+8ebP9Xy4C79+/r4giubLoNX8WsTh9QSbB4VwGXLiUMhaJ3zAeCb/UMqeED5EV
1ll+i9yS6s17mXLE8hXj+/fv9gHCF3hFfbXcNnyBXUscWeeLyqjPobD36zC878LzRdcjpR6VvlxX
UusmtV1l5a3e8oQTb4vubUC4AyDcAWZAuGuCoLMK+t9nCQEf+cHqlboTFvKdlfXQt2qmiIsQrbAh
C/t0CPeyZS4Kn4V8keXeI39uuSI0SrjHyp5Sz3n5iiGrr3PlSC1/mJda4kgVqiliv5b6jH1XVI+x
ezerDCntqqhsf+OhFhDuAAh3gCYQ7kLWQk1W9b+XxW9ycjI37kOHDpl//vmn8irfvdZ3n7MoirO3
t9f62oa+wevWravJVcZN8HPIHcB3J5AgKlPmovAxZD2N5bXevJcpRyxfhWIj58gjtCrXEkfWuaIy
KozK5vj27ZudeOmHD11LfKtzqnCP1aN878tY3FPbVV591FMePbzrgcHx7t07xmGEOwDCHaAZhbsm
g+p1v/+9Jru5yZA69FkrVTi6u7utS4vEtpDwlxCR8M4jFqcm2WlCnC9EtOKI0ORUuSUIrTyTNznV
nyyoNwmajOefv3v3rp0U6Sbg7d69u1SZi8KHKJ9aeUSEkwFVV/I5dmKr3ryXKUcsX43uqyUI5S9d
TxxZ54vKqDD6rLrS+UuXLllR7IfXPezC6z7WA2IszfCaFdWjxG+Rj3tYNyntKq8+ypbH/y6cnDqb
lulEuAMg3AHmlXAXWUsbXr582VopZbmTkHQrWAgtZecvV+cmszmxnUdenIcPH65aDlL/67x7sNB5
CSNNwvPFjp9nJ57kgiDRIlEVlunGjRtWGGkZQU2GLVPmlPA+cqNQft3ye07kCU3AVRrOKlpv3suU
I5avsn1vyqoybmWURgr3ojIqzMOHD82KFSvsJNLz589bq7uPWz5Rh1ZgGRsbi6YZXrNYPTrRXbSq
TFg3Ke0qrz7Klif8Tg+Gure03Kjy1YhNwgDhDgh3AKAdwSxBK7v4lvD5dO9ryU6J+2armxT0sByb
rwIIdwAEBwDtCOYgcsMaHh6eV/e+5iCo3M1YN1noTY4m2bp18WW9T520DAh3AAQHAO0I5ghyAzp4
8OC0pjnTbh4qr+/61Ux1k8WzZ8/sMp2qN61sI9ciCXhAuAMgOABoRwAACHcABAcA0I4AABDuAAgO
ANoRAAAg3AEQHAC0IwAAhDsAggOAdgQAAAh3AAQHwFxsR82wVN1szh8AAMIdEBwAUHM7KtO+mn33
xDB/jew7tBtnypJ+AAAId0BwAMCMt6Nmb4t/M3+jo6N2bWsAAIQ7AMIdYEbakf+9/r9165ZZvXq1
WbBggVm4cKHdFKYyuHiH49q1a6a1tdW0tLSYc+fOTYlb27wvX77c7gqpbdO1fbrPr1+/zKZNm5Lj
K5O/sMzaAVLxLl682G4vPz4+nhS3Y8+ePWZoaIibCQAQ7gAId4CZF+5yCXGCVsJVAjYvjr6+Pit2
3dbog4ODprOzs+r3Z86csec/f/5sTp06Zbq6uqriuHnzphXrqfGVyZ//Wen29PTYuHUorfb29uS4
xcDAgDl79iw3EwAg3AEQ7gAzL9x9K3TWeR9Z0SWCfdauXZsbn9xNZHV3YfR3zZo1ld+Uja8of/7n
jRs3Wuu+Q/8vW7YsOW4xMjJitm3bxs0EAAh3AIQ7wMwL9zLnZZEOXVTkZhKLb+fOndaqLu7evWut
3PXElyrc/Xj89FLjdg8acrUBAEC4AyDcAWaVcM8Sw0VpPnr0yKxfv97+L9/2Z8+e1RVfqnAP3V7K
lj0WDwAAwh0A4Q7Q1MJdwntycrJ0mpoAKt92ucnUG1+qcFfcoauMv3xkinCX3z0WdwBAuAMg3AGa
XrhrNRb5gTsBrAmfHR0dlQmf+qzVWorS1ITTlStXVk08rTW+WP7Cyand3d2VuHt7e826detKCfd3
797h4w4ACHcAhDtA8wt3CW1ZqX1L9eXLl82SJUvsd/JX1+oxRWl+/frV/n5iYmLKubLxxfKXtxyk
Dq0oMzY2Vkq49/f3s6oMACDcARDuALSjZqetrc2uSw8AgHAHQHAA0I6aFC0FqeUqAQAQ7gAIDgDa
URNz8OBB8/z5cyoCABDuAAgOANoRAADCHQDBAUA7oh0BACDcARAcALQjAABAuAMgOABoRwAACHcA
BAcA7QgAABDuAAgOANoRAAAg3AHBAQC0IwAAhDsAggOAdgQAAAh3AAQHAO0IAIC+md4ZEBwAQDsC
AEC4AyA4AGhHAACAcAdAcADQjgAAEO4ACA4A2hEAACDcARAcALQjAABAuAOCAwBoRwAACHcABAcA
7WieMTw8TCUA9yUg3AEQHADN3470/eDg4Lxtd4sWLfprcT9+/NgsXLjQbNmyZV71pc1079Sbl5kK
34j70k97Jq7J/fv3k9J9+vSp2b9/f11xINwBEO4A80a4b9261fz8+XNetru/WU6J9idPnnCvIdxn
pA5n8jp8+vTJ7Nq1KykPerAdHR2tKw6EOwCDAMC8Ee79/f3m6tWr0d9fu3bNtLa2mpaWFnPu3LnK
92vWrDFfv361/3/8+NGGe/Pmjf385csXez4v3devX5vly5fbB4eidFyY27dvm2XLltnzZ86cmfLA
cfHiRXtu8eLFdtAfHx/PTdMOmN4hnJV8wYIFZtOmTebFixfRes1LLyvurDqIladMHX3//t2sWrVq
Sn38+vXLliPrmhbVVeweitWTfjc2NmY2b948JY7fv3/bfCq/WeRd/yNHjpjnz59Xpb9v375KGdvb
22051q9fb169epWZ56Iy/fnzx5w+fdosWbLErFy50r6JSm0HqeF98uow696pN+9lylF0bVPYu3ev
+fDhQ+Hvh4aGzJ49e+qKA+EOgHAHmFfCXWzbti1XuPX19Zlbt25ZcSDhJVHQ2dlpzx07dsw8ePDA
/n/v3j37il+/d58lqPLSlVBVnJ8/fy5Mx4WRdU751G8kPs6ePVs539XVZXp6euw5HYrPTz8rzbBe
fCu5XuGvXbs2t05T0iu6JrHylK2jU6dO2Tz53Lx508Yb5qeWvPvfxerJ/W737t1THnyU95MnT2bW
R6xsKr/uUZ3Tw4nSc1baK1euWJcK8ejRI7Nhw4aahLvqqqOjw6YxMTFh2trakttBSviQlDpsVN7L
lKNMG8ji+vXr9t5KaQO63/XwWk8cCHcAhDvAvBPuL1++tFbNrN9LXGqQ93GDuQZdCUZx4sQJc/To
UXuI48ePZ/rPu/j9B4WidFwY35r648cPa711bNy40VpfHfpf1uxYmmG9yLrtRGARKekVXZNYecrW
kYSswrvz+qs3Hv5bgHry7n8Xqyf3O4loWU199Obg3bt3meGKrr8EpwSqRKb/gCOhHoarRbgrb36d
vH37NrkdpIQPSanDRuW9TDnKtIEQvW3zLehFbUAPYyMjI3XFgXAHQLgDzDvhLiTcJeDD72WBC1/f
6zW6E4vOJUKv1d+/f18Rn3JbkPtMan5i6bgwoeBQGIf/26zzReJHyMLoLOGh+1BILemFacfKU0sd
7dy501pTxd27d82BAwcy46u3rmL15P9u9erVFcu4xKTv8lO2bE506gHDuWeF+a5HuIfx6NqktoOU
8CGpddiIvJcpR5k24CP3J11fuciltgG5N/ltoJY4EO4ACHeAeSncNRlMFrAUkeezdOlS+3reCXaJ
NVnRfOtxSn6K0skTsjEBV0a4OeRX7qzFFy5ciArNsumVKU8tdaR864HJPUg9e/YsSejVUld59eT/
Ti4P7o2MXHE0n6LMg1CIVh+RhX06hHvZdlAUPouUOmxE3suUo0wb8NEbNuc2l1r+MC+1xIFwB0C4
A8xL4S5kYZO48r+XAJycnMyN+9ChQ+aff/6puMg4dxn3OTU/RekojCz6jm/fvtnJeH740P3DX1Yv
Vbg7lFbsfC3plSlPLXXkHpzkUhJODA6vaZm8u4nHKfXk/68HOllVZUHVZMhw8myZsvX29tq3CQMD
A1WuMuvWravJVSYs0/bt26vqRA+fZdpBUfgYsTpsRN7LlKNMG5giQHOOPEKLey1xINwBEO4A81a4
S1jpFXk4kdFNfNOhz1qFxNHd3W3dFySshIS/BmTnspGan6J0FEafJQZ1/tKlS/ahwQ+vvLjwyo9E
XSxN5VM+4E70yJqrVTWEJujFrLm1pBfWQaw8tdSRkA+4VhbxJxyG8RXl3Z+gqDcxcrnxw8fqKcy3
LO0HDx60E21jxMqmyak7duyoEp9acURocqrcO4RWnsmbnFpUJrkW6Q2Bm+CpybVl2kFR+JBYHYb3
Zb15L1OOMm2g3vFbb/jkQjWfNQDCHRDuAFCzcBdZy9hdvnzZWoNllZVocKucCC3p5i8D6SbGOWFV
Jj+xdBTm4cOHZsWKFXYC3fnz562V2sctcahDglHLEsbSlLhVWs7aLBcBTdzUK3wJFidg8iibXlgH
sfLUUkdCbiQ6JwEXq/NY3p1gUz1I0Kse/PCxegrT0QRcfZeyG2he2Q4fPly1HKT+d/77etjUeeVD
efKFoJ+XojKJGzdu2IdQvR3QZNgy7SAlvE+sDsP7st68lylHmWtb7/itNyduFSqEOwDCHQDmUDua
a33BfOnbJArlvgMQooe68I3RfOybUTnA4AYACHfKM+PIFUPW3TKrk8D8Qq55KW9jEO4ADG4AtKNZ
hD95ci4w18qThXy1tSZ3bFIqzG/kBqQ5EAh3AAQHANCOAAAQ7gAIDgDaEQAAINwBEBwAtCMAAIQ7
AIIDgHYEAAAIdwAEBwDtCAAAEO6A4ACAudaO5vNycACAcAdAcADArGlHZZZG1E6P/i6aAAAIdwAE
BwDtqAnzNzo6arZu3cpFBQCEOwCCA2D+tCN9//r1a7N8+fIqMXzt2jXT2tpqWlpazLlz56aEuX37
tlm2bJk9f+bMmSkb7Fy8eNGe0wY82tJ8fHw8N007cHmHePz4sVm4cKFZsGCB2bRpk3nx4kVV/NrU
Z2hoiAsLAAh3AIQ7wPwR7hLe2pr+8+fP9ru+vj5z69Yt+93v37/N4OCg6ezsrAqjbcolxvUbifyz
Z89Wznd1dZmenh57Tofia29vj6YZ5k+iXTsqiqdPn5q1a9dWnR8YGKhKEwAA4Q6AcAeY88Ldt4YL
iXKJah9fOCvMq1evKp9//PhhVq1aVfm8ceNG8+vXr8pn/S/rfCzNMH+yxt+/fz+3PCMjI2bbtm1c
WABAuAMg3AHmj3APkbU7dF+Ry4ofJhT2CuPwf5t1PivN8DtZ2Z1l/+rVq1N+r/TligMAgHAHQLgD
zFvhniW8U8R+1v9ZYVKEu5Af/KNHj8zevXvNhQsXomkCACDcARDuAPNOuGsy6OTkZDSu9+/fVz5/
+/bNLFmypCp86CrjL/eYKtwdSis8L997LO4AgHAHQLgDzGvhrsmlHR0dlcml+qyVYfww+jwxMWHP
X7p0yRw6dKgqfHd3dyV8b2+vWbduXTRNrT4jv3cn+Dds2GBXlhGapBpa19+9e4ePOwAg3AEQ7gDz
W7iLy5cvWyu6LOXa8Mit/uLCPHz40KxYscJOIj1//ry1uvu45SB1aEWZsbGxaJpatUZpOcu83GQ0
yVVuOxLtTsQ7+vv7WVUGABDuAAh3ANpRs7fJtrY2K+4BABDuAAh3ANpRk7ZJLQWp1WYAABDuAAh3
ANpRBH+i6Uxw8OBB8/z5cy4qACDcARDuALQjAABAuAMgOABoRwAAgHAHBAcA0I4AABDuAAgOANoR
AAAg3AEQHAC0IwAAhDsAggOAdgQAAAh3AAQHAO0IAAAQ7oDgAADaEQAAwh0AwQFAOwIAAIQ7AIID
gHYEAAAId0BwAADtCAAA4Q6A4ACgHQEAAMIdAMEBQDsCAEC4AyA4AIC2BADQ1H0yPTMgNgCA9gQA
MAv6YnplQGgAQLRNcXBwcHDM3FHVJzMsAcIdAAAYFwBmwf1MFQAdNAAAMC4AINwB6KABAIBxAQDh
DkAHDQAAjAuAcAeggwYAAMYFAIQ7AB00AAAwLgAg3IEOGgAAGBcYFwDhDkAHDQAAjAsACHcAOmgA
AGBcAEC4Ax00AAAwLgAg3AHooAEAgHEBAOEOQAcNAACMC4BwB6CDBgAAxgUAhDsAHTQAADAuACDc
AeigAQCAcQEQ7gB00AAAwLgAgHAHoIMGAADGBQCEO9BBAwAA4wIAwh2ADhoAABgXABDuAHTQAADA
uADA3QxzroPm4ODg4ODwDwCEOwAAYGUEAACEOwAAINwBAADhDgCAcAcAAIQ7AAAg3AEAAOEOAAAI
dwAAhDsAACDcAQAA4Q4AAAh3AABAuAMAAMIdAADhDgAACHcAAEC4AwAAwh0AABDuAAAIdwAAQLgD
AECzCPbwAAAAhDsAACDcAQAA4Q4AAPWKdwAAQLgDAADCHQAAEO4AAIBwBwAAhDsAAMIdAAAQ7gAA
0AziHQAAEO4AAIBwBwAAhDtAc4geDg4ODo6ZOwAA4Q6ApRIAgL4YAOEOwEABAAD0yQAIdwAGCAAA
+mYAhDsAgwPNAQCAvhkA4Q7A4AAAAPTNAAh3AAYHAAD6ZgCEOwCDAwAA0DcDINwBGBwAAIC+GQDh
DsDgUBfDw8NUAtec/NFu6JsBEO4AzT84NGrQqDeemQq/aNGihpZ9ugfhnz9/mnXr1k35fnJysvRu
jU+fPjX79++vfP7x44c5deqUaWlpsfV0+PBh8+3bt6qyhseCBQuavi004ppPZ/5S76npvPfK1OGB
AwfM8+fP6YQR7gAIdwCEe33hG1H+mRp4f//+bQ4dOpSZ/qNHj6zQLsOWLVvM6Oho5fPZs2dNb2+v
+fPnjz0uXrwYjfPff/81ly9fRijNAyFXJo+6p7Zu3UonjHAHQLgDNFK46/9bt26Z1atXW8vpwoUL
zZMnTyrnf/36Zdrb283ixYvN+vXrzatXr3LjiaUjEXj69GmzZMkSs3LlSjM4ODglzLVr10xra6u1
9p47d67qXEp4n8ePH9uyqEybNm0yL168qOQptEbXm/cy5cjLV+pgvmvXLvPp06fM316/ft10d3cn
3x9DQ0Nmz549Vd8tXbrUltd/UMiztOp3mzdvNt+/f4/eg69fvzbLly+vEnKxOlKY27dvm2XLltnz
Z86csW8ZfPRAoXO6L1Un4+PjuWlmXfPYdUhpV7H8/e9//7MWZ+VNaajdPHz4sFT+/Otbpg3Wm6+8
vqCWOtS9pXsMEO4ACHeABgp3DeZO+Gig1mDsuHLlirl//779XxbdDRs21CTcb968aTo6OqzYm5iY
MG1tbVXn+/r6rGjQeYlFiePOzs7k8CG+6JA7yNq1a3PzWm/ey5Qjlq8Unj17lptnWeIlliSI9ZAh
cRtD1nUJvRgSjRKYWaisRdZ25VMCUvXx+fPnpDpSGL0J0D2p30jkK6+Orq4u09PTU3kroPgkbGNp
hvVVz3Uoyp8eZu7evVvJn/Lq12FK/vzPZdpgvfmK9QVl63BgYKAqfUC4AyDcARog3H1rZXheIsG3
wMbiiZ2XZVEi0PH27duq8xIcYTq+ECgKHyJB4sROUb3Um/cy5Yjlq95ru2LFCnPnzh37v/LQ399v
RV8e27ZtMyMjI9F0FF9eHBKCHz9+LMxneH8V1ZHC+FZl+d2vWrWq8nnjxo1V10P/y8qcek/Xex2K
8peFPw8gJX+1tsG/ma+ydah7S/cYINwBEO4ADRTusfO+xa2R8UiIhOdjkx6LwofIAugskFevXq1L
uBelXaYcsXw1euBXPiXm85DLRJ4gFF+/fjVHjhyxVvEQ+TCniLKsfBbVkT6H+fKvQdZk2JhlOOu7
eq5DUf6EXGH0wHP06FH7oFGmrdTTBv9mvsrWofIilx1AuAMg3AFmuXAPzxetTFIUPguJFLkW7N27
11y4cKFhwj1W9pQVVvLy9TcG/lh+Yuck1o8dO2Zdg7KQL32RK05ePovqKE/s13I9Yt/Veh2K8if3
I1nJ5Soi1ya5w0yXcP+b+aqlDmN5p28GAIQ7QIOFu5YdrMVVRi4U/nfbt2+vcm/Qa3T/vCa3aTnD
PIrCx3j//n00r/XmvUw5Yvmq99rKXcSfKKo8awJiHnkWd1natSRkzA1G/vQSbLXks6iOFEZ149By
lPLZ98OHrjL+BNpU4V7rdSjKn/73yxfeT2WFe5k2+DfzVbYO9fCHxR3hDoBwB5hG4a7X6nolLrQu
c97EOH+imlY90SQ3/7wmxWnVEzfBc/fu3VXnNeHQTQDVoc9aLSQ1fIjyqVUvRDjJToJVvrxO/NWb
9zLliOWr3mt7/vx5OyHRpa0Jn1raMQ+5ushf30ergOzcudN8+fIlmr580t3EyrL5LKojhdFn1bXO
X7p0yT4o+OFl8XfhVUZ/XfusNMNrXs91KMqfVmVxq7U4P++iNhfmr5Y2+Dfy5X9Xtg7fvXuHjzvC
HQDhDjCdwl3LyWkdbw3K8on1hZ7/Ozdwyw1CIkoDehj3jRs3rFVYq55oJZDwvFYokVVQ1lOJ51AY
FoX30St85dcta+cEhpCgVRrOSltv3suUI5avslbfEF2rkydP2nS1rKPEcQyt+KGy+GgyY8omTsp7
zD++qEyxOlIYCUz552sCpB5I/E2ghFsOUodWlBkbG4umGV7z2HUouhZF+Xv58qV9sFG8EreawFnU
5sL81dIG/0a+/O/K1qEmR7OqDMIdAOEOwOAADUArkPiWbu7b/+PEiROzrl01W760bKrEPdA3AyDc
ARgcoAFoRZDh4WHu24DYMpoI92LkiqN7C+ibARDuAAwO0CDkJnTw4MGmylPeTq3kb/bkS/eU/PGB
vhkA4Q7A4AAAQN8MgHAHYHAAAAD6ZgCEOwCDAwAAfTMAINwBGBwAAOibARDuAAwOAABA3wyAcAdg
cAAAoG8GQLgDMDgAAAB9MwDCHYDBAQAA6JsBEO4ADA4AAPTNAAh3AAYHAACgbwZAuAMwOAAAAH0z
AMIdgMEBAIC+GQDhDsDgAAAA9M0ACHcABgcAAPpmAIQ7AI2BwQEAgL4ZAOEOwOAwVxgeHqYSuOYA
9M0ACHeA5hsc9H3eMZOD0UyFX7RoUUPreiYG5fv3709J98uXL+a///2vLd/ixYvN4cOHzcTERDSe
p0+fmv3791c+T05OFt4nFy9eNEuWLKmkoXSbnTLX/MCBA+b58+d0KIBwB0C4A8yMcG/GwWimwjei
PmZyIP706ZPZtWvXlDzs3r3b3Lt3z/z588ce+n/Pnj3RuLZs2WJGR0crnx89emTFeB43btwwPT09
lTSuX79u8zKXhJPqY+vWrXQogHAHQLgDNJ9wP3LkSJWF8fHjx2bfvn32/1+/fpn29nZrXV2/fr15
9epVZrxZafjfSeSdPn3aWmpXrlxpBgcHp4S5du2aaW1tNS0tLebcuXNV51LC+6gMCxcuNAsWLDCb
Nm0yL168qOQptCTXm/cy5cjLV5nBfe/evebDhw9Tfq94Q7K+cwwNDU0R9hLi3d3duWHWrl1rfvz4
kZyG8vj69WuzfPnyKjEcqyOFuX37tlm2bJk9f+bMGfPz58+q38jqr3O6L/XgMD4+nptm1jWPXQeh
elH9ACDcARDuAE0l3D9//my2bdtmBaoEksSZs8JeuXLFumUIWWM3bNhQk3C/efOm6ejosGnIfaOt
ra3qfF9fn7l165Y9//v3byuOOzs7k8NnCdYnT57Y/+UOojLl5bXevJcpRyxfKUhYy+KdlW9ncXfo
uu3cuTM3rrNnz1qB7HPo0CErWiWq9aAigZyH3GokwI8ePRq9JyW8VR+6z1LqSGH0JkBiXL9RGsqr
o6urq8rqr/j0cBlLM+shJ3YdBgYGqtIEQLgDINwBpk24F/m4S/xIoEpA+YJFQl0CqCi9IvEry6es
9463b99WnZdQC9PxxVRR+BBZW90DR1E91Zv3MuWI5auIN2/eVFnIw3zrYWvp0qWVa6v/fTeYED2s
jYyMVH23YsUKc+fOHfu/ytHf328f3kL0lkYWbx3v3r2L3pO+NTyljhTGf7MjC/+qVasqnzdu3Fh1
PfS/rPOxNMO6KroOqhfVDwDCHQDhDjDtwj0FCSoJoK9fv1a+K3KDSBW/YTwSbuH58KFCbgyp4UNk
RXWW26tXr9Yl3IvSLlOOWL5ifP/+3T5A+BNBw3xrUqWs0c4SLX90WdDzkJtJ3kOZX1aJ+TxkkZer
SZl7sqiO9DnMl38N/N9mnS+6ninXQenroQQA4Q6AcAdoSuGu1UVkYZ8O4R6ezxJjecIstVzyc5Z7
j3zCL1y40DDhHit7UTli+Ypx/Phx8+DBg2i+tXKKL3j1v8R5Hil5LfqdXF1S75HUdPPEfi3XI/Zd
0XWIlQsA4Q6AcAeYMeHe29tr/Y5D395169bV5Crz8ePHqu+2b99e5d4gVwT/vKy28pnOoyh8jPfv
30fzWm/ey5Qjlq+ia1vk7hSK9CKrcZbFXW9cZN13qNyalOyQi4m/xGToppJy7xXVkcKobhzfvn2z
/vZ++NBVxl/uMVW4x66DHkiwuAPCHQDhDtB0wl0T+Hbs2FEljLRqiZB/s9wKhFaeyZuc6k/203KF
ctvwz9+9e9dOrHQTPDWR0j8vFw83AVSHPvvLDBaFD1E+tXKIUL5866kEq3ygnfirN+9lyhHLV73X
WxMy9eAl0am0NWdBq+HkIR9u+ev7nD9/3k4GdfnXnAc91DnkGiPXEnf+0qVL9ihzTxbVkcLos+ra
peG7/Oj3WvnGhVf+9IAZSzO85kXXQX77+LgDwh0A4Q4wI8I9Zq3Vut3+cpD6X+JVaJUZnZew0aRA
X+j56TnxIzcIiSiJojA/8rmWdVYrlmgybHj+8uXL1rIq66nSdyuCpIb3kRuE8qv8KF9OpAmJUaXh
rLT15r1MOWL5Kju4h7/XtZJ4d2WTaA+XUfTRmxWVJYzj5MmTNrwmt0pg++ihwKUhi3Rs1ZlYmWJ1
pDAPHz60vvWy8OthQlZ3H7ccpA6tKDM2NhZNM7zmsesgNCmXVWUA4Q6AcAdgcICmQCu3NOPmSc1w
H2vJT4l7APpmAIQ7AIMDNAVaVWV4eJj72ENzGFQvAPTNAAh3AAYHaBrkJnTw4MGmypM/0XQmUH34
rmMA9M0ACHcABgcAAPpmAIQ7AIMDAADQNwMg3AEYHAAAgL4ZAOEOwOAAAEDfDIBwB2BwAAAA+mYA
hDsAgwMAANA3AyDcARgcAADomwEQ7gAMDgAAQN8MgHAHYHAAAKBvBkC4AwCDAwAAfTMAwh2AwQEA
AOibARDuAAwOAAD0zQAIdwAGBwAAoG8GQLgDMDgAAAB9MwDCHYDBAQCAvhkA4Q7A4DA/GB4ephK4
ZgD0zQAId4DmHxy+f/9uLl68aFasWGEWLlxoVq1aZT9PTk7OiwFs0aJFDc37dJfj58+fZt26dUm/
ffr0qdm/f39dcTQD4TU7cOCAef78OQ0dEO4ACHeAuTs4/Pr1y7S1tZmOjg7z9etX+92fP3/M69ev
zZ49e6ZdvM/WgXOmBt/fv3+bQ4cOJae/ZcsWMzo6WlcczXjNVKatW7fS0AHhDoBwB5i7g4MEe1dX
V+a527dvmytXrlTFcevWLbN69WqzYMECa51/8uRJVZhr166ZJUuWmKVLl5qenp4p6cqS39LSYhYv
Xmx27dplxsfHM/PYiLR8Hj9+bONQXJs2bTIvXryopOMfeXXlf6cHm9OnT9u0V65caQYHB6MWd+Wz
tbXVlvvcuXNJ+Uod0FWHnz59Svrt0NCQfRirJw79Rg91y5cvrxLKsTIqjO6lZcuW2fNnzpyxFv4y
94WfZtY1EyqbygiAcAdAuAPMycFh8+bNuVb1iYkJs3Hjxqo45JLgRJWEtESnQ0L7woULVtgq7I4d
O6rS1QOCBLbO6+jr6zPt7e25wr2etEJ84S93kbVr1+bWTZFwv3nzpn3gcWnrjUWecFcZlVf9VpZt
ifzOzs6kfKXw7Nmz5MH/7NmzVkDXE4d+I+Gt8nz+/DmpjAojS7+upX4jka+8lLkvwjSz8jowMFAV
LwDCHQDhDjCnBoci/27/vOLwLaFhvNu3bzdfvnypfH779m3VeT0EyDXHof9lhc0T7vWkFSJr7f37
95Pqpki4y+rrlyNM2/9fglWC08cX57F8NXrw37ZtmxkZGakrjqzrUlRGhXn16lXl848fP+w8ijL3
RexecKhsKiMAwh0A4Q6AcC8QtGFcEnP+ebmDhPhW9KIJnmXSCpE121l+r169Wpdw9/OclXb429C1
w6+HWL4aPfjLDSUU2LUI96xrGCujPofp+nVY5r6Ifac05G4DgHAHQLgDzMnBQYJRq8pkIcuo/K4b
JWjD8zGxXm9aWchP+tGjR2bv3r3WzaZRwj2W9yxRmpqvRg/+RXmpVbjXEq9fh2XqsyivWXEBINwB
EO4Ac2JwkH9xd3d35rmHDx+ay5cvJwsouSnI59vx7t27qvN6CAhdIvIs+vWmFeP9+/fRtMLPHz9+
nOKm45dDLhp58anMqSvzhPlq9OD/tyzuRWVUGJXN8e3bNzuxt5b7Ivad/OuxuAPCHQDhDjBnBweJ
nd27d1vx7sSXxJ3WxN63b58VWakCKpwwqtVBwsmpSsdNQuzt7a1aO7yMcC9KK2TDhg12BRcRTnSV
oJUPtROP/oRRrbaiSbJ+3Hfv3jXXr1+vpK36y8u7yuwmsurQZ+U1JV+NHvz1sCN//EYL96IyKow+
q650/tKlS3b5yVrui7xr5h7e8HEHhDsAwh1gTg8OWppPlnUtveg2YJIo9kV7ipgWErRaFlDLJGp1
kNAX3S37p0Mrh4yNjdUk3FPS8pE7iiZBuqUlnVgWWgFFYV14J6D1WwlI/TZM+8aNG3YCpdJX2rG8
q25lYVb8eghwK6MU5avMgJ66qozy2mjhXlRGhdHbG23wpcm458+fn3Jvpd4XeddM9Pf3s6oMINwB
EO4ADA61oAcCf/WQuZLWbEUru/iW8Ll272lZTj0IAdA3AyDcARgcCpAFWpMs3XresqLWOtmymdKa
S2gy8vDw8Jy79zTPQGUDoG8GQLgDMDgkoI18tMa53Be0m6lcIiSqZ3tacwm5AR08eHBa0yxacrQR
qEyalwFA3wyAcAdgcAAAAPpmAIQ7AIMDAAB9MwDCHQAYHAAA6JsBEO4ADA4AAEDfDIBwB2BwAACg
bwZAuAMwOAAAAH0zAMIdgMEBAADomwEQ7gAMDgAA9M0ACHcABgcAAKBvBkC4AzA4AAAAfTMAwh2A
wQEAgL4ZAOEOwOAAAAD0zQAIdwAGBwAA+mYAhDsAAwQAANAnAyDcARgoAACAvhgA4Q7QuAGDg4OD
g2PmDgCYyv8DTB5myyRN6rQAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAYkAAANTCAIAAADUhXaKAAA97klEQVR42u2dvU4rydaGW0JCBA4I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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis">
<APPENDIX ID="APP-01" MODIFIED="2010-11-29 14:57:00 +1100" MODIFIED_BY="Gail Y Higgins" NO="1">
<TITLE MODIFIED="2008-05-13 09:58:35 +1000" MODIFIED_BY="Narelle S Willis">Electronic search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2010-11-29 14:57:00 +1100" MODIFIED_BY="Gail Y Higgins">
<TABLE COLS="2" ROWS="4">
<TR>
<TH>
<P>Database</P>
</TH>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>CENTRAL</P>
</TD>
<TD>
<OL>
<LI>MeSH descriptor Fish Oils explode all trees in MeSH products</LI>
<LI>(fish oil*) in Clinical Trials</LI>
<LI>(cod liver oil*) in Clinical Trials</LI>
<LI>(fish liver oil*) in Clinical Trials</LI>
<LI>"omega-3" in Clinical Trials</LI>
<LI>"n-3 fatty acid*" in Clinical Trials</LI>
<LI>(icosapentaenoic acid* or eicosapentaenoic acid*) in Clinical Trials</LI>
<LI>(docosahexaenoate* or docosahexenate$) in Clinical Trials</LI>
<LI>(ameu* or efamed* or epax* or feniko* or fish oil* or himega*) in Clinical Trials</LI>
<LI>("k-85*" or "lachs 550*" or lipitac* or maxepa* or olemar* or optimepa* or pikasol*) in Clinical Trials</LI>
<LI>(promega* or "super era" or superepa*) in Clinical Trials</LI>
<LI>(#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11)</LI>
<LI>MeSH descriptor Kidney Transplantation, this term only</LI>
<LI>(kidney transplant* or renal transplant*) in Clinical Trials</LI>
<LI>(13 OR 14)</LI>
<LI>(12 AND 15)</LI>
</OL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>MEDLINE</P>
</TD>
<TD>
<OL>
<LI>kidney transplantation/</LI>
<LI>exp Fish Oils/</LI>
<LI>(fish adj2 oil).tw.</LI>
<LI>fish oil$.tw.</LI>
<LI>(cod adj2 oil$).tw.</LI>
<LI>omega 3 fatty acid$.tw.</LI>
<LI>n-3 fatty acid$.tw.</LI>
<LI>Eicosapentaenoic Acid$.tw.</LI>
<LI>Docosahexaenoic acid$.tw.</LI>
<LI>timnodonic acid$.tw.</LI>
<LI>(icosapentaenoic acid$ or eicosapentaenoic acid$).tw.</LI>
<LI>omega-3.tw.</LI>
<LI>(docosahexaenoate$ or docosahexenoate$).tw.</LI>
<LI>ameu.tw.</LI>
<LI>efamed.tw.</LI>
<LI>epax$.tw.</LI>
<LI>feniko.tw.</LI>
<LI>himega.tw.</LI>
<LI>k-85.tw.</LI>
<LI>lachs 550.tw.</LI>
<LI>lipitac.tw.</LI>
<LI>maxepa.tw.</LI>
<LI>olemar.tw.</LI>
<LI>optimepa.tw.</LI>
<LI>pikasol.tw.</LI>
<LI>promega.tw.</LI>
<LI>(super epa or superepa).tw.</LI>
<LI>or/2-27</LI>
<LI>and/1,28</LI>
</OL>
<P/>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>EMBASE</P>
</TD>
<TD>
<OL>
<LI>exp kidney transplantation/</LI>
<LI>Fish Oil/</LI>
<LI>ameu.tw.</LI>
<LI>efamed.tw.</LI>
<LI>epax$.tw.</LI>
<LI>feniko.tw.</LI>
<LI>fish oil$.tw.</LI>
<LI>himega.tw.</LI>
<LI>k-85.tw.</LI>
<LI>lachs 550.tw.</LI>
<LI>lipitac.tw.</LI>
<LI>maxepa.tw.</LI>
<LI>olemar.tw.</LI>
<LI>optimepa.tw.</LI>
<LI>pikasol.tw.</LI>
<LI>promega.tw.</LI>
<LI>(super EPA or superepa).tw.</LI>
<LI>or/2-17</LI>
<LI>Omega 3 Fatty Acid/</LI>
<LI>bilantin omega.tw.</LI>
<LI>conchol 36.tw.</LI>
<LI>(eicosa e or eicosapen).tw.</LI>
<LI>epaisdin.tw.</LI>
<LI>omacor.tw.</LI>
<LI>omega 3.tw.</LI>
<LI>omega 3 fatty acid$.tw.</LI>
<LI>sakana.tw.</LI>
<LI>sanhelios.tw.</LI>
<LI>eicosapentaenoic acid$.tw.</LI>
<LI>docosahexaenoic acid$.tw.</LI>
<LI>Docosahexaenoic Acid/</LI>
<LI>Icosapentaenoic Acid/</LI>
<LI>timnodonic acid$.tw.</LI>
<LI>icosapentaenoic acid$.tw.</LI>
<LI>(docosahexaenoate$ or docosahexenoate$).tw.</LI>
<LI>or/2-35</LI>
<LI>and/1,36</LI>
</OL>
<P/>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2016-08-11 10:40:37 +1000" MODIFIED_BY="Narelle S Willis" NO="2">
<TITLE MODIFIED="2015-01-12 17:45:48 +1100" MODIFIED_BY="Ann Jones">Risk of bias assessment tool</TITLE>
<APPENDIX_BODY MODIFIED="2015-01-12 17:45:54 +1100" MODIFIED_BY="Ann Jones">
<TABLE COLS="2" ROWS="22">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Potential source of bias</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Assessment criteria</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Random sequence generation</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Random number table; computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots; minimisation (minimisation may be implemented without a random element, and this is considered to be equivalent to being random).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Sequence generated by odd or even date of birth; date (or day) of admission; sequence generated by hospital or clinic record number; allocation by judgement of the clinician; by preference of the participant; based on the results of a laboratory test or a series of tests; by availability of the intervention.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information about the sequence generation process to permit judgement.</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Allocation concealment</B>
</P>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>Randomisation method described that would not allow investigator/participant to know or influence intervention group before eligible participant entered in the study (e.g. central allocation, including telephone, web-based, and pharmacy-controlled, randomisation; sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Randomisation stated but no information on method used is available.</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of participants and personnel</B>
</P>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</TD>
<TD>
<P>
<I>Low risk of bias</I>: No blinding or incomplete blinding, but the review authors judge that the outcome is not likely to be influenced by lack of blinding; blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias</I>: No blinding or incomplete blinding, and the outcome is likely to be influenced by lack of blinding; blinding of key study participants and personnel attempted, but likely that the blinding could have been broken, and the outcome is likely to be influenced by lack of blinding.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear</I>: Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Blinding of outcome assessment</B>
</P>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No blinding of outcome assessment, but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding; blinding of outcome assessment ensured, and unlikely that the blinding could have been broken.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>No blinding of outcome assessment, and the outcome measurement is likely to be influenced by lack of blinding; blinding of outcome assessment, but likely that the blinding could have been broken, and the outcome measurement is likely to be influenced by lack of blinding.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Incomplete outcome data</B>
</P>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data.</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>No missing outcome data; reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing bias); missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk not enough to have a clinically relevant impact on the intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome data, plausible effect size (difference in means or standardized difference in means) among missing outcomes enough to induce clinically relevant bias in observed effect size; &#8216;as-treated&#8217; analysis done with substantial departure of the intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Selective reporting</B>
</P>
<P>Reporting bias due to selective outcome reporting</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study protocol is available and all of the study&#8217;s pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; the study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing text of this nature may be uncommon).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias: </I>Not all of the study&#8217;s pre-specified primary outcomes have been reported; one or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. sub-scales) that were not pre-specified; one or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; the study report fails to include results for a key outcome that would be expected to have been reported for such a study.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to permit judgement</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>
<B>Other bias</B>
</P>
<P>Bias due to problems not covered elsewhere in the table</P>
</TD>
<TD>
<P>
<I>Low risk of bias: </I>The study appears to be free of other sources of bias.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>High risk of bias:</I> Had a potential source of bias related to the specific study design used; stopped early due to some data-dependent process (including a formal-stopping rule); had extreme baseline imbalance; has been claimed to have been fraudulent; had some other problem.</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Unclear: </I>Insufficient information to assess whether an important risk of bias exists; insufficient rationale or evidence that an identified problem will introduce bias.</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;Included studies: 15 (27 reports, participants)&lt;/p&gt;&lt;p&gt;Excluded studies: 48 (53 reports)&lt;/p&gt;&lt;p&gt;Ongoing studies: 1 (1 report)&lt;/p&gt;" WIDTH="350">
<FLOWCHARTBOX TEXT="&lt;p&gt;Included studies: 15 (20 reports)&lt;/p&gt;&lt;p&gt;Excluded studies: 44 (45 reports)&lt;/p&gt;" WIDTH="350">
<FLOWCHARTBOX TEXT="&lt;p&gt;2007 review: 65 reports&lt;br&gt;(Renal Register, MEDLINE, EMBASE, CENTRAL)&lt;/p&gt;" WIDTH="350"/>
</FLOWCHARTBOX>
<FLOWCHARTBOX TEXT="&lt;p&gt;New included studies: 0&lt;/p&gt;&lt;p&gt;Existing included studies: 5 (7reports)&lt;/p&gt;&lt;p&gt;New ongoing studies: 1 (1 report)&lt;/p&gt;&lt;p&gt;New excluded studies: 4 (4 reports) (wrong intervention)&lt;/p&gt;&lt;p&gt;New reports of previously excluded studies: 4 (4 reports)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="350">
<FLOWCHARTBOX TEXT="&lt;p&gt;2016 review update&lt;/p&gt;&lt;p&gt;Specialised register: 16 reports&lt;/p&gt;" WIDTH="350"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>